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Abstract 
Biological chemistry revolves around the abiogenetic interplay of high energy labile 
chemical linkages which shuttle energy and chemical potential, and stable and degradation 
resistant bonds that make up the biological polymers which offer structural and functional 
support. Insights into secondary metabolism in microorganisms have shed light on fascinating 
arrays of genetically encoded small molecule natural products which have utilized the chemical 
frameworks of transient high energy compounds, and replaced key labile bonds with those 
borrowed from stable structural molecules. Compounds such as these can be designed as mimics 
of enzymatic transition states, which thus inhibit the respective enzymes by binding to them, but 
are not turned over to products.  One such example is the Trojan horse tRNA synthetase inhibitor 
antibiotic microcin C7, which mimics the aminoacyl adenylate intermediate of the tRNA 
synthetase enzyme by replacing the high energy phosphodiester bond of the enzyme intermediate 
with a stable phosphoramine-amide linkage. Second examples are the phosphonate molecules 
which replace the high energy phosphoryl and carboxyl ester moieties of various enzyme 
intermediates by stable phosphonate linkages. These compounds in addition to possessing 
bioinhibitory activities are also thought to be store houses of carbon and phosphorous in the 
microbial metabolome as they cannot be easily degraded. The body of work presented in this 
dissertation delves into molecular mechanisms of enzymatic degradation of the stable 
phosphoramine-amide bond of microcin C7, as well as the hydrolysis of the phosphonate bond in 
a ubiquitous phosphonate molecule- phosphonoacetate. Both these studies, presented in the form 
of two chapters, involve the atomic resolution structure determination of the enzyme catalysts 
during various stages of their catalytic cycles, and in complex with different substrate molecules 
which delineate their specificity and selectivity. All structural investigations have been followed 
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by extensive biochemical validation of the structural results. These results have allowed us to 
postulate the reaction mechanisms for these catalysts. Our proposals reveal how enzymatic 
architectures have been borrowed from primary metabolism, and the enzyme active sites slightly 
tweaked to achieve remarkable and unprecedented chemical transformations by these enzymes of 
microbial secondary metabolism. Our studies also have implications for the design of inhibitors 
of these enzymes, as similar mechanisms may be used to avert the bioinhibitory action of various 
antibiotics by drug resistant pathogenic microorganisms. 
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Chapter 1: Introduction
1,2
 
 Interactions of prokaryotic microorganisms with human beings and plants in the 
biosphere is widespread and significant, with the number of bacterial cells within the human 
body exceeding that of the human eukaryotic cells themselves. This interaction is designed to be 
mutually beneficial to both the human or plant host and prokaryotes. However, certain 
microorganisms have been known to cause disease in human beings and plants, hence called 
pathogenic microorganisms. The mechanisms by which these pathogenic organisms cause 
disease are extremely diverse and affect nearly all types of tissues. With the advancement of 
medical science, humans have developed two frontline defense mechanisms to fight infections 
and diseases caused by microbes. The first line of defense are the vaccines, which are designed 
to tune the human host’s adaptive immune response to recognize and eliminate the pathogenic 
and harmful microbes, while selectively preserving the beneficial microbe population within the 
host. The second is the discovery and development of antibiotics, which are small organic 
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molecules, designed to target and kill the harmful microorganisms within the human body. 
Antibiotics are derived from naturally occurring molecules, which are used within the biosphere 
to render selective advantage during interactions of different living species for competition for 
nutrients and survival advantage. Serendipitous discovery and exploitation of these molecules by 
human beings dates back in ancient history (Forrest, 1982a, b; Lindblad, 2008) with numerous 
reports such as the use of the bark from cinchona tree, which contains the antibiotic quinine, used 
to treat malaria. Antibiotics generally have well defined mechanisms of action against the 
pathogenic microbes, and target specific biological processes within these microbes to either 
retard their growth (bacteriostatic antibiotics), or kill the microbe cell (bacteriocidal antibiotics). 
The first report of an isolated antibiotic molecule used to effectively treat infectious 
diseases is the development and use of penicillin, discovered by Alexander Fleming in 1928 
from the fungus Penicillium notatum. Penicillin was used to treat diseases such as syphilis and 
infections caused by staphylococci and streptococci. The term ‘antibiotic’ was coined by eminent 
microbiologist Selman Waksman in 1942 (Waksman, 1947), and is derived from antibiosis, 
which translates to ‘against life’. Hailed as a wonder drug, penicillin marked the beginning of the 
antibiotic age, in which antibiotics have been developed to treat almost all major human non-
viral infectious diseases. Thousands of antibiotic molecules have been discovered and applied to 
fight bacterial, fungal, protozoan and yeast infections. Synthetic derivatives of naturally 
occurring antibiotic molecules have also been generated with more desirable properties. These 
molecules have marked a decreased incidence of outbreaks of infectious diseases and have 
contributed to increased life expectancy in the world. 
However, repeated challenge of the pathogenic microorganisms against these antibiotics, 
as well as natural evolution of their genetic information leads to the microorganisms developing 
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resistance against these antibiotics, by which they are able to evade the action of the antibiotic 
molecules (Allen et al., 2010; Davies and Davies, 2010; Moellering, 1998). This process has led 
to the development of microbial resistance against nearly all available antibiotic molecules, and 
has precipitated to an immense medical and financial challenge. The arsenal available to fight 
infections is becoming increasingly limited and the rate of development of new molecules has 
not been able to keep pace with the emergence of antibiotic resistance. Several factors contribute 
to the incidence of antibiotic resistance among susceptible microorganisms. Primary among these 
is the widespread and indiscriminate overuse of antibiotics in the clinical environment, which 
exposes pathogenic microorganisms to an ever increasing concentration of different antibiotic 
molecules, which in turn increases the selection pressure to develop resistance against these 
antibiotic molecules (Goossens et al., 2005; Tacconelli et al., 2008). Secondly, the use of 
antibiotics in agriculture and livestock rearing also leads to increased exposure of pathogenic 
bacteria to antibiotic molecules. Many of the antibiotics present in agriculture and livestock feeds 
are also used for treating humans, and hence development of resistant bacterial strains can be 
transferred from one setting to the other very easily (Angulo et al., 2004; Mathew et al., 2007; 
Singer et al., 2003). Microbes are also proficient in genetic recombination and the transfer of 
genes from an antibiotic resistant microbe to a non-resistant microbe, which leads to spread of 
resistance among microbial species. Antibiotic resistance genes are usually borne on highly 
mobile genetic vehicles called plasmids, which are easily transmitted among microbes (Koch, 
1981). 
Microorganisms develop resistance to antibiotics by myriad mechanisms (Tenover, 
2006). Efflux pumps in the microbial cell walls and membranes actively transport the antibiotic 
molecule out of the cell and hence decrease its concentration within the cell. Consequently ever 
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increasing doses of antibiotics are required against such microbes (Li and Nikaido, 2009; Lin et 
al., 2009; Van Bambeke et al., 2000). A primary example is the tetA gene which affects the 
efflux of tetracycline out of the susceptible cells (Van Bambeke et al., 2003). The antibiotic 
target within the target cell can be altered and modulated, so that the antibiotic is no longer able 
to bind and engage the target. Random mutations within the antibiotic target genes may lead to 
the emergence and subsequent selection of microbe species which harbor a desensitized 
antimicrobial target. Modulation of the D-alanine-D-alanine dipeptide within the bacterial cell 
wall to D-alanine-D-lactate mediates resistance against vancomycin (French, 1998). Presence of 
additional antibiotic resistant enzyme targets within the susceptible cells mediates resistance 
against the topical antibiotic mupirocin (Patel et al., 2009). Antibiotics can also be chemically 
modified by specific enzymes within the target pathogenic microbe, which renders the antibiotic 
ineffective (Wright, 2005). Chemical modifications include, but are not limited to hydrolysis, 
acetylation, adenylation and phosphorylation of the antibiotic molecules. Hydrolysis of 
antibiotics is of particular concern against β-lactam antibiotics, such as the parent compound and 
derivatives of penicillin (Bradford, 2001). Also the aminoglycoside antibiotics, such as 
kanamycin and neomycin are acetylated by dedicated acetyltransferase and phosphotransferase 
enzymes (Smith and Baker, 2002). It is thus a continuous endeavor on part of the academic 
research as well as the pharmaceutical industry to search for antibiotics which have new and as 
yet unexplored mode of actions. Also new chemical classes of drug molecules are pursued to 
mitigate the effects of resistance against the current drug chemical entities. 
An underappreciated approach towards combating antibiotic resistance is inhibiting the 
processes which mediate resistance against the antibiotic. A shining example of application of 
this methodology is the development of clavulanate, which is an irreversible covalent inhibitor of 
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the β-lactamase enzyme which hydrolyzes the β-lactam antibiotics (Drawz and Bonomo, 2010). 
When used in conjunction with the β-lactam antibiotic meropenem, clavulanate was shown to be 
active against multi drug resistant (MDR) and extremely drug resistant (XDR) strains of 
tuberculosis causing Mycobacterium strains (Hugonnet et al., 2009). Clavulanate in conjunction 
with amoxicillin is clinically used under the trade name Augmentin. Similarly, β-lactam 
antibiotic ampicillin is clinically used in conjunction with the β-lactamase inhibitor sulbactam 
under the trade name Unasyn. Additional efforts are underway to develop inhibitors of the 
antibiotic efflux pumps, which would increase the efficacy of antibiotics such as tetracycline 
(Van Bambeke et al., 2000; Van Bambeke et al., 2003). Characterization of the aminoglycoside 
acetyltransferase enzymes and efforts towards the development of their mechanism based 
inhibitors (Chen et al., 2011; Magalhaes et al., 2008; Green et. al., 2012) is directed at improving 
the efficacy of these aminoglycoside antibiotics commonly used in the treatment regimen against 
tuberculosis. 
In this rich background of efforts to reinvigorate the efficacy of antibiotics by combating 
their inactivating processes, we have described the microbial mechanisms which can be 
employed to inactivate nucleoside antibiotics such as the Trojan horse aspartyl tRNA synthetase 
inhibitor antibiotic microcin C7 (McC7). The chemical mechanisms used to inactivate McC7 are 
distinct from previously used mechanisms employed by resistant microbes against aminoacyl 
tRNA synthetase inhibitor antibiotics (Hurdle et al., 2005). We describe the crystal structure of 
biochemical characterization of two enzymes- MccF and MccE which respectively hydrolyze 
and acetylate McC7 to render it ineffective (Agarwal et al., 2011b; Agarwal et al., 2012). Our 
investigations shed light on how similar enzymes already present in the microbial metabolome 
can be used to provide resistance against other nucleoside antibiotics. Our efforts also provide 
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the structural groundwork for the design of inhibitors against these enzymes. The structures of 
the two enzymes demonstrate how enzymes of the microbial primary metabolism have been 
borrowed by processes of secondary metabolism. Though the core tertiary structures of MccF 
and MccE resemble their counterparts from primary metabolism, subtle changes have been 
incorporated within the active sites to recognize and chemically modify McC7. A structure based 
explanation of enzymatic specificity, and biochemical validation of the structural findings is the 
underlying theme in this body of work. 
An emerging class of antibiotics is the phosphonate molecules (Metcalf and van der 
Donk, 2009). Phosphonate molecules mimic diverse phosphorylated enzyme intermediates, but 
have replaced the labile oxygen-phosphorus (O-P) bonds of these enzyme intermediates by stable 
carbon-phosphorus (C-P) bonds, while preserving both the tetrahedral geometry of the 
phosphorus atom and the charge on the phosphoryl oxygen atoms. Their applicability to 
medicine is exemplified by the anti-malaria phosphonate antibiotic FR-900098 and its 
derivatives (Uh et al., 2011), antifungal rhizocticin (Kugler et al., 1990), antibacterial 
plumbemycin and the broad spectrum antibiotics fosfomycin (Falagas et al., 2008) and 
dehydrophos (Circello et al., 2011). Besides antibiotics, phosphonate molecules find extensive 
use in agriculture and industry as well. Phosphonate molecules are also essential phosphorus, 
carbon and nitrogen sources. In view of their utilization as growth sources by microbes, it is not 
surprising that microbes have evolved myriad mechanisms to hydrolyze the C-P bonds in 
phosphonates to release phosphate and the corresponding organic molecules (White and Metcalf, 
2007). These hydrolysis mechanisms offer unprecedented insights into varied reaction 
mechanisms of microbial secondary metabolism. 
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A ubiquitous phosphonate molecule in the microbial metabolome is phosphonoacetate 
(PnA). Though the biogenic origin of PnA had not been established until last year, the 
widespread prevalence of phosphonoacetate hydrolase enzyme in prokaryotes hinted towards 
dedicated PnA biosynthetic machinery being present as well. Indeed, the biosynthesis of PnA 
was subsequently established from the most widespread phosphonate molecule- 2-aminoethyl 
phosphonate (Borisova et al., 2011). In this work, we have structurally and biochemically 
characterized the PnA biosynthetic enzyme PhnY. PhnY oxidizes phosphonoacetaldehyde 
(produced by the transamination of 2-AEP) to generate PnA. Our structural and kinetic data 
establishes that PhnY borrows the mechanism and substrate recognition motifs from the essential 
primary metabolic enzyme – glyceraldehyde 3-phosphate dehydrogenase. Slight structural 
perturbations in the active site have rendered the enzyme specific towards phosphonate 
molecules, albeit at a kinetic cost. We have also determined the structure of, and established a 
mechanistic proposal for PnA hydrolase enzyme PhnA (Agarwal et al., 2011a). The active site of 
PhnA has been adapted from the ubiquitous alkaline phosphatase enzymes, though the 
stabilization of the reaction intermediate required a structural reorganization of the bi-metallo 
active site to accommodate the phosphonate molecule. Our findings for the PhnA enzyme further 
build upon the findings from a recent report of the structure of the PhnA enzyme (Kim et al., 
2011), albeit with a different mechanistic proposal for reaction intermediate stabilization. This 
body of work is also motivated by structural explanation for substrate specificity within the 
enzyme active site, and biochemical validation of the structural findings. 
As has been mentioned previously, and will be delineated in the subsequent chapters, we 
have relied heavily on high resolution structure determination by the technique of X-ray 
crystallography. All enzymes investigated have been co-crystallized in the presence of their 
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respective substrates and cofactors, and inhibitors where applicable. We have further employed 
myriad biochemical assays and site specific mutagenesis to probe the role of enzyme active site 
amino acids in catalysis and in generating substrate specificity. 
Through our findings we have attempted to build an appreciation for the immense 
untapped potential for the discovery of enzymatic chemistry involved in small molecule natural 
product biosynthesis, modification and degradation. Further sequencing of microbial genomes to 
discover cryptic small molecule gene clusters, together with metagenomic approaches to 
discover novel small molecule natural products within the microbial metabolome will further 
enrich this field.  
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Chapter 2: Structural and biochemical characterization of antibiotic microcin C7 
inactivating enzymes
1
 
Abstract 
Several classes of naturally occurring antibiotics target the aminoacyl tRNA synthetase 
(aaRS) enzymes. The aspartyl tRNA synthetase inhibitor microcin C7 (McC7) consists of an 
aspartyl-adenylate conjugated to a hexapeptide carrier that facilitates active import into bacterial 
cells through an oligopeptide transport system. Subsequent proteolytic processing releases the 
toxic compound inside the target cell. As the processing proteases are broad spectrum non-
specific enzymes, producing strains of McC7 must protect themselves against auto-toxicity that 
may result from premature processing within the producer cell itself. The mccF and mccE genes 
confer resistance against McC7 by hydrolyzing the amide bond that connects the peptide and 
nucleotide moieties of McC7, and acetylating the backbone primary amine of the antibiotic 
respectively. We have determined the wild type apo crystal structure of MccF and of 
catalytically deficient mutant form of the enzyme in complex with the processed form of McC7 
and various other substrate analogs. The MccF structure is similar to that of dipeptide LD-
carboxypeptidase, but with an additional loop proximal to the active site that serves as the 
primary determinant for recognition of adenylated substrates. Wild-type MccF only hydrolyzes 
1
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permission of the publisher and is available from http://www.pnas.org/ and using DOI: 
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the aminoacyl-nucleotide conjugates that contain anionic side chains. We show that substitutions 
of two active site MccF residues result in a specificity switch towards hydrophobic aminoacyl-
nucleotide substrates. We also demonstrate that the enzyme is promiscuous for the acceptance of 
anionic side chains conjugated to other purine nucleotides. These results suggest how MccF-like 
enzymes may be used to avert various toxic aminoacyl-nucleotides. We also present 
characterization data for the acetylation mechanism of MccE through biochemical and structural 
biological studies of the acetyltransferase domain of MccE. We establish the activity of MccE 
against processed McC7 by kinetic analysis and show that enzyme activity is inhibited by 
adenosine monophosphate (AMP).  The co-crystal structure of the MccE-acetyl CoA binary 
complex reveals a structural similarity with the Gcn5-acetyltransferase superfamily but with a 
novel aromatic platform located adjacent to the thioester.  Ternary complex structures of MccE-
acetyl CoA with AMP, and MccE-CoA with the substrate mimics aspartyl sulfamoyl adenosine 
(DSA) and glutamyl sulfamoyl adenosine (ESA) show a mode of substrate recognition similar to 
those found in cap binding proteins and nucleotidyltransferases.    The ternary complex of MccE-
acetyl CoA with processed McC7 reveals a product structure with the acetyl group located on the 
-amino moiety. These studies also demonstrate the biochemical potential of mechanisms for the 
resistance against future antibiotics which may be developed as derivatives of McC7 or other 
naturally occurring aminoacyl nucleotide conjugates. They also serve to lay a platform for the 
development of inhibitors of these enzymes to circumvent bacterial resistant against McC7 and 
other antibiotics targeting aaRS enzymes. 
  
16 
 
Introduction 
Aminoacyl tRNA synthetase enzymes 
Aminoacyl-tRNA synthetases (aaRSs) are essential components of the ribosomal protein 
synthesis machinery. AaRSs catalyze the attachment of the correct amino acid to its cognate 
transfer RNA (tRNA), which is then utilized by the ribosome to elongate a peptide chain (Ibba 
and Soll, 2000; Ling et al., 2009). The aaRS reaction can be divided into two half reactions. The 
first acylation reaction involves the formation of an enzyme bound aminoacyl-adenylate (Figure 
2.1), which is then resolved into aminoacylated-tRNA through nucleophilic attack of the 2’ or 3’-
hydoxyl of the terminal adenine ribose of the tRNA in the second reaction (Ibba and Soll, 2000). 
Inhibition of either one of these two enzymatic steps disrupts tRNA charging, which, in turn, 
stalls elongation of growing polypeptide chains (Tao and Schimmel, 2000). In addition, several 
aaRS enzymes also harbor proofreading catalytic activities, in which misacylation of tRNA with 
a non-cognate amino acid can be corrected. 
Several features highlight the suitability of these enzymes for drug discovery: a) the 
divergence between prokaryotic and eukaryotic aaRSs can be exploited for the development of 
drugs that only target the bacterial enzymes (Raczniak et al., 2001); b) each aaRS is 
phylogenetically conserved, and antimicrobials that target a particular bacterial aaRS have the 
potential to inhibit homologous enzymes from a range of other bacteria (Raczniak et al., 2001); 
and c) most bacterial species contain twenty distinct aaRSs, each representing an independent 
target for drug discovery (Hurdle et al., 2005; Pohlmann and Brotz-Oesterhelt, 2004). 
Consequently, research efforts over the last two decades have focused on the identification and 
characterization of these natural product aaRS inhibitors.  
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AaRSs as targets for antibiotic development 
Several naturally occurring small molecule antimicrobials target the aaRSs, validating 
these enzymes as drug targets (Kim et al., 2003; M. Ibba, 2005; Robert Chênevert, 2003; 
Vondenhoff and Van Aerschot, 2011). One class of such natural product aaRS inhibitors consist 
of the polyketides such as mupirocin (targets IleRS) (Thomas et al., 2010), reveromycin (targets 
IleRS) (Fremlin et al., 2011), borrelidin (targetsThrRS) (Otoguro et al., 2003), and granaticin 
(targets LeuRS) (Hurdle et al., 2005). Mupirocin is currently the world’s leading topical 
antibiotic for the treatment of methicillin resistant Staphylococcus aureus (MRSA) infections 
(Boyce, 2001), and borrelidin was shown to be effective against Plasmodium, the causative agent 
for malaria (Otoguro et al., 2003), besides its anti-angiogenesis properties. Successes have also 
been achieved with synthetic aaRS inhibitors, such as benzoxaborole compound AN-2690 that 
inhibits LeuRS (Baker et al., 2006; Rock et al., 2007). AN-2690 is currently under clinical trials 
for the treatment of onychomycosis (Alley et al., 2007), which is a fungal infection targeting the 
fingers and toenails. 
A second class of aaRS inhibitors consist of non-hydrolyzable analogs of the aminoacyl-
adenylate intermediate that is generated during the first aaRS half reaction (Tao and Schimmel, 
2000). While such inhibitors can be readily generated by synthetic chemistry methods, they are 
ineffective as antibiotics because these compounds can also inhibit human aaRSs (Heacock et al., 
1996) and most lack in vivo activity as they do not readily penetrate bacterial cells (Kim et al., 
2003; Schimmel et al., 1998). Nature has overcome this limitation by using a “Trojan horse” 
strategy for the deployment of aminoacyl-adenylate analogs into target bacteria. In essence, the 
active portion of the drug (i.e. the aminoacyl-adenylate) is conjugated with a specialized module 
that facilitates transport into bacterial cells.  Once inside the cell, the Trojan horse module is 
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removed to yield the active compound, which can then exert antibiotic activity. Examples of 
naturally occurring aminoacyl-adenylate analog-based antibiotics that employ this Trojan horse 
strategy include the LeuRS inhibitor agrocin 84 (Figure 2.2; linked through a phosphoramidate 
bond to a D-glucofuranosyloxyphosphoryl moiety) (Reader et al., 2005), the SerRS inhibitor 
albomycin (Figure 2.2; containing a covalent linkage to a hydroxymate siderophore) (Stefanska 
et al., 2000) and the AspRS inhibitor McC7 (Figure 2.2) (Metlitskaya et al., 2006). 
 
Mechanism of resistance against aaRS inhibitors 
 The overarching chemical scheme for conferring resistance against aaRS inhibitors in 
producing strains is the presence of an additional aaRS enzyme (Ataide and Ibba, 2006; Hurdle 
et al., 2005). Mutations within the non-resistant housekeeping aaRS can also mediate immunity 
against the action of the antibiotic, though these mutations have usually been associated with 
fitness costs to the cell. Examples of biochemically characterized resistant aaRSs are encoded 
within the biosynthetic clusters of mupirocin, borrelidin, and agrocin84. In addition to these 
compounds, resistant aaRS enzymes have also been found for the TrpRS inhibitor indolmycin 
(Kitabatake et al., 2002; Vecchione and Sello, 2009) the trojan horse SerRS inhibitor albomycin 
(Zeng et al., 2009) and high throughput screening derived MetRS inhibitors SB-362916 and SB-
441513 (Gentry et al., 2003) among other examples. Genome sequencing and phylogenetic 
analysis studies suggest that these antibiotic resistant aaRS alleles are widespread in the 
microbiota, (Brown et al., 2003) which raises the possibility that the efficacy of the aaRS 
inhibitors as antibiotics may already be compromised. Most naturally occurring inhibitors target 
aaRS enzymes that adenylate and transfer hydrophobic or amphipathic amino acids. Inhibitors 
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that target aaRSs that utilize polar amino acids have not been found in the natural microbial 
metabolome, and to the best of our knowledge, small molecule high throughput screening 
strategies have not identified lead compounds against these aaRS enzymes (Payne et al., 2007). 
McC7 represents the only known compound that targets an aaRS enzyme for a charged 
hydrophilic amino acid transfer. 
 
Structure and antimicrobial activity of McC7 
McC7 was first isolated from Escherichia coli H22 in 1984 (Garcia-Bustos et al., 1984; 
Garcia-Bustos et al., 1985) and subsequent structure determination revealed that the drug 
consists of a heptapeptide (Met-Arg-Thr-Gly-Asn-Ala-Asp) with a formyl group at the 
methionine amino terminus and an adenylate linked at the main chain carboxyl of the terminal 
aspartyl residue through a phosphoramidate bond (Guijarro et al., 1995) (Figure 2.2). In addition 
to containing the carboxy-terminal aspartyl acyl-AMP anhydride mimic, McC7 is also esterified 
at the N-acyl phosphoramidate group via a 3-aminopropyl appendage. Functional studies 
demonstrate that aminopropylation contributes significantly to the potency of McC7, as half-
inhibition of AspRS with either a non-hydrolyzable aspartyl sulfamoyl-adenylate (DSA) or 
McC7 lacking the aminopropyl group requires a 10-fold higher concentrations than with mature 
McC7 (Metlitskaya et al., 2009). McC7 in its intact form is not bioactive. 
Bioactivity for McC7 is generated by the cleavage of the first six residues of the McC7 
heptapeptide to generate processed McC7 (2) (Figure 2.7). Processed McC7 consists only of the 
terminal aspartyl residue connected to the adenine nucleotide by a phosphoramide bond, and the 
aminopropyl appendage upon the phospho- oxygen atom. Processed McC7 thus mimics the 
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aspartyl adenylate formed by the aspartyl tRNA synthetase (AspRS) enzyme (1), and can thus 
bind to the AspRS active site to inhibit the charging of tRNA
Asp 
(Metlitskaya et al., 2006). 
Modeling studies suggest that the aminopropyl group likely binds to a pocket adjacent to the 
active site of its target AspRS (Metlitskaya et al., 2009). Processed McC7 is bioactive against 
several members of the Enterobacteriaceae family (Garcia-Bustos et al., 1985). The producer 
strain of McC7 – E. coli H22, was shown to inhibit the growth of the human pathogen Shigella 
flexneri and subsequently results in the clearance of the pathogen from the gut of gnotobiotic 
mice (Cursino et al., 2006). 
 
Biosynthesis of McC7 and the Trojan horse mechanism of action 
The McC7 biosynthetic cluster from E. coli H22 consists of six genes consisting of ORFs 
that encode for both production and autoimmunity (Gonzalez-Pastor et al., 1995). Subsequently, 
function of several of these genes has been experimentally verified, and the biochemical route 
for McC7 maturation has also been established (Figure 2.3) (Kazakov et al., 2008; Metlitskaya et 
al., 2009; Novikova et al., 2010; Novikova et al., 2007; Severinov et al., 2007; Tikhonov et al., 
2010).  The mccA gene codes for a seven-residue, ribosomally-synthesized peptide that 
represents one of the smallest structural gene identified (Gonzalez-Pastor et al., 1994). The 
MccA heptapeptide is carboxy-terminally conjugated to AMP by MccB to yield an unprocessed 
McC7 precursor (i.e. the seven-residue peptide with the carboxy-terminal adenylate). 
Biochemical reconstitution of the reaction in vitro demonstrates that two stoichiometric 
equivalents of ATP are consumed and the reaction proceeds through a cyclic succinimide 
intermediate (Roush et al., 2008). The reaction results in the conversion of carboxy-terminal 
21 
 
asparagine of unmodified MccA into an aspartate. Other genes in the cluster include mccC, 
which shares sequence identity with members of the major facilitator superfamily, and is likely 
the efflux pump for McC7 export. The mccD gene product contains signature motifs of an S-
adenosyl-methionine dependent enzyme, and the mccE gene product contains an amino terminal 
decarboxylase domain and a carboxy-terminal acetyltransferase domain. The combined actions 
of MccD and MccE were shown to be responsible for the installation of the propylamine ester on 
the nucleotide phosphate group (Metlitskaya et al., 2009) though the timing and function of these 
two enzymes remain to be determined. 
Following biosynthesis, the McC7 heptapeptide (adenylated at the carboxy terminus and 
esterified by propylamine at the nucleotide phosphate) is exported out of the producer cell, and 
taken up by sensitive bacterial strains by virtue of recognition of the heptapeptide by specific 
active transporters (YejABEF in the case of E. coli) (Novikova et al., 2007). Bacteria that lack 
this transporter have reduced virulence as this operon is necessary for competitive fitness 
(Eswarappa et al., 2008; Qimron et al., 2004; Yang et al., 1996). Once inside the target cell, 
McC7 is processed by a series of enzymatic steps. First, the formyl group is removed from the 
amino-terminal methionine by peptide deformylase. Deformylated McC7 is then progressively 
digested in the N to C direction by any one of three cellular aminopeptidases (PepA, PepB and 
PepN in E. coli) (Kazakov et al., 2008). Upon hydrolysis of the peptide bond connecting the 
sixth and seventh residues of the peptide, the toxic processed McC7 is released inside the target 
cell (Metlitskaya et al., 2009). It is only the processed form of McC7 that can inhibit AspRS. The 
first six amino acids of the peptide mediate the transport of the antibiotic inside the susceptible 
cells and their removal is necessary for antibiotic action. Hence McC7 is classified as a ‘Trojan 
horse’ antibiotic.  
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Mechanisms for self-immunity against McC7 
McC7 can be processed to its bioactive form within the producer cell, as the PepA-N 
proteases are present within E. coli H22 as well. This necessitates the presence of self-immunity 
mechanisms within the producer cell to protect against the action of the antibiotic. What is 
notable is that McC7 resistance is not mediated by a resistant AspRS enzyme, but rather through 
the different mechanism of chemical modifications of the antibiotic (Agarwal et al., 2011; 
Agarwal et al., 2012; Novikova et al., 2010; Tikhonov et al., 2010). Chemical modification 
mediated resistance against antibiotics, such as hydrolysis of polyketides and β-lactams, and 
acetylation and phosphorylation of aminoglycosides, has been documented before. However, this 
strategy is to date not found as a resistance mechanism against aaRS inhibitors and is therefore 
unique to McC7. 
Self-resistance against McC7 is mediated by the MccF enzyme, which has been 
experimentally shown to cleave the peptide bond between the main chain carboxylate of the 
aspartyl residue of processed McC7 and the nucleotide phosphoramine (Figure 2.3) (Tikhonov et 
al., 2010). The carboxy terminal domain of MccE (MccE
CTD
) also provides self-resistance for the 
producer cells against the action of processed McC7 by acetylating the antibiotic (Figure 2.3) 
(Novikova et al., 2010). Notably, MccE and MccF provide the only known examples of chemical 
modifications of an aaRS-targeting antibiotic to mediate resistance (Agarwal and Nair, 2012). In 
all other aaRS inhibitor antibiotics characterized, the principle mechanism for resistance has 
been the presence of an antibiotic resistant aaRS enzyme encoded by the biosynthetic cluster. It 
should also be noted that a McC7 resistant AspRS enzyme has not been isolated as yet.  
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Our studies described herein have structurally and biochemically characterized both 
immunity conferring enzymes for McC7- MccF and MccE
CTD
. Atomic resolution three 
dimensional structures for these catalysts have been determined using X-ray crystallography, and 
the structural findings have been corroborated with extensive biochemical analysis. These 
findings have been used to explain the substrate engagement and mechanism for MccF and 
MccE
CTD
. Structural and biochemical basis for the broad substrate scope for both enzymes has 
been established, with a view of development of resistance against other aaRS inhibitor 
molecules which can compromise their antibiotic efficacy. 
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Experimental procedures 
Cloning, protein expression and purification 
The construction of plasmid DNA bearing the wild type and Ser118Ala mutant MccF 
enzymes has been described previously (Tikhonov et al., 2010). These plamids were generously 
provided to us by the Severinov laboratory (Rutgers, The State University of New Jersey). All 
mutants were constructed using standard site directed mutagenesis protocols. All plasmids were 
sequeced (ACGT Inc., Wheeling- IL) to verify the site of mutagensis.  
The gene encoding the C-terminal acetyl transferase domain of MccE, encoded by amino 
acids 405 to 589 was amplified using the polymerase chain reaction with forward primer 5’-
AAGCAGCCGCATATGCGGAAGTATGATGTATCTCTTACGCC bearing an engineered 
NdeI restriction site (underlined) and the reverse primer 5’-
CTAGCTCGAGTTAACCAATTACTTTCGAATAAATATTTTGATC with an engineered XhoI 
restriction site (underlined). The PCR product was purified, and following restriction digest, was 
ligated into pET28a(+) plasmid (Novagen) to yield an amino-terminal hexa-histidine tag and a 
thrombin digestion site preceding the inserted gene.  The plasmid was sequenced to confirm the 
integrity of the coding sequence. 
MccF wild type and all MccF mutant enzymes were purified under identical conditions. 
All plasmids were transformed into competent E. coli Rosetta2(DE3) strains for recombinant 
protein expression. A single colony of the transformed cells was grown overnight in Luria-
Bertani (LB) medium supplemented with 100 µg/mL ampicillin and 25 µg/mL chloramphenicol. 
This was subsequently used to innoculate 6 L of LB medium similarly supplemented with 
antibiotics, and grown at 37° C till the O.D. at 600 nm reached 0.6. Isopropyl β-D-
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thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM and the culture was 
shifted to 18° C and grown for an additional 16 hours. All subsequent steps were performed at 4° 
C. The bacterial cells were harvested by centrifugation and resuspended in 20 mM Tris-HCl (pH 
8.0), 500 mM NaCl, 10% glycerol buffer and lysed by multiple passes through an Avestin C5 
homogenizer. The cell lysate was clarified by centrifugation and the supernatant was loaded onto 
a 5 mL bed volume His-Trap column (GE Biosciences) equilibrated with lysis buffer. 
Subsequent to loading, the column was extensively washed with 20 mM Tris-HCl (pH 8.0), 1 M 
NaCl, 30 mM imidazole buffer and eluted by a continous linear gradient to 250 mM imidazole 
concentration in the wash buffer. Protein purity was analyzed by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) and greater than 95% pure fractions were 
applied to Superdex-75 16/60 size exclusion chromatography column (GE Biosciences). The 
protein was isochratically eluted in 20 mM HEPES-Na (pH 7.5), 100 mM KCl buffer and 
concentrated to 0.6 mM final concentration before being flash frozen in liquid nitrogen and 
storage at -80° C in small aliquouts. For the purification of the MccF Asn220Leu/Lys247Leu 
mutant enzyme, all buffers were supplemented with 10% glycerol. 
Selenomethione incorporated MccF wild type enzyme was prepared by previously 
established protocols (Van Duyne et al., 1993). Culture was grown under identical conditions in 
M9 minimal medium supplemented with antibiotics and 5 g/L D-glucose. When the O.D. reached 
0.4, 100 mg/L L-leucine, 100 mg/L L-lysine, 100 mg/L L-valine, 50 mg/L L-threonine, 50 mg/L 
L-phenylalanine and 50 mg/L L-isoleucine amino acids were added to the culture medium. After 
20 minutes of further growth at 37° C, 50 mg/L L-selenomethione amino acid was added to the 
culture medium. When the O.D. reached 0.6, culture was induced with IPTG and grown for an 
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additional 16 hours at 18° C. The selenomethionine derivitized protein was purified identically to 
the wild type and mutant forms of MccF. 
The plasmid bearing the MccE
CTD
 was similarly transformed into competent 
Rosetta2(DE3) cells and recombinant protein expression carried out under identical conditions. 
The media was supplemented with 50 µg/mL kanamycin and 25 µg/mL chloramphenicol. The 
recombinant protein bearing the hexahistidine tag was isolated by Ni-NTA chromatography 
using the same protocol as that for the MccF enzyme. Greater than 95% pure fractions thus 
obtained were extensively dialyzed against 20 mM Tris-HCl (pH 8.0), 500 mM NaCl with the 
addition of 1 unit/mg of thrombin enzyme to proteolytically remove the hexahistidine tag. SDS-
PAGE was used to verify the complete digestion of the hexahistidine tag. The protein was 
concentrated and applied to Superdex-75 16/60 size exclusion chromatography column. The 
protein was isochratically eluted in 20 mM HEPES-Na (pH 7.5), 100 mM KCl buffer and 
concentrated to 0.6 mM final concentration before being flash frozen in liquid nitrogen and 
storage at -80° C in small aliquouts. All mutants of MccE
CTD
 were purified in an identical 
manner. 
 
Protein crystallization, X-ray diffraction data collection and structure determination 
Crystals of the apo MccF wild type enzyme and all other variants were grown using the 
hanging drop vapor diffusion technique. Commercially available sparse matrix crystallization 
screens were used to identify initial crystallization conditions. Three crystallization conditions 
could be reproduced- (i) 12% PEG 20000, 0.1 M MES-Na (pH 6.5) (ii) 10% PEG 8000, 8% 
ethylene glycol, 0.1 M HEPES-Na (pH 7.5), and (iii) 0.1 M Tris-HCl (pH 8.5) 8% PEG 8000. 
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Typically, 1 L of the protein (9 mg/mL in 20 mM HEPES-Na (pH 7.5), 100 mM KCl) was 
added to 1 L of the crystallization condition and equilibrated against the same solution at 9o C. 
Selenomethionine-incorporated MccF was crystallized under similar conditions. Complex with 
processed McC7, aspartyl-sulfamoyl-adenosine (DSA), glutamoyl-sulfamoyl-adenosine (ESA), 
glutamoyl-sulfamoyl-inosine (ESI) and glutamoyl-sulfamoyl-guanosine (ESG) were generated 
by soaking apo crystals with 5 mM final concentration of substrate compounds added to the 
crystallization condition for 12 hours to 2 days.  Crystals of the MccF-Trp186Phe in complex 
with AMP were generated by incubating the protein with 50 mM AMP and subsequent 
crystallization using the previous conditions. Crystals were vitrified by soaking in crystallization 
condition supplemented with 30% ethylene glycol prior to direct immersion in liquid nitrogen. 
All X-ray diffraction data was collected at the Life Sciences Collaborative Access Team (Sector-
21), Argonne National Laboratory, Lemont- IL. 
Initial crystallographic phases were determined by single wavelength anomalous 
diffraction utilizing anomalous scattering from the five selenium-substituted methionine residues 
per monomer of MccF. A four-fold redundant data set was collected from crystals of 
selenomethionine-incorporated MccF at the selenium absorption edge, to a limiting resolution of 
1.45 Å (overall Rmerge = 7.2, I/σ (I) = 13.7 in the highest resolution shell) utilizing a Mar 300 
CCD detector.  Data were indexed and scaled using the HKL2000 package (Otwinowski et al., 
2003). Selenium sites were identified and refined for phase calculation using HySS (Grosse-
Kunstleve and Adams, 2003), yielding an initial figure of merit of 0.439 (acentric/centric = 
0.454/0.137) to 1.45 Å resolution. The resultant electron density map was of exceptional quality 
and permitted most of the main-chain and 50% of side-chain residues to be automatically built 
using the phenix-autobuild procedure (Terwilliger et al., 2008). The remainder of the model was 
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fitted using Coot (Emsley and Cowtan, 2004) and further improved by rounds of refinement with 
REFMAC5 (Murshudov et al., 1997) and manual building. Subsequent rounds of model building 
and crystallographic refinement utilized data from a native crystal of MccF grown under similar 
conditions that diffracted to 1.30 Å resolution (overall Rmerge = 6.5, I/σ (I) = 6.7 in the highest 
resolution shell). Cross-validation, using 5% of the data for the calculation of the free R factor, 
was utilized throughout the model-building process in order to monitor building bias (Kleywegt 
and Brunger, 1996). 
The crystal structures of MccF mutants Ser118Ala, Asn220Ala/Lys247Ala/Ser118Ala 
and Trp186Phe in complex with AMP were determined to resolutions of 1.5 Å, 1.7 Å and 1.5 Å, 
respectively, and MccF-Ser118Ala co-crystal structures with DSA, ESA, ESI, ESG and 
processed McC7 to resolutions of 1.5 Å, 1.3 Å, 1.2Å, 1.23 Å and 1.3 Å respectively, were 
determined by molecular replacement using the coordinates of wild type apo MccF as a search 
probe. Each of the structures was refined and validated using the procedures detailed above. For 
each of the structures, the stereochemistry of the model was monitored throughout the course of 
refinement using PROCHECK (Laskowski et al., 1996).  
Initial crystallization conditions for MccE
CTD
 were obtained by sparse-matrix sampling 
method using commercial screens. Crystals of MccE
CTD
 were grown using the hanging vapor 
drop diffusion method. For crystallization of the apo protein, 1 µL of protein at 13.5 mg/mL 
concentration, incubated with 2 mM acetyl coenzyme A (acetyl CoA), or coenzyme A (CoA), for 
2 hours on ice, was mixed with 1 µL of precipitant solution (50 mM magnesium chloride, 50 
mM HEPES-Na (pH 7.0), 25% PEG550MME) and equilibrated over a well containing the 
precipitant solution at 9° C. Co-crystallization for substrate complexes involved further 
incubation of the protein with 5 mM of substrates for 1 hour on ice.  Crystals grew within 3 days 
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and were briefly soaked in precipitant solution with PEG concentration increased to 30% prior to 
flash-cooling in liquid nitrogen.  Ternary complex co-crystal structures with AMP, processed 
McC7, DSA, and ESA were grown under similar conditions and manipulated in the same 
manner. Co-crystals with AMP required incubation with 50 mM substrate prior to crystallization. 
The structure of MccE
CTD
-acetyl CoA complex was determined by molecular 
replacement (McCoy, 2007; McCoy et al., 2007; Qimron et al.) using the coordinates of a 
putative acetyltransferase (PDB entry 1NSL; 35% sequence identity), whose structure was 
determined by the Midwest Consortium for Structural Genomics (Brunzelle et al., 2004).  Use of 
the full-length structure as a search probe failed to yield a successful MR solution.  Noting the 
conservation in primary sequence was limited over the amino-terminal seventy residues, further 
efforts at MR utilized a model from which the amino terminal 70 residues were removed.  One 
such model, in which all non-conserved residues were changed to serine, resulted in two MR 
solutions without any packing clashes that were consistent with the self-rotation function data, 
with minimal clashes.  Following rigid body refinement of the initial MR solution, phases from 
the resultant model were further improved by two-fold density averaging and the use of Prime-
and-Switch maps (Adams et al., 2002; Terwilliger et al., 2008), allowing for a significant portion 
of the model to be manually rebuilt using XtalView (McRee, 1999).  Further manual fitting was 
interspersed with automated rebuilding using ARP/wARP (Perrakis et al., 1997) and rounds of 
refinement using REFMAC5 (Murshudov et al., 1997; Murshudov et al., 1999).  Cross-
validation, using 5% of the data for the calculation of the free R factor (Brunger, 1992), was 
utilized throughout model building process in order to monitor building bias.  Although clear 
density for acetyl CoA could be observed prior to crystallographic refinement, the ligand was 
manually built into the model only after the free R factor dropped below 30%. The 
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stereochemistry of the models was routinely monitored throughout the course of refinement 
using PROCHECK (Laskowski et al., 1996). 
 
The crystal structures of the MccE
CTD
-acetyl CoA ternary complex with AMP, McC7, 
DSA and ESA were all determined by the molecular replacement method using the final refined 
coordinates of the MccE
CTD
-acetyl CoA complex as a search probe. Multiple rounds of manual 
model building were interspersed with refinement using REFMAC5 to complete structure 
refinement.  Cross-validation used 5% of the data in the calculation of the free R factor.  Crystal 
parameters, data collection parameters and refinement statistics for each of the structures are 
summarized in Table 2.5. 
 
End point assays to monitor  hydrolysis of synthetic sulfamoyl nucleotide substrate analogs 
by wild type MccF enzyme 
Purified MccF enzyme was diluted to a final concentration of 0.2 µM in 20 mM HEPES-
Na (pH 7.5) buffer and incubated with 200 µM of substrates for 60 minutes in 75 µL assay 
volume at room temperature. The assays were quenched with equal volume of 4% formic acid 
and heating at 80° C for 10 minutes. The reactions were centrifuged and 100 µL volume was 
injected to a analytical C18 column (Vydac; 5 µm particle size, 4.6 × 250 mm) using an Agilent 
1260 high performance liquid chromatography (HPLC) system. Chromatography was performed 
using 2% acetonitrile as Buffer A and 80% acetonitrile as Buffer B. The elution gradient profile 
was as follows: wash with 5 mL of buffer A, elute with continous linear gradient to buffer B 
across 10 mL volume, wash with 5 mL Buffer B, reduce acetonitrile concentration to 2% using a 
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linear continous gradient across 4 mL volume, requilibrate with 6 mL Buffer A. All reactions 
were performed in triplicate. Peak fractions were manually collected and flash frozen in liquid 
nitrogen. The fractions were then lyophilized to dryness and resuspended in water. Electrospary 
ionization mass spectroscopy (ESI-MS) data was collected using a Waters Quattro II mass 
spectrometer equipped with a electrospray ion source at the Mass Spectrometry Laboratory at the 
School of Chemical Sciences, University of Illinois at Urbana Champaign. Control reactions 
lacking the enzyme were performed in identical conditions and similarly analyzed. 
 
Continuous coupled assay to determine the kinetic constants for the hydrolysis of ESA, ESI 
and ESG by wild type and mutant MccF enzymes  
Kinetics for cleavage of ESA, ESI and ESG by MccF was monitored by coupling the 
glutamate production to reduced nicotinamide adenine dinucleotide (NADH) generation by 
bovine glutamate dehydrogenase (bGDH) (Sigma G2626-50MG), which was monitored by 
continuous increase in absorbance at 340 nm wavelength using a Cary4000 UV-VIS 
spectrophotometer. The assays were performed at room temperature in 20 mM HEPES-Na 
(pH7.5), 100 mM KCl buffer. NAD
+
 and bGDH concentrations were kept fixed at 2 mM and 1.7 
µM respectively in the assays. Linear correlation between the initial rate of reaction and MccF 
enzyme concentration, at 500 µM substrate concentrations confirmed that the coupling 
enzymatic reaction was not rate limiting. MccF wild type enzyme and Trp186Phe, Arg246Ala, 
Asn220Ala and Lys247Ala mutants were assayed at 150 nM enzyme concentration. Ser118Ala, 
Trp186Ala and Asn220Ala/Lys247Ala mutants were assayed at 750 nM enzyme concentration. 
Baseline absorbance was observed for one minute before the reactions were initiated by the 
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addition of enzyme. All data points were collected in triplicate and kinetic parameters 
determined by fitting the data to the Michaelis-Menten equation. 
 
Discontinuous assay to determine the kinetic constants for the hydrolysis of DSA by wild 
type and mutant MccF enzymes 
Kinetics for the cleavage of DSA by MccF was determined by discontinuous HPLC 
separation of the reactant- DSA and product- sulfamoyl adenosine (SA) on an analytical scale 
C18 column (Vydac, 5μm particle size, 4.6 × 250 mm), monitored at 254 nm wavelength. MccF 
wild type, Asn220Ala and Lys247Ala mutant enzymes were assayed at 50 nM enzyme 
concentration. 75 µL enzymatic reactions were quenched by the addition of equal volumes of 4% 
formic acid and heating at 80º C for two minutes. 100 μL of the quenched reaction was injected 
to the C18 column and chromatography performed using 2% acetonitrile as buffer A and 80% 
acetonitrile as buffer B on an Agilent 1260 HPLC system. The elution gradient profile was as 
described previously. Different amounts of DSA without the addition of the enzyme were diluted 
into the reaction buffer, quenched and heated as above were injected, and a standard curve of the 
moles of reactant versus the area under the elution peak was determined. As the extinction 
coefficient of DSA and SA can be assumed to be the same at 254 nm wavelength, this standard 
curve was used to determine the number of moles of product formed in the subsequent enzymatic 
reaction time points. Measurements of the enzymatic rates were within the linear range of 
substrate turnover with respect to time, which was confirmed by the linear correlation between 
the measured initial rates and enzyme concentration across four different enzyme concentrations 
for each substrate concentration used. All data points were collected in triplicate and kinetic 
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parameters determined by fitting the data to the Michaelis-Menten equation. Steady state kinetic 
parameters for DSA hydrolysis by the Asn220Ala and Lys247Ala mutant enzymes were 
determined in an identical manner. 
 
Discontinuous assay to monitor the hydrolysis of FSA by MccF mutant enzyme 
Hydrolysis of phenylalanine-sulfamoyl-adenosine (FSA) by MccF-
Asn220Leu/Lys247Leu  was monitored in a manner identical to the kinetics determination of 
DSA hydrolysis by wild type MccF. 135 μM FSA was incubated with 450 nM of MccF-
Asn220Leu/Lys247Leu enzyme at room temperature in 20 mM HEPES-Na (pH 7.5) buffer. 
Enzyme dilutions were made in 20 mM HEPES-Na (pH 7.5) 100 mM KCl buffer. Reactions 
were initiated by the addition of enzyme. Aliquots from the reaction mixture were taken at 
different time points, quenched and substrate and products were separated by HPLC. Substrate 
and product peak elution fractions were collected, lyophilized and dissolved in water and 
analyzed by ESI-MS to confirm the identity of the substrate and product chemical species. 
Calibration curve between number of moles of substrate and area under the substrate peak was 
generated and used to calculate the amount of substrate consumed at different time points. 
 
Isothermal titration calorimetry to determine disassociation constant for binding of AMP 
to MccE
CTD
 
Measurements were made at 25° C using a VP-ITC calorimeter (MicroCal, Inc, 
Northampton, MA). Protein after size exclusion chromatography was extensively dialyzed 
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against 50 mM potassium phosphate buffer (pH 7.0) and concentrated to a final concentration of 
0.2 mM, followed by incubation with a final concentration of 0.5 mM acetyl CoA for 1 hour on 
ice. A stock of (AMP) at a concentration of 50 mM was prepared in the spent dialysis buffer. The 
protein sample in a 1.4495 mL reaction cell was injected with 25 successive 10 µL aliquots of 
(AMP) at a spacing of 300 seconds, with spent dialysis buffer in the reference cell. Based on the 
crystallographic results, the number of binding sites for (AMP) was presumed to be one. Data 
was fitted by nonlinear regression using a single site binding model (MicroCal Origin), and 
thermodynamic parameters were calculated using the Gibbs free energy equation (ΔG = ΔH - 
TΔS), and the relation –RTlnKa = ΔG. 
 
Continuous assay to determine MccE
CTD
 kinetic parameters 
Reaction rates were measured spectrophotometrically by determining the rate of increase 
in absorbance at 412 nm due to the reaction between the free sulfhydryl group of CoA, generated 
by the enzymatic transfer of the acetyl group from acetyl CoA to the substrate molecule, and 
5,5’-dithiobis(2-nitrobenzoic acid) (DTNB). The assays were performed at room temperature in 
a final volume of 100 µL and monitored continuously using a CARY UV-VIS 
spectrophotometer. Each reaction consisted of 2.5 mM final concentration of DTNB and 1.5 mM 
acetyl CoA. Five different substrate concentrations were used and the assays were initiated by 
the addition of the enzyme to a final concentration of 100 pM and the increase in absorbance was 
monitored for 5 minutes. Rates for each substrate concentration were measured in triplicate. 
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Results and discussion 
MccF overall three dimensional structure and description of the catalytic triad 
MccF wild type structure in the apo state was determined by single wavelength 
anomalous dispersion to a resolution of 1.2 Å and refined to R/Rfree of 0.184/0.201. The relevant 
data collection and refinement statistics are presented in Table 2.1. Barring the hexa-histidine 
tag, six residues at the N-terminus and three residues at the C-terminus, all amino acids have 
been described in the final model. The model also incorporates several molecules of ethylene 
glycol which bear their origin to the crystallization condition and cryo-protectant. The crystal 
asymmetric unit consists of two monomers, and represents a single biological homodimer unit as 
determined by analytical size exclusion chromatography. A total surface area of 3681 Å
2
 is 
occluded between the two monomer chains. Multiple hydrogen bonds exist at the dimer interface 
between basic arginine side chains and acidic carboxylate and hydroxyl side chains. One of these 
interactions is the hydrogen bond between the side chain of Arg254 of one monomer and Thr223 
of the other monomer. Mutation of Arg254 to alanine resulted in insoluble protein, which is 
suggestive of disruption of dimer packing due to loss of these hydrogen bonding interactions.  
Each MccF monomer can be divided into three distinct domains (Figure 2.4A). The 
amino terminal domain comprises of residues 7-164 and is made up of four parallel β sheets 
flanked by α helices on either side of β sheet. It is followed by a rather unusually long single 
loop made up of residues 165-208 which is henceforth referred to as the ‘catalytic loop’. The 
carboxy terminal domain is made of residues 209-341 and has a six membered mixed β sheet 
flanked by three α helices on one side of the sheet.  The catalytic loops are positioned in between 
the amino and carboxy terminal domains. Dimerization is mediated by helices and loops from 
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both the amino and carboxy terminal domains and the catalytic loops are positioned opposite to 
the dimerization surface. Two α helices from the carboxy terminal domains contact each other at 
the dimer interface and essentially provide all the substrate recognition residues for coordination 
of the substrate acidic side chain (vide infra) (Figure 2.4B). The MccF dimer forms a solvent 
exposed concave cavity which houses both the monomer active sites which point towards each 
other. 
Numerous contacts exist between residues of the catalytic loop and the side chain and 
main chain atoms of the amino and carboxy termini domains. These interactions serve to position 
the catalytic loop correctly. Strong ion pair exists between the side chains of Glu182 and 
Arg193, which lends conformational rigidity to this extended loop region. The carboxy and 
amino terminal domain arrangements, and the secondary structure elements are conserved 
between MccF and the metal independent LD-carboxypeptidase (PDB ID: 1ZRS) (Korza and 
Bochtler, 2005), with the notable absence of the catalytic loop in the LD-carboxypeptidase crystal 
structure. Sequence alignment of MccF with LD-carboxypeptidases identifies greatest sequence 
divergence in the region encoding for the catalytic loop, and thus can be used as a differentiation 
marker to identify LD-carboxypeptidases mis-annotated as MccF like proteases in sequence 
databases (Figure 2.5). Analysis of MccF homologs’ catalytic loop sequences reveals that 
hydrophobic residues corresponding to Trp186 are conserved, suggesting that these proteins 
should also interact with adenylated targets. Curiously, many MccF homologs are encoded by 
genes that are not part of recognizable McC7-like biosynthetic operons. A recent crystal structure 
report of a MccF homolog from Bacillus anthracis, which is does not produce McC7 or any 
other known small molecule natural product of similar structure, has reported a nearly identical 
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arrangement of the catalytic loop tryptophan residue (Nocek et al., 2012). The intracellular 
function of these proteins remains to be determined. 
Serine proteases have been shown to catalyze peptide and ester bond hydrolysis by an 
extensively studied ‘charge relay’ mechanism which comprises of an invariant serine 
nucleophile, a general acid-base histidine and a carboxylate side chain from an aspartate or 
glutamate residue with the histidine side chain in hydrogen bonding distance to both serine and 
carboxylate side chains (Hedstrom, 2002). Crystal structure of MccF identifies the catalytic triad 
residues to be Ser118, His311 and Glu243, and is thus consistent with the earlier report of 
Ser118Ala mutant to be catalytically inactive (Tikhonov et al., 2010). The Glu243 side chain is 
buried in a polar environment with one of the oxygen atoms of the carboxylate side chain being 
hydrogen bonded to the Nδ1 of His311 side chain and also to a well ordered water molecule. The 
second oxygen atom is hydrogen bonded to Tyr137 side chain hydroxyl and side chain amide of 
Asn218. Nε2 atom of His311 side chain is appropriately placed at a distance of 2.8 Å from the 
Ser118 side chain hydroxyl to act as the general acid-base catalyst. Rather unexpectedly, 
alternate conformations can be assigned to the Ser118 side chain in one of the monomer active 
sites. Coordination with His311 is possible in only one of these conformations and the serine 
hydroxyl is hydrogen bonded to two well ordered water molecules in the other conformation. 
Two ethylene glycol molecules are bound on the other face of the catalytic triad in the other 
monomer. 
We next determined the 1.5 Å resolution crystal structure of the MccF-Ser118Ala mutant 
in the apo form to refinement statistics of R/Rfree 0.163/0.190 (Table 2.1). The alignment of the 
wild type structure to the Ser118Ala mutant structure unequivocally establishes that the loss in 
catalytic activity of the Ser118Ala mutant enzyme is due to the loss of the catalytic serine side 
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chain hydroxyl nucleophile, as all catalytic site and neighboring residue side chains align very 
well with each other and no major overall structural changes are apparent. Hence we hypothesize 
that the co-crystal complexes of the MccF-Ser118Ala enzyme with different substrate molecules 
are descriptive of the productive state of substrate binding by MccF. 
 
Crystal structure of MccF-Ser118Ala enzyme in complex with the physiological substrate- 
processed McC7 
In order to delineate the interactions between processed McC7 and MccF enzyme, 
crystals of the catalytically inactive MccF-Ser118Ala mutant were grown and soaked with 
processed McC7. The difference electron density maps displayed unambiguous density for 
processed McC7 in both subunits of the enzyme, and were used to model in the processed McC7 
molecule to obtain a model at 1.3 Å resolution which has been refined to R/Rfree of 0.174/0.186 
(Table 2.1) (Figure 2.6). Analogous to extensive literature on serine proteases, the interactions of 
the processed McC7 molecule are herein described with reference to the nucleotide binding site 
as the P1 site, and the aspartate side chain of processed McC7 as the P1’ interaction site. 
The interactions at the P1 site are primarily modulated by the π-stacking interactions of 
the adenine ring of processed McC7 and coordination of the 2’ and 3’ ribose hydroxyls (Figure 
2.6). The adenine ring stacks against the indole side chain of the residue Trp186. The Trp186 
residue is harbored on the ‘catalytic loop’ (Figure 2.4), and is thus absent from the LD-
carboxypeptidase active site (Korza and Bochtler, 2005) (Figure 2.5). The absence of a co-crystal 
structure of the LD-carboxypeptidase LcdA with its physiological substrate precludes the 
comparison of the substrate binding sites of the two enzymes, though the absence of the catalytic 
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loop provides a possible explanation for the reported inability of LcdA to detoxify McC7 and its 
analogs (Tikhonov et al., 2010). 
The 2’ and 3’ hydroxyl groups of the ribose sugar are respectively positioned 2.9 Å and 
2.7 Å away from the side chain carboxylate oxygen atoms of Glu277 and engage in hydrogen 
bonding interactions. The 2’ hydroxyl is also positioned 2.7 Å away from guanidine side chain of 
Arg246, which in turn is also hydrogen bonded to Ser183 side chain hydroxyl. Interaction 
between carboxy terminus domain residue Arg246 and catalytic loop residue Ser183 could play a 
role in maintaining the proper conformation of the catalytic loop, and thus the positioning of the 
Trp186 side chain for stacking with the adenine group of McC7. This is also exemplified by an 
extensive set of hydrogen bonding and salt bridge interactions formed by the polar residues in 
the primary sequence vicinity of Trp186, which lend rigidity to the conformation of the catalytic 
loop.  
Interaction with the enzyme backbone atoms stabilize the oxyanion reaction intermediate, 
with the carbonyl oxygen of the phosphoramidate linkage positioned 3.05 Å and 2.8 Å away 
from the backbone amide nitrogen atoms of Asp119 and Gly92 respectively. One of the 
phosphate oxygen atom is positioned 2.95 Å away from the backbone amide nitrogen of Gly91. 
Unexpectedly, the propylamine appendage to the phosphate is fully extended and pointing 
outwards from the active site. The terminal primary amine does not find any interaction partners, 
and neither is the propyl chain buttressed by hydrophobic side chain residues. Similar lack of 
interactions for the propylamine appendage were observed in the crystal structure of MccE
CTD
 
with processed McC7 (PDB ID: 3R9G) (Agarwal et al., 2011). However the conformation of 
processed McC7 is very different in the two structures. While the aspartate side chain and 
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propylamine appendage are essentially parallel for MccE
CTD
, they are perpendicular to each 
other for MccF (vide infra).  
The aspartate side chain of processed McC7 is coordinated at the P1’ position of the 
MccF active site. One of the carboxylate oxygen atoms is bound to the side chain of Lys247 and 
is positioned 3.1 Å away from it (Figure 2.6). The other carboxylate oxygen is 2.9 Å away from 
the side chain amide nitrogen of Asn220. This oxygen atom is also tightly coordinated by the 
guanidine side chain of an alternate conformation of Arg254 residue from the other MccF 
monomer (shown in grey in Figure 2.6). The distance between the oxygen atom and the 
guanidine nitrogen atoms is 3.05 Å and 2.9 Å. In the other conformation of Arg254 side chain, it 
mediates dimerization between the MccF monomers by coordinating to the Thr223 side chain 
hydroxyl as observed in the MccF wild type apo enzyme structure. The guanidine nitrogen atoms 
of Arg254 are also 3.2 Å and 3.25 Å away from the side chains of Asn220 and Thr221 
respectively, of the other MccF monomer. These alternate conformations of Arg254 side chain 
and synergistic substrate binding interactions described here are observed for both MccF 
monomers. Side chains of Thr221 and Asn218 also point inwards towards the highly polar 
tightly coordinated substrate binding site. It should be noted that Asn218 also modulates the 
correct positioning of the catalytic triad residue Glu243. 
MccF can also hydrolyze and inactivate unprocessed McC7, in which the hexapeptide 
Trojan horse has not been cleaved off (Tikhonov et al., 2010). Our numerous attempts at crystal 
soaking as well as co-crystallization with intact McC7 failed to yield the substrate in the active 
site of the enzyme. However, the co-crystal structure of MccF-Ser118Ala in complex with 
processed McC7 offers rationale for acceptance of McC7 as a substrate by the enzyme. The 
amino terminal backbone nitrogen atom of processed McC7 is positioned without any specific 
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contacts with the enzyme, and points outwards from the active site. Peptide elongation upon that 
nitrogen atom would most probably lead to the Trojan horse carrier hexapeptide being solvent 
exposed without specific interactions with the MccF enzyme. Also the McC7 amino acid 
immediately upstream of the aspartate residue is an alanine, which could easily be 
accommodated in the solvent exposed substrate binding site of MccF without creating steric or 
conformational clashes with the enzyme. 
 
Structure and kinetics for hydrolysis of synthetic sulfamoyl adenylates of aspartate and 
glutamate by MccF 
 Numerous in-vitro assays were unsuccessfully trialed to measure the kinetics for the 
hydrolysis of processed McC7 by MccF. The hydrolysis products of processed McC7 could not 
be detected by coupling to an aspartate dehydrogenase enzyme (Yang et al., 2003), nor could be 
retained reproducibly on HPLC reverse phase or ion exchange columns. Attempts at derivatizing 
the primary amines, or the free carboxylates of the processed McC7 hydrolysis products for 
detection by gas chromatography mass spectroscopy (GC-MS) were also unsuccessful. Hence, 
we shifted our attention to synthetic sulfamoyl adenylates of aspartate (DSA) (3 in Figure 2.7) 
and glutamate (ESA) (4) to monitor the kinetics of hydrolysis by MccF wild type and mutant 
enzymes. These synthetic substrates were previously reported to be accepted as substrates by the 
MccF enzyme, as well as inhibit bacterial growth with an identical mode of action as that for 
McC7 (Novikova et al., 2010; Tikhonov et al., 2010; Van de Vijver et al., 2009a; Van de Vijver 
et al., 2009b). Synthetic aminoacyl sulfamoyl adenylates have been demonstrated to inhibit 
various other cellular primary and secondary metabolic processes which involve adenylated 
enzyme intermediates and have thus gained attention as antibiotic candidates (Finking et al., 
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2003; Gutierrez-Lugo and Bewley, 2011; May et al., 2005; Qiao et al., 2007; Tremblay et al., 
2008). 
Hydrolysis of both ESA and DSA was found to be tractable by kinetic assays and HPLC 
analysis (Figure 2.7B). ESI-MS on the HPLC purified reactants and products for the MccF 
catalyzed hydrolysis of DSA and ESA substrates confirmed the site of hydrolysis (Figure 2.8). 
The mode of binding for DSA and ESA by the enzyme was determined by crystal structure of 
MccF-Ser118Ala mutant in presence of both substrates (Figure 2.9) (Table 2.2).  
 Inability of the MccF-Ser118Ala mutant enzyme to hydrolyze DSA and ESA was 
confirmed spectrophotometrically and by HPLC analysis. In order to delineate the interactions 
between ESA and MccF enzyme, crystals of the catalytically inactive Ser118Ala mutant were 
obtained and soaked with ESA. The difference electron density maps displayed unambiguous 
density for ESA in both subunits of the enzyme, and were used to model in the ESA molecule to 
obtain a model at 1.3 Å resolution, which has been refined to R/Rfree of 0.179/0.197 (Figure 2.9).  
As observed in the crystal structure of MccF-Ser118Ala with processed McC7, the 
interactions at the P1 site for ESA are modulated by the π-stacking interactions of the adenine 
ring of ESA by Trp186 side chain. Mutation of Trp186 to phenylalanine resulted in a fourfold 
increase in the KM for the enzyme (Table 2.3). Crystal structure of the Trp186Phe/Ser118Ala 
mutant enzyme in the apo state shows that the phenylalanine side chain is essentially parallel to 
the indole ring for the wild type enzyme and thus can make stacking interaction with the 
substrate, which is further confirmed by the 1.5 Å resolution cocrystal structure of the MccF-
Trp186Phe mutant enzyme in complex with adenosine monophosphate (Figure 2.10). A 
Trp186Ala mutation resulted in complete loss of observable activity for the enzyme. The π-
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stacking of the adenine ring is consistent with the mode of binding of McC7, and its analogs with 
the McC7 detoxifying enzyme MccE
CTD
, in which the adenine ring stacks between tryptophan 
and a phenylalanine side chains, mutations to alanine of either one of which lead to complete 
loss of activity of MccE
CTD 
(Agarwal et al., 2011). The 2’ and 3’ ribose hydroxyls are 
coordinated by side chains of Glu277 and Arg246. Mutation of Arg246 to alanine did not alter 
the kcat of the enzyme, but instead lead to a fivefold increase in the KM for the substrate. 
In contrast to identical interactions at the P1 site for ESA and processed McC7, 
variability was found at the P1’ site for ESA recognition. The glutamate side chain of ESA 
contacts both Asn220 and Lys247 side chains, but the ESA carboxylate is skewed towards the 
Lys247 primary amine. In contrast to the aspartate carboxylate of McC7 in which only one of the 
oxygen atoms contacted Lys247 side chain, both the ESA oxygen atoms are within hydrogen 
bonding distance of Lys247 now. Though one of the ESA oxygen atoms still contacts the 
Asn220 side chain amide, this coordination distance is now increased to 3.1 Å. This oxygen atom 
has also lost contacts with Asn218 and Thr221 side chains. This greater reliance on the side 
chain of Lys247 is evident from kinetic analysis as well. Mutation of Lys247 to alanine leads to 
over 30 fold reduction in the catalytic efficiency of the enzyme. Loss in the interaction with 
Asn220, by mutagenesis of Asn220 to an alanine, can be compensated by interactions of both 
oxygen atoms to Lys247, which is evident from only 2 fold increase in KM and no change in kcat 
for ESA hydrolysis. However mutation of both Asn220 and Lys247 residues to alanine lead to 
complete loss in detectable catalytic activity for the enzyme. Crystal structure of the MccF-
Asn220Ala/Lys247Ala/Ser118Ala mutant enzyme in the apo state (determined to a resolution of 
1.7 Å and R/Rfree 0.173/0.201) shows no rearrangement of the P1 site residues and hence loss in 
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activity can be attributed solely to the loss in coordination for the glutamate side chain of ESA at 
the P1’ site (Figure 2.11). 
The mode of stabilization of the oxyanion transition state formed during hydrolysis of 
ESA was found identical to that for processed McC7 described previously. The carbonyl oxygen 
atom of the amide bond is positioned 3.2 Å and 2.8 Å away from the backbone amide nitrogen 
atoms of Asp119 and Gly92 residues respectively. The other sulfate oxygen atom, which would 
carry the propylamine arm by analogy to the processed McC7 cocrystal structure, finds no 
interaction partners with the enzyme and is pointing outward from the active site. 
In order to confirm that the nature of aspartate chain coordination is preserved between 
DSA and processed McC7 we determined the co-crystal structure of MccF-Ser118Ala enzyme in 
complex with DSA to a resolution of 1.5 Å and to refinement statistics of R/Rfree of 0.181/0.202 
(Figure 2.9A). Briefly, the interactions at the P1 site, of the sulfamoyl oxygen atoms and the 
oxyanion hole are essentially identical to ESA and processed McC7 co-crystal structures. The 
DSA aspartate chain is also similarly coordinated as for processed McC7. The two carboxylate 
oxygen atoms are individually coordinated by Asn220 and Lys247. The oxygen atom 
coordinated by Asn220 (3.1 Å) is also in hydrogen bonding distance to Asn218 (3.3 Å) and 
Thr221 (3.1 Å) side chains. Thus the binding of DSA, which is distinct from that of ESA, 
mimics the binding of processed McC7 in the MccF active site.  
As estimated by the ratio of kcat/KM, cleavage of DSA appears to be about 8 fold more 
efficient than the hydrolysis of ESA by the enzyme (Table 2.3). This substrate preference is 
reflected by an order of magnitude higher turnover number for DSA, while the KM for the two 
substrates is comparable. This reflection of substrate preference by change of kcat and not KM is 
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in concert with the earlier work with serine proteases such as chymotrypsin, elastase and pepsin 
(Baumann et al., 1970, 1973; Sachdev and Fruton, 1975; Thompson and Blout, 1973), in which 
synthetic substrates designed with altered binding interactions at the P1’ and subsequent 
downstream binding subsites have lead to non-significant changes in the KM for these enzymes, 
while displaying large variations in the kcat. For MccF, the order of magnitude increase in kcat for 
DSA as compared to ESA can be attributed to the differential mode of stabilization of the 
acylenzyme transition state (formed after the departure of the adenine sulfonamide) in the active 
site. As the aspartate chain makes more contacts with the enzyme than the glutamate side chain, 
the activation energy for the formation of this transition state would be lower, leading to an 
increase in the rate of hydrolysis of DSA. It should also be noted that the mutations at the P1 
site- Trp186Phe and Arg246Ala, had much larger alterations in the KM values for ESA 
hydrolysis, and much less significant changes in kcat values. 
 
MccF active site can accommodate other purine nucleobases at the P1 site 
 In order to explore whether the MccF active site can accept nucleobases other than 
adenine at the P1 position, we investigated the hydrolysis of ESI (5 in Figure 2.12A) and ESG 
(6) by wild type MccF enzyme. ESI and ESG are identical to ESA except the identity of the 
nucleobases. Glutamyl nucleotide conjugates were chosen in place of aspartyl nucleotide 
conjugates for this study, as their hydrolysis could be monitored by a continuous coupled 
spectrophotometric assay, as opposed to a discontinuous HPLC based assay for DSA described 
previously. ESI and ESG were generously synthesized and provided by Gaston Vondenhoff and 
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Dr. Arthur Van Aerschot (Laboratory of Medicinal Chemistry, Rega Institute for Medical 
Research, Katholieke Universiteit Leuven, Belgium). 
Wild type MccF could indeed catalyze the efficient cleavage of both ESI and ESG, as 
judged by separation of the reactants and products by HPLC (Figure 2.12B). ESI-MS confirmed 
that the site of hydrolysis remained as the amide connecting the amino acid and the sulfamoyl-
amine (Figure 2.13). We next determined the crystal structure of MccF-Ser118Ala enzyme in 
complex with ESI and ESG to limiting resolutions of 1.2 Å and 1.23 Å respectively, with 
refinement statistics of R/Rfree of 0.159/0.175 and 0.155/0.172 respectively. 
As anticipated, MccF active site accommodates the glutamate side chain of ESI and ESG 
in an identical manner as that for ESA in the P1’ site. At the P1 site, the nucleotide ribose 2’ and 
3’ hydroxyls are also identically coordinated by Glu277. However slight variations are found in 
the π-stacking interactions with the indole side chain of Trp186. 
While π-stacking interactions can provide extensive surface area for van der Waals 
contact, such interactions result in electrostatic repulsion as the delocalized π-electrons result in a 
concentration of negative electrostatic potential. However, the electrostatic potential of 
heterocyclic adenine and guanine nucleobases of DNA/RNA differ markedly from that of 
homocyclic conjugated systems such as benzene. Calculations of the electrostatic potential map 
of adenine illustrates that the negative charge is concentrated on N1, N3, and N7, while C8 and 
N9 have significant positive potential (Boehr et al., 2002).  Similar studies on the electrostatic 
potential of tryptophan suggest a relatively greater negative potential on the six-member ring of 
the indole side chain, than on the five-member heterocycles (Dougherty, 1996). In the MccF-
Ser118Ala co-crystal structure with ESA, the side chain of Trp186 and the adenine ring of the 
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substrate are oriented to maximize favorable electrostatic interactions between the two 
heterocyclic π-electron systems (Figure 2.14A). The N1 and N3 of the adenine, which have the 
greatest negative potential, are positioned furthest away from the six-membered ring of the 
indole side chain (which would bear the greatest negative potential). In addition, the positive 
potential bearing C8 and N9 positions of the adenine are stacked nearest to the indole six-
membered ring. The electronegative N3 is also positioned near the basic guanidine side chain of 
Arg246. The two ring systems are aligned so as to minimize the electrostatic repulsion between 
the two heterocyclic π-electron systems. 
This juxtapositioning of the inosine nucleobase is nearly identical to that for adenine. 
However the KM for the hydrolysis of ESI (91 µM) is higher than that for ESA. This increase in 
KM for ESI can be attributed to a decrease in van der Waals contact with Trp186 side chain, as 
the inosine is not aromatic across the entirety of the fused heterocycles due to the presence of a 
double bonded carbonyl oxygen at the C6 atom of the inosine ring. This oxygen atom is also 
markedly electron rich, as revealed by electrostatic potential map of inosine (Schramm, 2007) 
which can cause electrostatic repulsion with the indole electron rich six member ring (Figure 
2.14B). The kcat for the hydrolysis of ESI, which has previously been shown to be dependent on 
the interactions in the P1’ site of the enzyme is nearly identical to that for ESA (Table 2.4). 
The guanine nucleobase is also not aromatic across the entirety of the fused heterocycles 
due to the presence of similar double bonded carbonyl oxygen at the C6 atom of the guanine 
ring. Hence the finding that the KM for the hydrolysis of ESG (33 µM) is lower than that for ESA 
was unexpected. However the cocrystal structure of MccF with ESG provides a rationale for this 
kinetic observation. The primary amine at the C2 carbon atom of the guanine ring is hydrogen 
bonded to the side chain hydroxyl of Ser183. This hydrogen bonding also causes a slight rotation 
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of the guanine ring, as compared to the adenine ring of ESA, so that it makes more extensive van 
der Waals contact with the six member ring of the Trp186 indole (Figure 2.14C). Consistent with 
our previous hypothesis, the kcat for ESG hydrolysis was found to be nearly the same as that for 
ESA hydrolysis (Table 2.4). 
These results demonstrate that the MccF active site can indeed accept different purine 
nucleobases at the P1 site and accommodate different length of carboxylate side chains at the P1’ 
site, albeit with slight structural modifications and kinetic proficiency alterations.  
 
Modulation of substrate specificity of MccF at the P1’ position 
As demonstrated earlier (Tikhonov et al., 2010), and structurally and kinetically 
characterized in the previous sections, MccF is specific for the presence of acidic side chain 
coordination to the adenine nucleotide. The substrate recognition elements for the adenine 
nucleotide and the acidic side chain are separate and not coupled to distant structural features by 
enzyme conformational changes. Also, independent changes at the P1 or the P1’ positions of the 
enzyme lead to compromise of catalytic activity. Consistent with the previous engineering efforts 
of serine proteases (Leis and Cameron, 1994; Perona and Craik, 1995), we hypothesized that by 
changing amino acid side chains at the P1’ position, we could engineer the enzyme to accept 
sulfamoyl adenylates of hydrophobic amino acids as substrates. Contacts to side chain 
carboxylate of McC7, DSA and ESA are provided by the side chains of Asn218, Asn220, 
Thr221, Lys247 and Arg254. Asn218 was not mutated as it provides contacts to position the 
catalytic triad residue Glu243. Mutation to alanine of Arg254 had lead to insoluble protein.  
Thr221 side chain hydroxyl was not in coordination for the ESA side chain, and is also 3.6 Å 
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away from the backbone amide nitrogen of Asp119. Hence by a process of elimination, residues 
chosen for mutagenesis were Asn220 and Lys247. We created four double mutant combinations 
in which both these residues were mutated to either leucine or phenylalanine and tested their 
activity against the hydrolysis of FSA. All mutants had compromised stability and solubility. The 
proteins were particularly poorly behaved for the three mutants who had either of the side chains 
mutated to phenylalanine, with the Asn220Phe/Lys247Phe being completely insoluble after cell 
lysis. The Asn220Leu/Lys247Leu mutant enzyme could be purified and gel filtration 
chromatography confirmed that it existed as a dimer in solution, and hence used for activity 
analysis against FSA. Time resolved HPLC separation of substrates and products showed that 
Asn220Leu/Lys247Leu enzyme could indeed catalyze FSA cleavage, albeit the reaction was 
much slower than that of wild type enzyme with physiological substrates like DSA and ESA 
(Figure 2.15A,B). ESI-MS analysis of the reactant and product peaks confirmed that the site of 
cleavage was at the sulfamoyl amide bond (Figure 2.15C,D). The rate of cleavage of FSA by 
Asn220Ala/Lys247Ala enzyme is negligible under similar experimental conditions, which 
demonstrates that the acceptance of hydrophobic sulfamoyl adenosine as a substrate is due to the 
introduction of hydrophobic side chains in the P1’ recognition site. However the poor stability of 
the mutant enzyme and slow catalytic rate represents an enzymatic system in which all 
requirements for substrate recognition and catalysis have not been currently satisfied.  
 
Altered reaction mechanism for the hydrolysis of McC7 by MccF 
The co-crystal structure of MccF in the presence of its physiological substrate-processed 
McC7 also poses a mechanistic challenge regarding the protonation of the α-amine of the 
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departing carboxy terminal peptide after the cleavage of the scissile peptide bond. The pKa of the 
catalytic triad histidine side chain has been determined to be close to 7.0 (Bachovchin et al., 
1981) and can thus protonate the departing α-NH2 of the peptide, which would have a pKa of 
greater than 9.0. However, in the case a phosphoramide leaving group, such as the adenosine 
phosphoramide of McC7, the pKa of the α-NH2 would be close to 4.5 (Gamcsik et al., 1993), and 
thus not possible to be protonated by the catalytic histidine side chain (His311 for MccF). 
However the lone pair of electrons on the α-amine of adenosine phosphoramine is in conjugation 
with the phosphate oxygen atom, which in turn is within hydrogen binding distance with the 
backbone amide nitrogen of Gly91 (Figure 2.16). Hence we propose that the α-amine, in this 
case, overcomes the requirement of protonation by the catalytic histidine side chain residue, as 
the developing negative charge on the α-amine nitrogen can then be delocalized by resonance 
conjugation to the significantly more electronegative phosphate oxygen atom, which is also in 
hydrogen bonding distance to a backbone amide nitrogen atom (Figure 2.16). This interaction 
constitutes the ‘second oxyanion hole’ for the stabilization of an altered transition state in the 
catalytic cycle of MccF. 
 
Overall three dimensional structure of MccE
CTD 
 MccE is a bi-domain protein with the C-terminal domain (CTD) mediating acetylation of 
the backbone primary amine of the aminoacyl nucleotide conjugates, independent of the N-
terminal domain. As the full length MccE protein could not be crystallized despite our 
exhaustive crystallization screening efforts, we focused our attention to the MccE
CTD
. Limited 
proteolysis was used to determine the domain boundaries for the CTD, but this approach was 
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unsuccessful due to recalcitrance of MccE to proteolytic digestion. Hence we cloned numerous 
construct of the MccE
CTD
 based on sequence similarity with other known GCN5 related N- 
acetyltransferase (GNAT) enzymes. Primary among these were the E. coli RimI and RimJ 
enzymes, which have been structurally and kinetically characterized for the acetylation of 
ribosomal proteins (Vetting et al., 2008; Vetting et al., 2005a). Various MccE
CTD
 constructs were 
purified and screened for crystallization. Only the construct encompassing the residues Asp409 
to Ile589 could be crystallized reproducibly and diffraction data collected. Crystals could only be 
obtained in the presence of the physiological cofactor- acetyl CoA. No crystals could be obtained 
in the presence of either CoA, or other CoA molecules such as succinyl CoA and acetoacetyl 
CoA. 
 The three-dimensional structure of MccE
CTD
 was solved by the molecular replacement 
method using the coordinates of the putative ribosomal N-acetyltransferase YdaF from B. subtilis 
(PDB entry 1NSL; 30% sequence identity) (Brunzelle et al., 2004).  A successful molecular 
replacement solution could only be identified using a truncated search model from which the 
amino terminal 70 residues were removed.  Extensive manual and automated rebuilding led to a 
complete model of the protein chain, encompassing residues Asp409 through Ile589.  The 
addition of solvent molecules and acetyl CoA at positions with suitably well-defined electron 
density features resulted in the final model with a free R factor of 0.227 and good Ramachandran 
statistics.  All data collection and refinement data are listed in Table 2.5. 
The overall structure of MccE
CTD
 consists of a GNAT superfamily fold consisting of 
seven antiparallel  strands flanked by four  helices (Dyda et al., 2000; Vetting et al., 2005b) 
(Figure 2.17A).  The structure is similar to that of uncharacterized acetyltransferase YdaF from 
B. subtilis (PDB code: 1NSL; RMSD of 1.6 Å over 176 aligned C atoms) and Salmonella 
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typhimurium RimL (PDB code 1S7L; RMSD of 1.2 Å over 174 aligned C atoms) (Brunzelle et 
al., 2004; Vetting et al., 2005c). The structure of the polypeptide can be roughly divided into two 
domains: an amino-terminal domain composed of two large -helices separated by a short 310 
helix and a carboxy-terminal / fold that corresponds to the acetyl CoA binding site. The most 
significant deviations from other GNAT family members are along the amino-terminal 70 
residues that define the ligand-binding site of MccE
CTD
.  Unlike Salmonella, RimL that is shown 
to be a dimer both in solution and in the crystal (Vetting et al., 2005c), and B. subtilis YdaF that 
shares the same dimerization interface in the crystal (Brunzelle et al., 2004), MccE
CTD
 is a 
monomer in the crystal as well as in solution, as determined by the elution profile on size 
exclusion chromatography with calibrated standards (Figure 2.18).  
Within the MccE
CTD
 co-crystal structure, clear electron density corresponding to acetyl 
CoA can be observed at a position similar to that observed in other structures of GNAT family 
members (Figure 2.17B).  The adenosine group is located at the surface of the molecule and 
engages in crystal packing contacts with the adenine ring of a symmetry-related molecule of 
MccE
CTD
. The pantetheine and pyrophosphate moieties engage in hydrogen bonding and van der 
Walls interactions with the polypeptide, in a manner similar to that observed in the co-crystal 
structure of RimL (Vetting et al., 2005c).  Electron density is evident for the entire ligand, and 
the acetyl group is situated at the base of the active site pocket, where the carbonyl group 
hydrogen bonds with the backbone amide of Tyr510 (O-N distance of 3.1 Å) and is flanked by 
residues Ser553 and Glu572.  These residues are implicated to act as general acid/base catalysts 
for the acetyltransferase reaction and substitution of either of these residues for alanine was 
shown to compromise the catalytic activity and biological function of MccE (Novikova et al., 
2010). 
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Interactions with the physiological substrate – processed McC7 
Processed McC7 was generously provided by the Severinov laboratory (Rutgers, The 
State University of New Jersey) and used to obtain a 1.35 Å resolution co-crystal structure with 
MccE
CTD
-acetyl CoA. In the structure, clear electron density can be observed for the entire 
substrate molecule, including the aspartyl side chain and the propylamine decoration on the 
phosphoramidate oxygen.  Unexpectedly, the structure also shows continuous electron density 
corresponding to the attachment of an acetyl group on the -amino nitrogen of processed McC7 
(Figure 2.19).  Density for the substrate molecule is equally clear for both molecules in the 
crystallographic asymmetric unit, confirming that the structure presents a view of the acetylated 
processed McC7 product complex. 
The binding pocket for the substrate is composed of a number of hydrophobic residues.  
The substrate molecule is oriented perpendicular to the central  strands of the GNAT fold, 
resulting in the deposition of the tail of the CoA donor near the -amino group of the peptide 
portion of the acceptor substrate.  The CoA donor and the substrate are located on opposite sides 
of polypeptide and acetyl transfer occurs through a cavity in the center of MccE
CTD
. 
In the co-crystal structure, the polypeptide makes minimal contacts with the amino acid 
aspartyl side chain of the substrate.  Instead, the most significant determinant for substrate 
specificity is the adenine ring of the substrate.  The ring is sandwiched between two aromatic 
residues, Trp453 and Phe466, which are located within the two large helices in the amino 
terminus of MccE
CTD
, resulting in a strong -stacking interaction with the aromatic adenine ring 
of the substrate (Figure 2.19).  The two aromatic residues are part of a hydrophobic cluster that 
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also includes Ile440, Met451, Val493, and Trp511, all of which engage in van der Waals contact 
with the adenine ring of the substrate. 
Aside from this sandwich -stacking interaction, there are minimal contacts between the 
polypeptide and the substrate molecule. With respect to the aminoacyl portion of the substrate, 
the main chain carbonyl oxygen is within hydrogen bonding distance (2.6 Å) from N2 of 
Asn497, while for the side chain, the closest interacting residue is Lys545, in which N is 3.7 Å 
away from O2 of processed McC7.  The ribose oxygen atoms are engaged in hydrogen bonding 
interactions with Ser495 (O2’- O distance of 3.3 Å) and the backbone carbonyl of Tyr510 (O3’-
O distance of 3.3 Å).  One of the phosphoramine oxygen atoms is within hydrogen bonding 
distance (2.9 Å) from the indole nitrogen of Trp453. Other than the -stacking interaction with 
Trp453 and Phe466, there are minimal contacts with any of the polar atoms of the adenine ring. 
Both N6 and N7 are solvent exposed, while N3 is 3.1 Å away from the indole nitrogen of 
Trp511. 
Although the 3-aminopropyl group of McC7 is directed outwards to bulk solvent and 
does not make contacts with the polypeptide, electron density corresponding to this modification 
can clearly be observed in the co-crystal structure.  The acetyl group is situated in a hydrophobic 
cleft defined by Ile508, Tyr510, and Ile544, where the acetyl oxygen is located within hydrogen 
bonding distance (3.0 Å) from the backbone carbonyl of Ile508. 
The mode of purine base engagement by -stacking interactions between two aromatic 
amino acid side chains (Trp453 and Phe466 of MccE
CTD
) is reminiscent of recognition 
mechanisms used by eukaryotic and viral protein that recognize the 7-methylguanosine cap at the 
5’ end of host messenger RNA (mRNA) (Fechter and Brownlee, 2005), and by bacterial and 
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viral nucleotidyltransferases, such as DNA/RNA ligases and RNA capping enzymes (Shuman 
and Lima, 2004).  With respect to mRNA cap binding proteins, despite the fact that each contain 
structurally distinct folds, they all share a hydrophobic binding pocket where the methylated 
guanosine is sandwiched between two aromatic residues, one of which is usually a tryptophan or 
tyrosine (Guilligay et al., 2008; Hodel et al., 1996; Marcotrigiano et al., 1997; Mazza et al., 
2002).  Preference for the methylated over non-methylated guanosine is dictated by a stronger 
interaction between the delocalized positive charge on the 7-methylguanosine and the -
electrons of the aromatic residues.  In the nucleotidyltransferase superfamily, the purine 
nucleotide substrate is similarly sandwiched between a conserved aromatic residue and a 
conserved aliphatic residue, and additional contacts with either a conserved glutamate 
(phage/bacterial DNA ligase), threonine (viral DNA ligase), or lysine (RNA capping enzymes) 
residue. 
In order to determine whether MccE
CTD
 could indeed recognize and bind purine 
ribonucleotides independent of the identity of the aminoacyl conjugates, we used isothermal 
titration calorimetry to monitor binding between AMP and MccE
CTD
.  The binding isotherm for 
the interaction was fitted by nonlinear regression using a simple bimolecular interaction model. 
Two concentrations of AMP were used to generate binding isotherms and independently fitted. 
The data is consistent with a 1:1 interaction between the ligand and protein with a dissociation 
constant of about 1.03 mM (Figure 2.20A) (Table 2.6). We also determined the 1.3 Å resolution 
co-crystal structure of MccE
CTD
-acetyl CoA in complex with AMP. The cocrystal structure 
shows clear electron density for both AMP and for the intact acetyl group of acetyl CoA (Figure 
2.20B).  The location of the AMP is nearly identical to that occupied by the adenosine moiety in 
the co-crystal structure with processed McC7.  The remainder of the substrate binding cleft is 
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occupied by a number of solvent molecules.  The polypeptide engages AMP with a similar set of 
interactions as those observed in the co-crystal structure with McC7.  Additionally, the side chain 
of Asn497 is now oriented towards the AMP, where O1 is within hydrogen bonding distance 
(3.2 Å) from the O2’ of the ribose. 
An indirect evidence for the requirement of the structural recognition of the adenine ring 
of McC7 for its acetylation by MccE
CTD
 is presented by the crystal structure of the E. coli RimI 
and RimL enzymes. Though MccE
CTD
 and RimI are highly homologous to each other at the 
primary sequence level, RimI has been shown to be unable to acetylate and provide resistance 
against McC7 (Severinov laboratory, unpublished results). In order to facilitate the structural 
comparison between the active sites of MccE
CTD
 and RimI, we determined the crystal structure 
of RimI in the presence of acetyl CoA to a limiting resolution of 1.8 Å (Figure 2.21). The overall 
structures, and the mode of binding of acetyl CoA for MccE
CTD
 and RimI are remarkably similar, 
and a similar pair of parallel planar side chains is evident in the crystal structure of RimI which 
could sandwich the adenine ring of McC7 by π-stacking interactions. However the adenine 
binding pocket of RimI is occluded by the presence of the side chains and Glu19 and Asn68 side 
chains. This steric occlusion of the adenine binding pocket by Glu19 and Asn68 side chains 
likely contributes to the inability of RimI to acetylate processed McC7. 
In contrast, the E. coli RimL enzyme has demonstrated to acetylate processed McC7. We 
determined the crystal structure of the RimL enzyme to a limiting resolution of 1.8 Å. Though 
the crystal structure proved recalcitrant to crystallographic refinement owing to twinning or other 
pathologies associated with the X-ray diffraction data, an incomplete model demonstrated the 
presence of a pair of parallel planar amino acid side chains which are appropriately positioned 
for π-stacking interactions with the adenine ring of McC7. This putative adenine binding site is 
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not occluded by other amino acid side chains, and likely presents a structural explanation for the 
acetylation of McC7 by RimL. 
 
Substrate promiscuity of MccE
CTD
 explained by cocrystal structures with DSA and ESA 
MccE
CTD
 has been demonstrated to acetylate a wide variety of amino nucleotide 
conjugates in addition to the physiological substrate- processed McC7. It was shown to acetylate 
DSA, ESA and the leucyl-sulfamoyl-adenosine (LSA) (Novikova et al., 2010). In order to probe 
the determinants of substrate promiscuity for the enzyme, we obtained crystal structure of the 
MccE
CTD
 in presence of acetyl-CoA and DSA and ESA. Crystallization was also attempted in the 
presence of LSA, valinyl-sulfamoyl-adenosine (VSA) and prolyl-sulfamoyl-adenosine (PSA), 
but diffraction quality crystals could not be obtained in the presence of these substrates and 
acetyl CoA. 
MccE
CTD
 engages DSA and ESA through contacts similar to those observed in co-crystal 
structure with processed McC7 (Figure 2.22).  The primary determinant for substrate 
engagement is the π-stacking of the adenine ring. No contacts could be observed for either the 
aspartyl or the glutamyl amino acid side chains. In each of the two structures, no electron density 
can be observed for the acetyl group of the donor, suggesting that hydrolysis of the thioester has 
occurred in situ.  In addition, the side chain of Cys546 is rotated towards the active site pocket 
where it forms a covalent disulfide linkage with CoA.  Although these structures suggest that 
MccE
CTD
 proceeds through an enzyme-acetyl intermediate, this is unlikely as mutational analysis 
of the equivalent residue in RimL suggest that this cysteine does not play a role in catalysis.  A 
similar cysteyl-acetyl linkage is observed in the RimL co-crystal structure (Vetting et al., 2005a). 
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The lack of specific contacts with substrate also explains the ability of MccE
CTD
 to 
detoxify the structurally distinct seryl-tRNA synthetase inhibitor albomycin (Novikova et al., 
2010) and establish the structural premise for the observed substrate promiscuity for the enzyme.  
Processed albomycin is composed of an N
4
-carbamyl-5-methyl-4-imino-cytidine conjugated to a 
thioxylofuranosyl pyrimidine (Stefanska et al., 2000), and the nucleoside moiety may be 
similarly accommodated into the MccE
CTD
 hydrophobic substrate-binding pocket.  The rate and 
specificity for the modification of processed albomycin by MccE
CTD
 is not yet clear as these 
studies were conducted as end-point assays using whole cell extracts (Novikova et al., 2010). 
 
Kinetic analysis for the acetylation of ESA by MccE
CTD
 
To further characterize the acetylation activity of the MccE
CTD
 enzyme for aminoacyl 
nucleotide conjugated substrates, we carried out kinetic analysis of MccE
CTD
 by reacting 5,5’-
dithiobis(2-nitrobenzoic acid) (Ellman’s reagent) with the free sulfhydryl of the product CoA 
that is formed upon acetylation of the substrate.  Using ESA as a substrate, the 
spectrophotometric studies yield a KM value of 55 ± 7 M and kcat value of 23.7 ± 2.2 min
-1
.  As 
neither the side chain of the sulfamoyl adenylate or the propylamine of McC7 makes any specific 
contacts with MccE
CTD
, the kinetic constants for DSA and processed McC7 are likely very 
similar to those experimentally determined for ESA. The kcat value obtained for MccE
CTD
 is in 
close agreement with that of the S. typhimurium RimL acetyltransferase for a ribosomal peptide 
substrate (Vetting et al., 2005a), though the KM value obtained for MccE
CTD
 is nearly 50 times 
higher than that for RimL. However the kcat values for the N-acetylation of aminoglycoside 
antibiotics by the respective resistance causing acetyltransferase enzymes is nearly two orders of 
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magnitude higher than that for MccE
CTD 
(Hamano et al., 2004; Norris et al., 2010). Curiously, 
these N-acetyltransferases also display remarkable substrate promiscuity. 
 
Model for the synergistic activity for full length MccE  
Full length MccE enzyme is a bi-domain protein. Putative enzymatic role can be assigned 
to the MccE N-terminal domain (MccE
NTD
), in addition to the characterized McC7 acetylating 
activity of the MccE
CTD
. Together with MccD, full length MccE was shown to contribute 
towards the attachment of the propylamine appendage upon the phosphoramide oxygen atom 
(Metlitskaya et al., 2009). Sequence homology identifies MccD to be a S-adenosyl-methionine 
(SAM) dependent methyl transferase, while MccE
NTD
 bears homology to pyridoxal-5’-phosphate 
(PLP) dependent decarboxylases. The in-vitro activity for either MccD or MccE enzymes has not 
been reconstituted as yet. The chemical structure of McC7 or processed McC7 does not bear a 
methyl group on any nucleophillic nitrogen or oxygen atom. Hence the postulate that MccD 
would transfer a methyl group from SAM, without the recruitment of radical chemistry, is highly 
unlikely. We propose that MccD instead transfers a 2-ammoniobutanoate moiety from SAM to 
one of the phosphoramide oxygen atoms (Figure 2.23). The reaction mechanism would involve 
nucleophilic attack on the Cγ atom of the methionine side chain of SAM, rather than at the Cε 
methyl group. This enzymatic reaction has been reported before in the biosynthesis of 
polyamines in plants and nicotianamine biosynthesis in archaea (Dreyfus et al., 2009; Roje, 
2006). The transfer of 2-ammoniobutanoate would convert SAM to methyl-thio-adenosine 
(MTA). The 2-ammoniobutanoate could then be decarboxylated by MccE
NTD
 to generate the 
propylamine appendage. This hypothesis is lent further credence by the sequence homology of 
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MccE
NTD
 with Type III ornithine and diaminopimelate decarboxylase enzymes (Gokulan et al., 
2003). 
The putative transfer of 2-ammoniobutanoate from SAM to the phosphoramide oxygen 
atom could be succeeded by the removal of the McC7 Trojan horse hexapeptide within the 
producer cell by the action of the PepA-N proteases. In the event that this proteolysis event 
precedes the decarboxylation by MccE
NTD
, MccE
CTD
 could act concomitantly with MccE
NTD
 to 
acetylate the now free aspartate main chain primary amine to prevent the synthesis of a toxic 
species within the producer cell. A concomitant action on one substrate molecule by two 
different domains of the MccE enzyme cannot be ruled out by a steric argument. The 
propylamine appendage of processed McC7 points outwards from the active site of MccE
CTD
 and 
does not make any contacts with the enzyme. Hence it is sterically ‘available’ to be accepted 
within the MccE
NTD
 active site. As the propylamine appendage of the McC7 makes it a more 
potent AspRS inhibitor (Metlitskaya et al., 2009), it is conceivable that the McC7 biosynthetic 
machinery has been evolved to position a self-immunity determinant to act synergistically with 
an antibiotic maturation event. 
MccE
NTD
 and MccE
CTD
 can also share some McC7 recognition structural motifs. Our 
current hypothetical model for the full length MccE enzyme is based upon the recognition of the 
adenine moiety by π-stacking interactions in MccECTD, while the aspartate side chain (which also 
points outwards from the MccE
CTD
 active site) and the carboxylated propylamine appendage are 
recognized within the MccE
NTD
, as shown in Figure 2.23. This hypothesis is currently under 
investigation. 
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Future directions 
 Several questions remain with respect to the natural biological role of the MccF enzyme. 
The ubiquitous presence of the MccF gene in the microbial metabolome across diverse 
ecological niches makes us speculate that MccF might have a conserved biological function 
associated with growth and fitness of these microbes. Several other small molecule stable 
aminoacyl nucleotide conjugates are produced as natural products by bacteria. Primary examples 
with demonstrated biological activities are agrocin 84 (Reader et al., 2005), albomycin 
(Pramanik et al., 2007), ascamycin (Osada and Isono, 1985; Ubukata et al., 1985), pacidamycin 
(Winn et al., 2010), capuramycin (Reddy et al., 2008) and polyoxins (Zhang and Miller, 1999), 
among others. Our results have demonstrated that mutations within the E. coli MccF active site 
can expand upon the substrate scope of the enzyme. The enzyme is also intrinsically pre-
organized to recognize different nucleotides. Hence it can be speculated that homologs of MccF 
might offer resistance against the bioinhibitory activities of several more natural products, other 
than McC7. As inhibitors of antibiotic degrading enzymes can be valuable adjuvants to the 
dosing regimen of an antibiotic, as exemplified by the development of clavulanic acid adjuvant 
in broad spectrum antibiotic amoxicillin (Drawz and Bonomo, 2010; Hugonnet et al., 2009), 
inhibitors of MccF might allow the aminoacyl nucleotide natural products to explore and even 
more diverse target spectrum. Our structural and kinetic results have provided a framework 
which would make the development of inhibitors of MccF easier. This process would also be 
aided by previous extensive literature on the development of synthetic inhibitors for serine 
protease enzymes. 
 Our inability to reconstitute the enzymatic activity for the MccD and MccE enzymes 
continues to rankle and confound us. We have unsuccessfully trialed a variety of experimental 
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conditions to install either the aminopropyl or the 2-ammoniobutanoate moieties on the purified 
MccB reaction product. Future efforts will be directed at abolishment of the MccE activity 
within the producer cell, and then isolating a McC7 biosynthetic pathways intermediate 
compound. This could serve as the physiological substrate for the MccE enzyme in-vitro. This 
abolishment of activity for the MccE enzyme would be carried out by site directed mutagenesis 
within the MccE
NTD
, and not by knocking out the entire MccE enzyme, as the activity of the 
MccE
CTD
 is associated with fitness costs for the producer cell (Novikova et al., 2010). As 
mentioned before, efforts to crystallize full length MccE enzyme have not borne fruit as of now. 
Presumably, the presence of the physiological substrate of the enzyme will serve to restrict the 
conformational flexibility of the bi-domain protein, and make the enzyme more amenable to 
crystallization. 
 Several antibiotics have been demonstrated to biologically active only when associated 
with peptidyl Trojan horse carriers. Examples of these peptidyl-Trojan horse dependent 
antibiotics are rhizocticins (Kugler et al., 1990), plumbemycins (Fredenhagen et al., 1995) and 
dehydrophos (Circello et al., 2011), among others. It has also been demonstrated that just by 
changing the nature of the peptidyl Trojan horse carrier, the antifungal rhizocticins can be 
converted to antibacterial plumbemycins, as they share a common bioinhibitory chemical entity. 
Hence it is conceivable that the microbial target spectrum for McC7 can be expanded by altering 
the amino acids in the Trojan horse hexapeptide. The first steps towards this direction have been 
reported in literature (Van de Vijver et al., 2009b; Vondenhoff et al., 2011). This process would 
also be aided by the structural and biochemical characterization of the McC7 import machinery. 
Import of McC7 into susceptible relies on the YejABEF ATP-binding cassette (ABC) transporter 
(Eswarappa et al., 2008; Novikova et al., 2007), with the YejA protein acting as the extracellular 
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McC7 recognition determinant. We have been able to generate crystals of E. coli YejA in 
presence of MccA and collect preliminary native diffraction data sets. Elucidation of the YejA-
MccA complex structure would allow for the rational redesign of the antibiotic with decreased 
minimum inhibitory concentration (MIC) values and better pharmacokinetic profiles. Semi-
synthetic alteration in the identity of the Trojan horse carrier to analogous dipeptides 
(rhizocticins and plumbemycins), sugar molecules (agrocin 84) or siderophores (albomycin) can 
also expand upon the target spectrum of McC7. 
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Tables 
Table 2.1 Data collection and refinement statistics for MccF wild type enzyme, Ser118Ala 
and Ser118Ala in complex with processed McC7. 
 MccF (native) Ser118Ala MccF-McC7 
Data collection    
Cell dimensions    
a, b,c (Å), (o) 54.4,85.9,73.1, 101.2 54.5,85.8,73.2, 101.2 54.3,85.7,72.9, 101.3 
Resolution (Å)
1 50-1.2 (1.24-1.2) 50-1.5 (1.55-1.5) 50-1.3 (1.35-1.3) 
Rsym (%) 6.8 (35.2) 6.9 (12.1) 5.0 (28.2) 
I/(I) 38.7 (3.9) 46.3 (19.2) 29.8 (4.5) 
Completeness(%) 98.9 (93.8) 99.7 (99.8) 97.2 (93.8) 
Redundancy 7.3 (5.8) 4.6 (4.6) 4.4 (4.1) 
Refinement    
Resolution (Å) 25-1.2 25-1.5 25-1.3 
No. reflections 192,327 99,890 148,363 
Rwork / Rfree
2 18.3/20.1 17.7/19.8 17.4/18.6 
Number of atoms    
Protein 5,313 5,188 5,277 
Ligand - - 70 
Water 961 981 978 
1. Highest resolution shell is shown in parenthesis. 
2. R-factor = (|Fobs|-k|Fcalc|)/ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% of the 
diffraction data not used in refinement. 
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Table 2.2 Data collection and refinement statistics for MccF Ser118Ala enzyme in complex 
with DSA, ESA, ESI and ESG. 
 MccF-ESA MccF-DSA MccF-ESI MccF-ESI 
Data collection     
Cell dimensions     
a, b, c (Å)  
(o)
54.5, 85.9, 73.1  
101.2 
54.4, 85.7, 72.9 
101.3 
54.5, 86.1, 73.2 
101.2 
54.4, 85.7, 73.0 
101.2 
Resolution (Å)
1 50-1.35 (1.4-1.35) 50-1.5 (1.55-1.5) 40–1.20 (1.22–1.2) 50–1.23 (1.25–1.23) 
Rsym (%) 4.5 (14.5) 5.8 (24.4) 6.2 (62.6) 9.0 (41.5) 
I/(I) 39.6 (9.5) 27.9 (5.4) 27.5 (2.0) 26.6 (3.3) 
Completeness(%) 98.2 (96.2) 95.6 (85.0) 98.5 (96.2) 100.0 (100.0) 
Redundancy 3.8 (3.6) 6.0 (5.3) 5.8 (5.3) 6.2 (6.0) 
Refinement     
Resolution (Å) 25-1.3 25-1.5 25-1.20 25-1.23 
No. reflections 149,510 94,666 193215 180541 
Rwork / Rfree
2 17.9/19.7 17.9/20.2 0.159 / 0.175 0.155 / 0.172 
Number of atoms     
Protein 5,261 5,261 5343 5335 
Ligand 64 62 64 66 
Water 957 864 617 589 
1. Highest resolution shell is shown in parenthesis. 
2. R-factor = (|Fobs|-k|Fcalc|)/ |Fobs|and R-free is the R value for a test set of reflections consisting of a random 5% of the 
diffraction data not used in refinement. 
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Table 2.3 Steady state kinetic parameters for DSA and ESA hydrolysis by MccF wild type 
and mutant enzymes. 
 
 KM (µM) kcat (min
-1
) 
kcat/KM (M
-1 
s
-
1
) 
Relative  
kcat/KM 
1
 
DSA 
Wild type 74.3 ± 6.1 417.7 ± 33.3 9.4E4 1.00 
Asn220Ala 186.3 ± 20.2 133.4 ± 12.2 1.2E4 0.13 
Lys247Ala 133.9 ± 15.1 196.3 ± 20.1 2.4E4 0.26 
Ser118Ala n.d.
 2
 n.d.   
ESA 
Wild type 51.6 ± 4.9 35.0 ± 4.1 1.1E4 1.00 
Trp186Phe 218.8 ± 19.4 23.3 ± 4.0 1.8E3 0.16 
Arg246Ala 154.3 ± 16.3 33.7 ± 2.5 3.6E3 0.32 
Asn220Ala 105.9 ± 9.5 37.2 ± 4.9 5.9E3 0.52 
Lys247Ala 238.9 ± 25.2 5.0 ± 0.3 3.5E2 0.03 
Trp186Ala n.d. n.d.   
Asn220Ala/Lys247Ala n.d. n.d.   
Ser118Ala n.d. n.d.   
 
1 kcat/KM of mutant enzyme relative to wild type enzyme 
2 n.d.: no detectable activity precluded kinetic parameter determination 
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Table 2.4 Steady state kinetic parameters for ESA, ESI and ESG hydrolysis by MccF wild 
type enzyme. 
 
 
 KM (µM) kcat (min
-1
) kcat/KM (M
-1 
s
-1
) 
ESA 57.6 ± 4.2 36.7 ± 3.1 1.06E4 
ESI 90.9 ± 10.5 38.1 ± 4.2 0.70E4 
ESG 33.4  ± 2.2 34.9 ± 3.1 1.74E4 
 
* Determined in an independent experiment from Table 2.4. 
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Table 2.5 Data collection, phasing and refinement statistics for MccE
CTD
 enzyme in the apo 
form, and in complex with processed McC7, DSA, ESA and AMP. 
 Acetyl CoA DSA ESA AMP McC7 
Data collection      
Space group P21212 P21212 P21212 P21212 P21212 
Cell dimensions      
a, b, c (Å) 78.9, 94.7, 53.9 78.9, 94.8, 53.3 78.9, 94.8, 53.4 78.5, 94.9, 53.3 77.9, 95.1, 53.2 
Resolution (Å)1 50-1.6 (1.66-1.6) 50-1.25 (1.29-1.25) 50-1.2  (1.24-1.2) 50-1.3  (1.35-1.3) 50-1.35 (1.4-1.35) 
Rsym (%) 6.1 (36.1) 6.3 (42.7) 6.5 (44.7) 6.5 (23.5) 6.6 (49.7) 
I / (I) 28.7 (4.8) 46.9 (2.9) 51.7 (3.3) 40.5 (11.2) 45.7 (2.6) 
Completeness(%) 98.8 (96.9) 99.5 (96.6) 99.3 (96.0) 99.8 (100.0) 99.2 (95.2) 
Redundancy 7.2 (7.1) 9.1 (5.4) 8.6 (6.9) 12.1 (11.8) 6.5 (4.4) 
Refinement      
Resolution (Å) 25.0-1.6 25.0-1.25  25.0-1.2  25.0-1.3 25.0-1.35  
No. reflections 50,128 105,359  118,379  93,420  82,500 
Rwork / Rfree
2 20.3/22.8 18.2/20.2  18.5/19.9  17.6/19.7  18.7/21.6 
Number of atoms      
Protein 2800 2864  2836 2787  2787  
(Ac)CoA 102 96 96 102 96 
Substrate - 62 64 46 76 
Water 419 610 665 696 517 
1. Highest resolution shell is shown in parenthesis. 
2. R-factor = (|Fobs|-k|Fcalc|)/ |Fobs|and R-free is the R value for a test set of reflections consisting of a 
random 5% of the diffraction data not used in refinement. 
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Table 2.6 Thermodynamic parameters obtained by fitting the isothermal titration 
calorimetry binding isotherms to a bimolecular interaction model for binding of AMP to 
MccE
CTD
. Isotherms were obtained for two concentrations of AMP and similarly analyzed. 
 
 50mM AMP 20mM AMP 
N 1.08 1.10 
K
*
 963 ± 97 M
-1
 948 ± 23 M
-1
 
ΔH -1.4E4 ± 475.5 cal/mol -1.5E4 ± 174.2 cal/mol 
ΔS -34.4 cal/mol.deg -37.8 cal/mol.deg 
ΔG -4.1E3 cal/mol -4.1E3 cal/mol 
 
* This value refers to association constant 
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Figures 
 
Figure 2.1 Two-step mechanism of aaRS enzymes. In the first step, the cognate amino acid is 
adenylated, which is then transferred to the ribose hydroxyl of the tRNA molecule in the second 
step. One molecule of ATP is consumed in this process. The tRNA molecule is shown in surface 
representation in purple. 
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Figure 2.2 Structures of trojan horse aminoacyl-nucleotide conjugate natural product 
aaRS inhibitors- agrocin 84 (top), albomycin (middle) and microcin C7 (bottom). The 
Trojan horse moieties which need to be removed prior to inhibitory action of the molecule are 
shown in blue. The tri-hydroxamate siderophore moiety of albomycin is shown coordinating a 
ferrous ion. 
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Figure 2.3 Biosynthetic pathway for the production and self-immunity for microcin C7 
antibiotic. The chemical transformations at each enzymatic step are highlighted in red. 
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Figure 2.4 Crystal structure of wild type MccF in the apo state. (A) MccF monomer structure 
showing the three domain architecture. The amino terminal domain is shown in  blue, the 
catalytic loop in green and the carboxy terminal domain in pink. The active site residues are 
shown in stick ball representation with the carbon atoms colored yellow. (B) Homodimer 
organization of MccF. One dimer is colored as before. The other dimer is colored grey. 
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Figure 2.5 Sequence alignment of E. coli MccF (Ec_MccF) with homologs from human 
pathogens B. anthracis (Ba_MccF), Vibrio parahaemolyticus (Vp_MccF), plant pathogen 
Dickeya zeae (Dz_MccF) and LD-carboxypeptidase LcdA from P. aureginosa (Pa_MccF). 
Note the absence of the catalytic loop from Pa_LcdA (marked by black dashed line under the 
sequence). The catalytic triad residues (highlighted in pink boxes) are conserved among all 
sequences, but McC7 recognition residues (highlighted in green boxes) are absent from LcdA, 
with the exception of Arg254 which also mediates enzyme dimerization, and is hence conserved 
in LcdA. 
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Figure 2.6 Stereo view of processed McC7 bound to the active site of MccF. Stereo view 
showing the active site features of the MccF-S118A in complex with processed McC7. The 
MccF carbon atoms are shown in yellow ball-and-stick and the McC7 carbon atoms are colored 
in green. Superimposed is a difference Fourier electron density map (contoured at 2.7σ over 
background in blue) calculated with coefficients |Fobs| - |Fcalc| and phases from the final refined 
model with the coordinates of McC7 deleted prior to one round of refinement. 
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Figure 2.7 Hydrolysis of DSA and ESA by MccF. (A) Chemical structures of AspRS enzyme 
reaction intermediate- aspartyl adenylate (1), processed McC7 (2), DSA (3) and ESA (4). The 
phosphoester bond in 1 is shown in green, the phosphoramine-amide in 2 is shown in blue, and 
the sulfamoyl-amide bond in 3 and 4 is shown in red. (B) HPLC separation of the reactants DSA 
and ESA in blue, and the product SA in red. The substrate peaks are marked by arrows. 
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Figure 2.8 ESI-MS spectrum for the reactants and products of hydrolysis reactions of DSA 
and ESA by wild type MccF enzyme. (A) and (C) Spectrum for the substrates DSA and ESA 
respectively. (B) and (D) product SA from the hydrolysis reaction of DSA and ESA respectively. 
The major peaks are labeled with their respective m/z values. Inset shows the chemical species 
corresponding to the peak mass. 
 
 
78 
 
 
Figure 2.9 Stereo views of DSA and ESA bound to the active site of MccF. Stereo view 
showing the active site features of the MccF-S118A in complex with (A) DSA and (B) ESA. The 
MccF carbon atoms are shown in yellow ball-and-stick and the substrate carbon atoms are 
colored in green. Superimposed is a difference Fourier electron density map (contoured at 2.7σ 
over background in blue) calculated with coefficients |Fobs| - |Fcalc| and phases from the final 
refined model with the coordinates of DSA and ESA deleted prior to one round of refinement. 
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Figure 2.10 Active site view of the co-crystal structure of Trp186Phe MccF with AMP. 
Enzyme side chain residue carbon atoms are colored in yellow, AMP carbon atoms are colored 
in green. Superimposed is a difference Fourier electron density map (contoured at 2.7σ over 
background in blue) calculated with coefficients |Fobs| - |Fcalc| and phases from the final refined 
model with the coordinates of AMP deleted prior to one round of refinement. MccF N-terminal 
domain is colored blue, C-terminal domain is colored pink and the catalytic loop is colored 
green. 
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Figure 2.11 Active site view of Ser118Ala/Asn220Ala/Lys247Ala MccF. Enzyme side chain 
residue carbon atoms are colored in yellow. Superimposed is a difference Fourier electron 
density map (contoured at 2.7σ over background in blue) calculated with coefficients |Fobs| - 
|Fcalc| and phases from the final refined model with the coordinates of the side chains of Ala-118, 
Ala-220, and Ala-247 deleted prior to one round of refinement. MccF N-terminal domain is 
colored blue, C-terminal domain is colored pink and the catalytic loop is colored green. 
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Figure 2.12 Hydrolysis of ESI and ESG by MccF. (A) Chemical structures of ESI (5) and ESG 
(6). The sulfamoyl-amide bond in 5 and 6 is shown in red. (B) HPLC separation of the reactants 
ESI and ESG in blue, and the products SI and SG in red. The substrate peaks are marked by 
arrows. 
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Figure 2.13 ESI-MS spectrum for the reactants and products of hydrolysis reactions of ESI 
and ESG by wild type MccF enzyme. (A) and (C) Spectrum for the substrates ESI and ESG 
respectively. (B) and (D) products SI and SG from the hydrolysis reaction of ESI and ESG 
respectively. The major peaks are labeled with their respective m/z values. Inset shows the 
chemical species corresponding to the peak mass. 
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Figure 2.14 Ligand binding at the P1 site for MccF-Ser118Ala in complex with (A) ESA, 
(B) ESI and (C) ESG. Ligands are shown in stick-ball representation with the carbon atoms 
colored green. Side chain atoms of MccF residues Ser183, Trp186, Arg246 and Glu277 residues 
are shown in stick-ball representation with carbon atoms colored yellow. Hydrogen bonds are 
shown as black dashes. 
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Figure 2.15 Cleavage of FSA by MccF Asn220Leu/Lys247Leu mutant enzyme. (A) Time 
resolved HPLC separation of the substrate (FSA) and the product (SA). The inset shows the 
chemical structure of FSA with the site of cleavage marked by an arrow. (B) Reaction 
progression, determined by the rate of appearance of the product, fit to a sigmoidal curve. (C) 
ESI-MS spectrum of the substrate FSA with the monoisotopic masses shown for the major peak 
shown in inset. (D) ESI-MS spectrum of the product SA with the monoisotopic masses shown 
for the major peak shown in inset. 
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Figure 2.16 Catalytic cycle for the hydrolysis of McC7 by MccF. The catalytic triad residues 
are shown in blue. The phosphor- moiety of the phosphoramide is shown in red, and the scissile 
amide bond is shown in green. Putative hydrogen bond interactions are shown as dashes. 
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Figure 2.17 (A) Ribbon diagram showing the overall structure of MccE
CTD
 (in cyan) in complex 
with acetyl CoA (yellow ball-and-stick). (B) Close-up view of the acetyl CoA binding site.  
Superimposed is a difference Fourier electron density map (in blue), calculated with coefficients 
|Fobs| - |Fcalc| and phases from the final refined model with the coordinates of acetyl CoA deleted 
prior to one round of refinement.  The map is contoured at 3 over background. 
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Figure 2.18 Size exclusion chromatography elution profile for MccE
CTD
. MccE
CTD
 elution 
profile is shown as a solid line with linear fit (dashed line) of peak elution volumes for molecular 
weight standard proteins shown as square dots. Chromatography was performed using Superdex 
200 HR 10/30 analytical gel filtration column (GE Lifesciences) in buffer 20 mM HEPES-Na 
(pH 7.5), 100 mM KCl, at a flow rate of 0.5 mL/min. The molecular weight standards were Blue 
Dextran (~2,000,000 Da), beta-amylase (~200,000 Da), Albumin (~66,200 Da), carbonic 
anhydrase (~29,000 Da) and cytochrome c (~12,400 Da) and were obtained from Sigma. 
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Figure 2.19 Stereoview of the active site of MccE
CTD
 in complex with CoA and acetylated 
McC7. Superimposed is a difference Fourier electron density map (contoured at 3 over 
background and shown in blue) calculated with coefficients |Fobs| - |Fcalc| and phases from the 
final refined model with the coordinates of substrate deleted prior to one round of refinement. 
The adenine stacking residues Trp453 and Phe466 are labeled. 
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Figure 2.20 ITC and crystallographic demonstration of AMP binding to MccE
CTD
. (A) Raw 
data and corresponding binding isotherm for the interaction of MccE
CTD
 with AMP. (B) 
Stereoview of the active site of MccE
CTD
 in complex with acetyl CoA and AMP.  Substrate and 
protein residues are colored and the superimposed difference Fourier electron density map 
(contoured at 3 over background and shown in blue) is calculated as in Figure 2.18. 
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Figure 2.21 Structure of RimI in complex with acetyl CoA. RimI is shown in carton 
representation with acetyl CoA shown in yellow ball-and-stick. The putative adenine π-stacking 
amino acid side chains are shown in ball-and-stick with the carbon atoms colored grey. The 
Glu19 and Asn68 side chains which occlude the adenine binding site are shown in ball-and-stick 
with the carbon atoms colored green. 
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Figure 2.22 Active site of MccE
CTD
 in complex with DSA and ESA. (A) Stereoview of the 
active site of MccE
CTD
 in complex with CoA and DSA.  The DSA substrate is colored in yellow, 
the CoA molecule is colored in cyan, polypeptide residues colored in green include Trp-453 and 
Phe-466 that form a -stacked sandwich with the adenine ring of the substrate and Cys-546 that 
is disulfide bonded to the CoA thiol.  Superimposed is a difference Fourier electron density map 
(contoured at 3 over background and shown in blue) calculated with coefficients |Fobs| - |Fcalc| 
and phases from the final refined model with the coordinates of DSA deleted prior to one round 
of refinement. (B) Stereoview of the active site of MccE
CTD
 in complex with CoA and ESA.  
Substrate and protein residues are colored as above and the superimposed difference Fourier 
electron density map (contoured at 3 over background and shown in blue) is calculated as 
above. 
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Figure 2.23 Proposed hypothetical model for the concomitant action of the MccE bi-
domain protein. We postulate that MccD transfers a 2-ammoniobutanoate moiety from S-
adenosyl-methionine to the phosphoramide oxygen atom, and releases methyl-thio-adenosine 
(top). The 2-aamoniobutanoate moiety is then decarboxylated by MccE
NTD
 to generate McC7 
(bottom right). In the event that the non-specific PepA-N cleavage occurs prior to 
decarboxylation by MccE
NTD
, subsequent decarboxylation by MccE
NTD
 would generate the toxic 
processed McC7 within the producer cell. In such a scenario, MccE
CTD
 would concomitantly 
acetylate the aspartyl primary amine to generate a non-toxic species within the producer cell 
(bottom right).  
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Chapter 3: Structural and biochemical characterization of enzymes of a novel phosphonate 
degradation pathway provide missing links for the biosynthesis and degradation of 
phosphonoacetate
1,2
 
Abstract 
 Phosphonates are ubiquitous natural organic compounds characterized by the presence of 
a carbon-phosphorus (C-P) bond that is resistant to enzymatic and chemical degradation 
commonly afforded upon oxygen-phosphorus (O-P) bond-containing phosphate esters. Due to 
the stability of the phosphonate bond, natural and synthetic phosphonates have commercial 
application as antibiotics, herbicides and detergents. Several microbial species have evolved 
dedicated enzymatic machineries for the hydrolytic degradation of the phosphonate molecules 
for their utilization as carbon and phosphorus sources. Previous investigations have revealed that 
phosphonoacetaldehyde (PnAA) and phosphonoacetate (PnA) can be enzymatically hydrolyzed 
to generate phosphate and either acetaldehyde or acetate, respectively. A recently discovered 
PnAA oxidase gene in Sinorhizobium meliloti 1021 links these two hydrolytic processes and 
provides a previously unknown catabolic mechanism for PnA production in the microbial 
metabolome. Central to this study was the discovery of a previously unknown PnAA 
dehydrogenase enzyme, in addition to a PnA specific metal dependent hydrolase. Here, we carry 
1
Parts of this chapter have been reproduced from: 
Agarwal V, Borisova SA, Metcalf WW, van der Donk WA, Nair SK. Chem Biol. 2011 Oct 28;18(10)1230-40. 
Referred to as ‘Agarwal et.al., 2011’ in this chapter. Reproduced with the permission of the publisher and is 
available from http://www.cell.com/ and using DOI: 10.1016/j.chembiol.2011.07.019. 
2
Parts of this chapter are in preparation for publication: 
Agarwal V, Chen JH, Chekan J, Borisova SA, Metcalf WW, van der Donk WA, Nair SK. Structural and 
functional characterization of phosphonoacetaldehyde dehydrogenase enzyme provides missing link for 
phosphonoacetate degradation, 2012, in preparation for publication. 
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out full biochemical and structural biological characterization of this PnAA dehydrogenase 
enzyme - PhnY. We present crystal structures of PhnY in the apo state, as well as complexes 
with substrate, cofactor and product. Kinetic characterization of structure-based active site 
mutants demonstrates how a highly conserved enzyme active site has been modified by Nature to 
generate new metabolic activities. We also present detailed biochemical and structural 
characterization of the PnA hydrolase enzyme- PhnA that provides insights into the mechanism 
of C-P bond cleavage. The 1.35 Å resolution crystal structure reveals a catalytic core similar to 
those of alkaline phosphatases (AP) and nucleotide pyrophosphatases (NPP) but with notable 
differences, such as a longer metal-metal distance. Detailed structure-guided analysis of active 
site residues and four additional cocrystal structures with PnA substrate, acetate, 
phosphonoformate (PnF) inhibitor, and a covalently bound transition state mimic provide insight 
into active site features that may facilitate cleavage of the C-P bond. These studies expand upon 
the array of reactions that can be catalyzed by enzymes of the AP superfamily. 
  
109 
 
Introduction 
Natural occurrence and application of phosphonate molecules 
 Phosphonates are organic molecules characterized by the presence of C-P bond in place 
of the O-P bond found in phosphate esters. Consequently, the oxidation state of the phosphorus 
atom in phosphonate is +3, as compared to +5 found in phosphate and phosphate esters. 
However, the tetrahedral geometry around the phosphorus atom is preserved in phosphonates, 
and, in combination with their remarkable recalcitrance towards chemical and enzymatic 
hydrolysis, renders phosphonates as competitive inhibitors of biochemical processes that involve 
phosphoryl group transfer reactions (Metcalf and van der Donk, 2009). Nature has utilized this 
chemical mimicry in the development of several compounds which have potent antibiotic, 
herbicidal, and other bio-inhibitory activities. One class of such compounds includes the 
rhizocticins and plumbemycins that utilize the unnatural amino acid- (Z)-L-2-amino-5-
phosphono-3-pentenoic acid to competitively inhibit the β-γ replacement of phosphohomoserine 
catalyzed by threonine synthase (Borisova et al., 2010). The antimalarial phosphonate molecule 
FR900098 acts as a competitive inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase 
and stalls isoprenoid production in Plasmodium falciparum (Zingle et al., 2010). Phosphonate 
molecules, such as glyphosate find extensive application in agriculture as an herbicide. 
Glyphosate inhibits the essential enzyme- 5-enolpyruvateshikimate-3-phosphate synthase 
(EPSPS) (Steinrucken and Amrhein, 1984). X-ray crystallographic studies of EPSPS in complex 
with glyphosate show that glyphosate functions by occupying the binding site of the 
phosphoenolpyruvate, mimicking an intermediate state of the ternary enzyme substrate complex 
(Schonbrunn et al., 2001). Chemical structures of some naturally occurring phosphonate 
molecules and the enzyme reaction intermediates which they mimic are shown in Figure 3.1. 
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Several synthetic phosphonate molecules find applications in detergents, fuels, water purification, 
and in pulp and paper manufacture, among other uses. 
 Phosphonate compounds also occur in nature in the form of phosphonylated biological 
macromolecules such as lipids, sugars and glycoproteins. Their presence in the biosphere is 
exemplified by estimates that up to 30% of the available phosphorus in the oceans exist in the 
form of phosphonic acids (Clark et al., 1999). In light of the fact that phosphorus is often the 
limiting growth nutrient in the natural environment, it is not surprising that microbes have 
evolved metabolic pathways for the hydrolysis of phosphonate compounds for their subsequent 
utilization as sources for phosphorus, and carbon.  
 
Enzymatic routes for biodegradation of phosphonate molecules 
 Until recently, only four distinct pathways for the degradation of phosphonate 
compounds had been characterized (Figure 3.2A). The most widespread and substrate 
promiscuous pathway among these is the C-P lyase pathway, which utilizes a membrane 
associated multi-enzyme complex to catalyze phosphonate bond hydrolysis using [Fe-S]-based 
radical chemistry (Kamat et al., 2011; Shames et al., 1987; Wackett et al., 1987). All other 
phosphonate degradation pathways absolutely require a substrate with a β-carbonyl moiety 
adjacent to the phosphonate bond. PnAA (1 in Figure 3.2), produced by transamination of the 
most abundant naturally occurring phosphonate molecule- 2-aminoethylphosphonate (2-AEP), is 
hydrolyzed by the enzyme- phosphonatase through a bicovalent catalytic mechanism involving a 
Schiff-base intermediate (Morais et al., 2000). Phosphonopyruvate (PnPy), formed either by the 
enzymatic isomerization of phosphoenolpyruvate (Seidel et al., 1988), or by transamination of 
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phosphonoalanine (Ternan et al., 1998), is hydrolyzed by the enzyme- phosphonopyruvate 
hydrolase, using a mechanism similar to the isomerization of PnPy, differing only in the 
nucleophile which attacks the metaphosphate intermediate (Chen et al., 2006). Lastly, enzymatic 
hydrolysis of PnA (2 in Figure 3.2) to phosphate and acetate has been demonstrated. Phosphate 
starvation-independent PnA hydrolysis activity was observed in the crude extracts of 
Pseudomonas fluorescens 23F (McMullan et al., 1992). The enzyme was subsequently purified 
from the native producer, and shown in vitro to catalyze the zinc-dependent hydrolysis of PnA 
(McGrath et al., 1995). Subsequently, the corresponding gene (designated phnA) was cloned and 
the gene-product was heterologously expressed in bacteria and yeast (Kulakova et al., 1997). 
PnA hydrolysis activity has since been demonstrated in Streptomyces spp. (Panas et al., 2006), 
Penicillium spp. (Forlani et al., 2006), marine bacteria, and coral holobionts (Thomas et al., 
2010), establishing the presence of PhnA-mediated PnA hydrolysis in the microbial metabolome. 
It should be noted that the biogenic origins of PnA had not be established until this stage, and 
have been elucidated very recently only (Borisova et al., 2011). 
 Apart from the highly promiscuous C-P lyase pathway, the C-P bond-cleaving enzymes 
in the other three pathways require the presence of a β-carbonyl moiety adjacent to the 
phosphorus atom. However, the utilization of this β-carbonyl moiety by the three enzymatic 
mechanisms is vastly different. The PnAA hydrolyzing enzyme uses this group to generate a 
Schiff-base intermediate that activates the phosphonate group for attack by an active site 
nucleophile and provides resonance stabilization for the developing negative charge on carbon 
(Morais et al., 2000). PnPy hydrolase utilizes the β-carbonyl group for stabilization of the 
pyruvate leaving group by delocalizing the developing negative charge on the methylene group 
to the carbonyl oxygen (Chen et al., 2006; Kulakova et al., 2003; Ternan et al., 2000). The 
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mechanism employed by PnA hydrolase suggested by the co-crystal structures presented 
previously and in this study (Agarwal et al., 2011; Kim et al., 2011), also requires charge 
delocalization onto the β-carbonyl. 
 
Biosynthesis and degradation of PnA in Sinorhizobioium meliloti 1021 
 The enzymatic basis of conversion of 2-AEP into PnA and its subsequent hydrolysis to 
phosphate in the soil dwelling bacterium S. meliloti 1021, has recently been characterized 
(Borisova et al., 2011) (Figure 3.2B). The corresponding gene cluster consists largely of 
previously described enzymatic activities, including those for transamination of 2-AEP to PnAA 
(catalyzed by the ORF phnW) and for hydrolysis of PnA into inorganic phosphate (catalyzed by 
the ORF phnA). However, this cluster also includes a novel nicotinamide adenine dinucleotide 
(NAD
+
) dependent aldehyde dehydrogenase (ALDH) (phnY) whose gene product was shown to 
carry out the oxidization PnAA to PnA. PhnY thus provides a biogenic route for the production 
PnA and establishes a fifth pathway for microbial phosphonate degradation. Further 
bioinformatic analysis demonstrates that similar 2-AEP degradation pathways are present across 
many different bacterial species and PnAA oxidation might be widespread across diverse 
microbial populations (Villarreal-Chiu et al., 2012). Indeed, an NADP
+
-dependent PnAA 
oxidation activity was subsequently reported in the cell-extracts of a marine Roseobacter- 
Roseovarius nubinhibens ISM (Cooley et al., 2011). 
 Primary sequence analysis reveals PhnA to be a member of the alkaline phosphatase (AP) 
superfamily that can catalyze a range of phosphoryl and sulfuryl transfer reactions (Coleman, 
1992; Galperin et al., 1998). APs, and the related NPPs, catalyze the hydrolysis of phosphate 
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monoesters and diesters, respectively. The active site of these enzymes consists of a bi-metallo 
core and contains a catalytically required Ser or Thr that forms a covalent phosphoenzyme 
intermediate (Holtz et al., 1999). S. meliloti 1021 PhnA was shown to catalyze the hydrolysis of 
PnA to yield phosphate and acetate (Borisova et al., 2011). 
 Here, we present detailed biochemical and crystallographic characterization of the PnAA 
dehydrogenase PhnY from S. meliloti 1021 in the apo form, and of cocrystal complexes with the 
physiological substrate- PnAA, with and without the presence of the cofactor NAD
+
 in the active 
site. To facilitate the description of how the PhnY active site is primed for ‘phosphonated’-
aldehyde dehydrogenation, in comparison to phosphorylated-aldehyde substrates of primary 
metabolism, we have also determined the crystal structure of wild type PhnY in complex with 
glyceraldehyde-3-phosphate (G3P) (3 in Figure 3.2)  and NAD
+
. This is also the first report of a 
non-phosphorylating ALDH enzyme in complex with the reaction product- PnA, which allows 
for a comparison between the substrate and product binding interactions within the enzyme 
active site. We present kinetic characterization of structure guided site-specific mutants. Our 
structural and biochemical data, in the context of previous studies on the reaction mechanism of 
ALDHs, allow for the mechanistic proposal of the catalytic cycle for the oxidation of PnAA to 
PnA by PhnY. 
 In order to elucidate the mechanistic basis for C-P (rather than O-P) bond hydrolysis 
within the AP bi-metallo active site, we present detailed kinetic and structural studies of PhnA 
from S. meliloti 1021. Crystal structures of the wild-type PhnA enzyme confirm structural 
similarity to APs but with notable differences that likely direct activity toward the cleavage of a 
C-P bond. Kinetic analyses of metal-substituted PhnA and corresponding anomalous scattering 
diffraction experiments on zinc- and manganese-containing PhnA establish the in vitro metal 
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preference. Cocrystal structures with substrate PnA, product acetate ion, inhibitor PnF, and the 
transition state mimic vanadate, together with kinetic and structural analysis of site-specific 
active site variants, suggest a plausible mechanism for PnA hydrolysis by PhnA. Our results 
expand upon a very recent study of a PnA hydrolase from P. fluorescens 23F (Kim et al., 2011). 
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Experimental procedures 
Cloning, protein expression and purification 
 The construction of plasmid DNA bearing the wild type and PhnY and PhnA enzymes 
has been described previously (Borisova et al., 2011). These plamids were generously provided 
to us by the laboratories of Dr. Wilfred A. van der Donk and Dr. William W. Metcalf (University 
of Illinois at Urbana Champaign). All mutants were constructed using standard site directed 
mutagenesis protocols. All plasmids were sequeced (ACGT Inc., Wheeling- IL) to verify the site 
of mutagensis.  
 PhnY wild type and all PhnY mutant enzymes were purified under identical conditions. 
All plasmids were transformed into competent E. coli Rosetta2(DE3) strains for recombinant 
protein expression. A single colony of the transformed cells was grown overnight in Luria-
Bertani (LB) medium supplemented with 50 µg/mL kanamycin and 25 µg/mL chloramphenicol. 
This was subsequently used to innoculate 6 L of LB medium similarly supplemented with 
antibiotics, and grown at 37° C till the O.D. at 600 nm reached 0.6. Isopropyl β-D-
thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM and the culture was 
shifted to 18° C and grown for an additional 16 hours. All subsequent steps were performed at 4° 
C. The bacterial cells were harvested by centrifugation and resuspended in 20 mM Tris-HCl (pH 
8.0), 500 mM NaCl, 10% glycerol buffer and lysed by multiple passes through an Avestin C5 
homogenizer. The cell lysate was clarified by centrifugation and the supernatant was loaded onto 
a 5 mL bed volume His-Trap column (GE Biosciences) equilibrated with lysis buffer. 
Subsequent to loading, the column was extensively washed with 20 mM Tris-HCl (pH 8.0), 1 M 
NaCl, 30 mM imidazole buffer and eluted by a continous linear gradient to 250 mM imidazole 
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concentration in the wash buffer. Greater than 95% pure fractions thus obtained were extensively 
dialyzed against 20 mM Tris-HCl (pH 8.0), 500 mM NaCl with the addition of 1 unit/mg of 
thrombin enzyme to proteolytically remove the hexahistidine tag. Sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) was used to verify the complete digestion of 
the hexahistidine tag. The protein was then concentrated by spin filtration and were applied to 
Superdex-75 16/60 size exclusion chromatography column (GE Biosciences). The protein was 
isochratically eluted in 20 mM HEPES-Na (pH 7.5), 300 mM KCl buffer and concentrated to 0.2 
mM final concentration before being flash frozen in liquid nitrogen and storage at -80° C in 
small aliquouts.  
 Selenomethione incorporated PhnY wild type enzyme was prepared by previously 
established protocols (Van Duyne et al., 1993). Culture was grown under identical conditions in 
M9 minimal medium supplemented with antibiotics and 5 g/L D-glucose. When the O.D. reached 
0.4, 100 mg/L L-leucine, 100 mg/L L-lysine, 100 mg/L L-valine, 50 mg/L L-threonine, 50 mg/L 
L-phenylalanine and 50 mg/L L-isoleucine amino acids were added to the culture medium. After 
20 minutes of further growth at 37° C, 50 mg/L L-selenomethione amino acid was added to the 
culture medium. When the O.D. reached 0.6, culture was induced with IPTG and grown for an 
additional 16 hours at 18° C. The selenomethionine derivitized protein was purified identically to 
the wild type and mutant forms of PhnY. 
 The plasmid bearing the wild type PhnA was similarly transformed into competent 
Rosetta2(DE3) cells and recombinant protein expression carried out under identical conditions. 
The media was supplemented with 50 µg/mL kanamycin and 25 µg/mL chloramphenicol. No 
exogenous metal ions were supplemented in the growth media.The recombinant protein bearing 
the hexahistidine tag was isolated by Ni-NTA chromatography using the same protocol as that 
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for the PhnY enzyme. Greater than 95% pure fractions thus obtained were extensively dialyzed 
against 20 mM Tris-HCl (pH 8.9), 50 mM NaCl with the addition of 1 unit/mg of thrombin 
enzyme to proteolytically remove the hexahistidine tag. SDS-PAGE was used to verify the 
complete digestion of the hexahistidine tag. Protein was then loaded onto a Q-sepharose ion 
exchange column (GE Biosciences) equilibrated in the dialysis buffer and eluted by a linear 
continuous gradient to dialysis buffer supplemented with 1 M NaCl. Concentrated elution 
fractions were directly applied to Superdex-75 16/60 size exclusion chromatography column. 
The protein was isochratically eluted in 20 mM HEPES-Na (pH 7.5), 100 mM KCl buffer and 
concentrated to 1 mM final concentration before being flash frozen in liquid nitrogen and storage 
at -80° C in small aliquouts. The purified recombinant protein was a monomer in solution as 
determined using analytical size exclusion chromatography. PhnA protein used in the activity 
assays did not have the N-terminal hexahistidine tag removed. 
 
Protein crystallization, X-ray data collection and structure determination 
 The crystals of PhnY were grown at 15° C using hanging drop vapor-diffusion method by 
mixing 1 μL protein sample at 8 mg/mL concentration, with equal volume of reservoir mother 
liquor. Apo-form crystals were obtained in mother liquor containing 22-25% PEG3350, 0.1 M 
sodium cacodylate buffer (pH 6.5), 0.2 M sodium phosphate dibasic and 5-10% glycerol within 
two days and grew to their maximum size in one week. For crystallization in presence of 
cofactor NAD
+
, substrate PnAA, product PnA, and substrate analog G3P, the salt in mother 
liquor needed to be substituted from sodium phosphate. Several salts at various concentrations 
were trialed for this purpose. 0.2 M ammonium chloride was found to be the best candidate, as 
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judged by crystal morphology, and subsequently used for growing all crystals. Crystals were 
cryoprotected by brief soaking in mother liquor supplemented with 25% glycerol and vitrified in 
liquid nitrogen. The crystals appeared as plates which cracked instantly on exposure to the 
cryoprotectant solution. A number of different cryoprotectants were thus trialed and glycerol was 
found to be the best candidate, as judged by X-ray diffraction patterns and spot splitting. 
 A fourfold redundant data set was collected from a single crystal of S. meliloti 1021 
PhnY to a limiting resolution of 2.1 Ǻ (overall Rmerge = 0.072, I/σ(I) = 2.9 in the highest 
resolution shell) utilizing a Mar 300 CCD detector (LS-CAT, Sector 21 ID-D, Advanced Photon 
Source, Argonne, IL). Data were indexed and scaled using the HKL-2000 package (Otwinowski 
et al., 2003). The structure of PhnY was solved by SAD phasing using procedures described 
previously. Most of the main chain could be built using ARP/wARP (Perrakis et al., 1997). 
Cross-validation used 5% of the data in the calculation of the free R factor (Kleywegt and 
Brunger, 1996). The remainder of the model was fitted using XtalView and further improved by 
rounds of refinement with REFMAC (Murshudov et al., 1997; Murshudov et al., 1999) 
interspersed with rounds of manual building using XtalView (McRee, 1999). 
 The cocrystal structures of PhnY in complex with PnAA, NAD
+
-PnAA, NAD
+
-PnA, and 
NAD
+
-G3P, were determined to resolutions of 2.1 Å, 2.1 Å, 2.1 Å and 2.24 Å, respectively, by 
molecular replacement using the coordinates of apo PhnY as a search probe. Cross-validation 
was routinely used throughout the course of model building and refinement using 5% of the data 
in the calculation of the free R factor. For each of the structures, the stereochemistry of the 
model was monitored throughout the course of refinement using PROCHECK (Laskowski et al., 
1996).  
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 Apo wild type PhnA protein at a final concentration of 20 mg/mL in 20 mM HEPES-Na 
(pH 7.5), 100 mM KCl buffer was used for sparse matrix crystallization screening trials, using 
the hanging drop vapor diffusion technique. Diffraction quality crystals were obtained in two 
mother liquor conditions at 9º C, 25% PEG 3350, 0.2 M sodium chloride, 0.1 M Tris-HCl 
(pH 8.5) and 25% PEG 3350, 0.2 M ammonium acetate, 0.1 M HEPES-Na (pH 7.5). Crystals 
typically took three days to grow and were briefly soaked in mother liquor supplemented with 15% 
glycerol prior to vitrification in liquid nitrogen. PhnA mutants were crystallized according to the 
protocols for wild-type enzyme. The PhnA mutant Thr68Ala was incubated with 2 mM zinc 
chloride and 10 mM PnA for 2 hours on ice prior to sparse screening for crystallization. Co-
crystals of PhnA Thr68Ala mutant in complex with PnA were obtained in the crystallization 
condition 20% PEG 3350, 0.2 M ammonium chloride and briefly soaked in cryoprotectant 
solution of mother liquor supplemented with 20% glycerol, 5 mM zinc chloride and 50 mM PnA 
prior to vitrification in liquid nitrogen. Co-crystals of the complex with PnF were obtained by 
soaking apo protein crystals in 10 mM of PnF in the mother liquor for 12 hours. Metal ions were 
soaked by supplementing the mother liquor with 5 mM of zinc chloride, 5 mM manganese 
chloride, or 5 mM of iron(II) ammonium sulfate for 3 hours. To generate the covalently bound 
vanadate complex, apo protein was incubated on ice for 10 minutes with 2 mM freshly boiled 
sodium orthovanadate solution and then crystallized in the manner described above. 
 A ten-fold redundant data set was collected from crystals of S. meliloti 1021 PhnA to a 
limiting resolution of 1.35 Ǻ (overall Rmerge = 0.068, I/σ(I) = 1.8 in the highest resolution shell) 
utilizing a Mar 300 CCD detector (LS-CAT, Sector 21 ID-D, Advanced Photon Source, Argonne, 
IL). The structure of PhnA was solved by single wavelength anomalous diffraction utilizing 
anomalous scattering from a mercury derivative (six-fold redundancy with Rmerge = 0.084, I/σ(I) 
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= 3.2 in the highest resolution shell). Data were indexed and scaled using the HKL-2000 package 
(Otwinowski et al., 2003). Mercury sites were identified using HySS and the heavy atom 
substructure was imported to SHARP for maximum likelihood refinement and phase calculation, 
yielding an initial figure of merit of 0.497 to 1.9 Ǻ resolution. Solvent flattening using DM 
further improved the quality of the initial map and most of the main chain could be built using 
ARP/wARP (Perrakis et al., 1997). Cross-validation used 5% of the data in the calculation of the 
free R factor (Kleywegt and Brunger, 1996). The remainder of the model was fitted using 
XtalView and further improved by rounds of refinement with REFMAC (Murshudov et al., 1997; 
Murshudov et al., 1999) interspersed with rounds of manual building using XtalView (McRee, 
1999). 
 The co-crystal structures of PhnA with PnA, acetate, PnF, and vanadate were determined, 
to resolutions of 2.1 Å, 2.0 Å, 1.6 Å, and 1.8 Å, respectively, by molecular replacement using the 
coordinates of native PhnA as a search probe. Each of the structures was refined and validated 
using the procedures detailed above. Cross-validation was routinely used throughout the course 
of model building and refinement using 5% of the data in the calculation of the free R factor. For 
each of the structures, the stereochemistry of the model was monitored throughout the course of 
refinement using PROCHECK (Laskowski et al., 1996). Relevant data collection and refinement 
statistics are provided in Table 3.2. 
 
PhnY enzyme kinetics 
 The kinetics of conversion of PnAA to PnA by wild type PhnY enzyme and site specific 
mutants of PhnY were determined by monitoring the concomitant and equimolar reduction of the 
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NAD
+
 by PhnY using procedures described previously (Borisova et al., 2011). The Asn158Ala, 
Arg290Ala and Glu385Ala mutant enzymes were assayed at 15 μM final enzyme concentration 
and 1 mM final PnAA concentration. The low level activity precluded determination of KM 
values. kcat values were verified by a linear correlation between the rate of change of absorbance 
and enzyme concentration used in the assay for each mutant enzyme. The Cys291Ala and 
Glu254Ala mutant enzymes were assayed at various substrate and enzyme concentrations but no 
activity could be observed. Activity for G3P was monitored at 2 mM final concentration of 
substrate using three different enzyme concentrations (7 µM, 15 µM and 20 µM final enzyme 
concentrations). The low level activity precluded determination of KM values. The Glu254Asp 
mutant protein was quite unstable during purification processes and could not be concentrated 
above ~ 20 µM concentration. Hence comparison assays for G3P dehydrogenation between the 
wild type and Glu254Asp enzymes were conducted at 10 µM enzyme concentration. 
 
PhnA enzyme kinetics 
 The generous help of Dr. Svetlana A. Borisova in conducting the kinetics experiments for 
PhnA is gratefully acknowledged. The formation of inorganic phosphate from PnA by the action 
of N-terminally hexahistidine tagged PhnA (PhnA-N-His) was detected by a discontinuous assay 
using a Malachite Green phosphate assay kit (BioAssay Systems, Hayward, CA). Assay mixtures 
(500 µL total volume) containing 50 mM HEPES-Na (pH 7.5) and 0.42 µM PhnA-N-His were 
pre-incubated at 30° C for 8 minutes and the reaction was initiated by the addition of PnA stock 
solutions to final concentrations of 0-400 µM. Aliquots of the reaction mixture (80 µL) were 
taken out every 20 seconds over a period of 2 minutes, quenched by the addition to 20 µL of 
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Malachite Green reagent prepared as per the manufacturer’s instructions, and incubated at room 
temperature for 30 minutes for color development. The assays were done in duplicate. The 
absorbance at 620 nm was plotted against the reaction time and the rate of A620 increase was 
converted to the rate of phosphate formation using a linear calibration curve prepared with 
known concentrations of inorganic phosphate standard (0-40 µM). The initial rates of phosphate 
formation were fit to the Michaelis-Menten equation (V0=([S]*Vmax)/([S]+KM)) using the IGOR 
Pro 6.1 software package (WaveMetrics, Portland, OR) in order to determine steady state kinetic 
parameters of PhnA-N-His.  
 To evaluate the divalent metal dependence of PhnA-N-His, 10 µM ZnCl2, MgCl2 × 6H2O, 
MnCl2 × 4H2O, CoCl2 × 6H2O, or (NH4)2Fe(SO4)2 × 6H2O were added to the assay mixture prior 
to the pre-incubation period and assays were performed as described above. The concentrations 
of PhnA-N-His were adjusted (0.07-0.48 µM) to allow for the detection of product formation 
within the linear range of the assay. Assays in the presence of oxygen-sensitive Fe(II) were set 
up in an anaerobic chamber obtained from Coy Laboratory Products, Inc. (Grass Lake, MI) 
under an atmosphere of N2 and H2 (95%/5%). The aliquots of buffer-enzyme solution containing 
Fe(II) were subsequently brought outside the glove box in tightly capped eppendorf tubes, 
followed by pre-incubation and reaction initiation with PnA as described above. 
 Metal-free PhnA-N-His was prepared by treatment of the protein with 8.3 mM EDTA 
sodium salt  at 4° C for 3 hours with gentle agitation followed by size exclusion chromatography 
using a PD-10 desalting column (GE Healthcare, Piscataway, NY) eluted with 50 mM HEPES-
Na (pH 7.5), 0.2 M NaCl, 10% glycerol. The resulting apo PhnA-N-His was tested in the activity 
assay as described above with and without addition of Zn
2+
, Mn
2+
, or Fe
2+
. When combinations 
of two divalent metal cations were studied (at 10 µM each) initial rates of product formation 
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were measured at 200 µM PnA. Enzymatic activity of PhnA mutants purified as above but not 
treated with EDTA (at 10 µM, except for the Thr68Ala mutant at 5 µM) was measured as 
described above in the presence of 20 µM Mn
2+
 and 0.2 or 1.0 mM PnA. The formation of Pi was 
monitored over a period of 0.5-1 hours.  
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Results and discussion 
Overall crystal structure of wild type PhnY in apo state 
 The structure of PhnY from S. meliloti 1021 has been determined in the wild type apo 
state to 2.1 Å resolution. Crystallographic phases were determined by single wavelength 
anomalous diffraction data collected on crystals of selenomethionine labeled protein, followed 
iterative rounds of manual building and automated refinement to generate a final model with 
R/Rfree = 0.199/0.246. The crystallographic asymmetric unit consists of eight protein chains 
comprising four sets of biologically relevant homodimers. The arrangement of these protein 
chains as sets of homodimers is consistent with the behavior of PhnY as a dimer in solution, as 
judged by its elution profile using size exclusion chromatography (Figure 3.3). Members of the 
aldehyde dehydrogenase (ALDH) superfamily have been previously found to exist as dimers as 
well as tetramers in solution. 
 Each PhnY monomer has a tertiary structure that can be divided into three distinct 
domains (Figure 3.4). Residues 1-123, 147-256 and 461-475 together constitute the ‘cofactor-
binding domain’ and adopt a classical α/β Rossmann fold. Residues 257-460 comprise of the 
‘catalytic domain’ with a α/β fold comprised of a central seven membered β sheet flanked by α 
helices on either side. Residues 124-146, together with residues 476-486 constitute the three-
membered antiparallel β sheet ‘oligomerization’ domain that provides the principal contacts for 
dimerization. The secondary structure loops at the interface of the cofactor-binding domain and 
the catalytic domain of PhnY provide nearly all the residues implicated in substrate binding and 
catalysis (vide infra). The active site is located at the solvent occluded interface between the 
cofactor-binding and catalytic domains, with the catalytic nucleophile- Cys291 positioned on a 
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loop that connects the third and fourth β sheet of the catalytic domain. Another distinctive long 
loop region in the vicinity of the active site at the domain interface spans residues 440-467 and 
connects the penultimate β strand of the catalytic domain to a short α helix of the cofactor 
binding domain, and finally culminates in a β strand in the oligomerization domain.  
 ALDH superfamily of enzymes can be divided into three subfamilies based on the 
reaction catalyzed. These are the phosphorylating ALDHs, the non-phosphorylating ALDHs, and 
the coenzyme A dependent non-phosphorylating ALDHs. The structure of PhnY is similar to that 
of members of non-phosphorylating ALDH superfamily. A DALI search against the Protein Data 
Bank identifies the strongest structural homology to G3P dehydrogenase (GAPDH) from 
Streptococcus mutans (Cobessi et al., 1999) (PDB Code 2EUH, Z-score=54.3 , RMSD=1.6 Å 
over 468 aligned C atoms), aminoaldehyde dehydrogenase from Pisum sativum (Tylichova et 
al., 2010) (PDB Code 3IWK, Z-score=53.1 , RMSD=1.9 Å over 468 aligned C atoms), human 
succinic semialdehyde dehydrogenase (Kim et al., 2009) (PDB Code 2W8R, Z-score=52.6, 
RMSD=1.8 Å over 464 residues), and betaine dehydrogenase from P. aeruginosa (Diaz-Sanchez 
et al., 2011b) (PDB Code 2WOX, Z-score=52.3, RMSD=1.8 Å over 463 residues). 
 Electron density corresponding to a phosphate ion (presumably originating from the 
crystallization mother liquor) can be observed at the active site of PhnY (Figure 3.5). The 
phosphate ion is present near Cys291, where the three of the four phosphate oxygen atoms are 
coordinated by hydrogen bonds with the side chains of Asn158 (Nδ2 - O1 distance of 3.1 Å), 
His159 (Nε2 - O2 distance of 2.8 Å), Arg290 (Nη2 - O2 distance of 3.3 Å) and Arg447 (Nη2 - 
O3 distance of 3.3 Å). A primary sequence alignment of ALDHs that catalyze dehydrogenation 
reaction for a phosphorylated substrates and ALDHs which do not require phosphorylated 
substrates identifies the strict conservation of this basic, phosphate binding pocket formed by 
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three Arg and one His/Tyr residues in the former (Figure 3.6). The basic phosphate binding 
pocket is found conserved in the S. meliloti 1021 PhnY, Roseobacter PhnY and the S. mutans 
GAPDH, while being absent from the succinic semialdehyde and betaine dehydrogenases. Hence 
a primary sequence alignment of a non-phosphorylating ALDH enzyme can used to predict 
whether the enzyme substrate would be phosphorylated or non-phosphorylated, by the presence 
or absence of the basic phosphate binding pocket. 
 
Cocrystal structure with physiological phosphonate substrate PnAA 
 Freshly prepared PnAA was synthesized as described previously (Borisova et al., 2011), 
and generously provided by Dr. Svetlana A. Borisova (Mining Microbial Genomes theme, 
Institute for Genomic Biology, University of Illinois at Urbana Champaign). Enzymatically 
synthesized PnAA was used at 10 mM concentration without further purification. Crystals of 
PhnY with covalently bound PnAA were obtained by incubating the wild type enzyme with 5 
mM PnAA, and subsequent crystallization using solutions devoid of phosphate salts. A complete 
dataset was collected from a single crystal and the structure determined using the apo PhnY 
structure as a search model for molecular replacement. The resultant 2.1 Å resolution cocrystal 
structure is nearly identical to that of the apo structure with no secondary or tertiary structural 
rearrangements apparent. The |Fobs| - |Fcalc| difference electron density map shows unambiguous 
density for all atoms of PnAA in the active site of all eight protein monomers in the 
crystallographic asymmetric unit (Figure 3.7A). PnAA is bound at the interface of the cofactor-
binding and catalytic domains. The side chain thiol of Cys291 undergoes a 120
o 
rotation, relative 
to the apo structure, which correctly positions this residue for interactions with the substrate. The 
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Cys291-Sγ atom in this conformation is 3.0 Å and 3.3 Å away from the backbone amide nitrogen 
atoms of Cys291 and Thr292 respectively. Similar interactions, in related members of the ALDH 
superfamily, have been implicated in modulating the nucleophilicity of the Cys side chain for 
nucleophilic attack. 
 Two lines of evidence suggest that Cys291 engages PnAA through a covalent linkage: 
first, continuous electron density in the |Fobs| - |Fcalc| map is consistent with the substrate aldehyde 
carbon atom positioned 1.65 Å away from the Cys291-Sγ atom, indicative of covalent bond 
between these two atoms. Second, the electron density at the aldehyde carbon atom suggested 
that the stereochemistry is not planar sp
2
, as would be expected for an aldehyde moiety. Instead, 
the bond angle between the three atoms- (i) PnAA-aldehyde O (ii) PnAA-Cβ (iii) PnAA-Cα 
atoms is 111°, and the bond angle the aldehyde (i) PnAA-aldehyde O (ii) PnAA-Cβ (iii) Cys291-
Sγ atoms is 107.7° (phosphonate carbon atom of PnAA is denoted as Cα, the aldehyde bearing 
carbon atom of PnAA is denoted as Cβ) (Figure 3.7B). These bond angles are indicative of a 
tetrahedral sp
3
 stereochemistry at the PnAA-Cβ atom, which can be only be generated by the 
nucleophilic addition of the Cys291 side chain thiol (Cys291-Sγ) on the PnAA-Cβ atom to 
generate a tetrahedral thiohemiacetal reaction intermediate. Thus the hydrogen atom, which 
would occupy the fourth position in the tetrahedral geometry around the PnAA-Cβ atom, would 
point opposite to the plane defined by (i) PnAA-Cα (ii) PnAA-aldehyde O (iii) Cys291-Sγ atoms. 
Consistent with the proposed reaction mechanism for ALDH enzymes, this geometry would 
revert back to planar sp
2
at the PnAA-Cβ atom once the hydride is transferred to the nicotinamide 
ring of NAD
+
 cofactor to generate a thiolate ester of the substrate with the Cys291-Sγ atom 
(Figure 3.10), but as crystals were grown without the cofactor, this structure represents the 
substrate in the form of a catalytically relevant covalent tetrahedral thiohemiacetal intermediate. 
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The mechanistic scheme for the reaction catalyzed by PhnY is discussed in greater detail in later 
sections. 
 The covalent bond between the Cys291-Sγ atom and the PnAA-Cβ atom converts the 
PnAA aldehyde moiety into a hydroxyl group; with the hydroxyl oxygen positioned 3.1 Å from 
the amide side chain of Asn158 (Figure 3.7A). As next nearest interaction partner for this 
hydroxyl is His159 (positioned 4.0 Å away), Asn158 provides the principal interaction for the 
stabilization of the tetrahedral thiohemiacetal intermediate hydroxyl. An additional stabilizing 
interaction is provided by the backbone amide nitrogen atom of Cys291 residue. Thus the side 
chain of Asn158 and main chain amide nitrogen atom of Cys291 constitutes the ‘oxyanion hole’ 
for stabilization of the thiohemiacetal intermediate hydroxyl.  
 Interactions with the oxygen atoms of the PnAA substrate phosphonate moiety are 
provided by Arg108 (Nη1 – O1 distance of 2.9 Å) (Nη2 – O1 distance of 3.0 Å), Arg290 (Nη2 - 
O2 distance of 3.1 Å) (Nε – O3 distance of 2.8 Å) and Arg447 (Nη2 – O1 distance of 2.8 Å) 
(Figure 3.13A). Additional interactions include a hydrogen bond with His159 (Nε2 – O3 distance 
of 2.6 Å) and a water-mediated hydrogen bond with the backbone carbonyl oxygen atom of 
Gly445 (not shown in figure 3.7). 
  
Kinetics of PnAA oxidation by wild type and mutant PhnY enzymes 
 The structural model of the PhnY in covalent complex with PnAA described in the 
previous section has been verified by extensive mutational and kinetic analysis. Cys291, Asn158, 
His159, Arg108, Arg290 and Arg447, which contribute to substrate engagement, were targeted 
for mutagenesis to alanine, and the change in kinetic properties of the mutant enzymes was 
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determined by monitoring the increase in absorbance at 340 nm due to production of reduced 
nicotinamide adenine dinucleotide (NADH) during the course of oxidation of PnAA to PnA 
(Borisova et al., 2011). For the wild type enzyme, the Michaelis-Menten steady state kinetics 
parameters calculated from at least three independent initial rate measurements for each different 
substrate concentration yielded kcat = 2.1 ± 0.4 sec
-1
 and KM = 3.2 ± 0.2 µM for PnAA which are 
in good agreement with the already published values (Borisova et al., 2011) (Table 3.1).  
 No activity could be observed when the catalytically requisite residue Cys291 was 
replaced by Ala. The PhnY-His159Ala mutation led a modest decrease in kcat to (16.33 ± 1.36) × 
10
-2
 sec
-1
 and an increase in KM value to 136.61 ± 12.39 µM with respect to PnAA. However, the 
Asn158Ala mutation resulted in a kcat of (4.25 ± 0.44) × 10
-3
 sec
-1
 that is reduced by nearly 500-
fold relative to the wild-type. KM values for the mutant enzyme could not be determined as the 
initial rates could not be reproducibly measured at lower substrate concentrations. A linear 
correlation of this kcat value with enzyme concentration used in the assay verified that the 
measured absorbance increase was at a fully saturating substrate concentration. Replacement of 
Arg108 by Ala led to 80 fold decrease in kcat to (25.36 ± 0.94) × 10
-3
 sec
-1
 and a 25 fold increase 
in KM to 75.08 ± 10.38 µM with respect to PnAA. The Arg290Ala mutation results in a drastic 
decrease in kcat to (4.75 ± 0.77) × 10
-3
 sec
-1
. For this particular mutant the KM value for could not 
be determined. The Arg447Ala mutation reduced the kcat value to (35.13 ± 4.88) × 10
-3
 sec
-1
 and 
drastically increased the KM to 392.93 ± 27.82 µM. As all of the above residues directly contact 
the PnAA substrate, the KM values for mutations at these sites have been determined with respect 
to PnAA.  
 As noted before, binding of PnAA in a productive conformation in the PhnY active site 
requires a 120° rotation of the catalytic Cys-Sγ atom. This rotation is affected upon substrate 
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binding. Hence it can be inferred that the PhnY active site is not pre-organized in a catalytically 
proficient conformation. The required catalytically proficient conformation is achieved by the 
covalent binding of the PnAA-Cβ to Cys291 side chain, and the subsequent rotation of the 
Cys291 side chain, which in turn is driven by the favorable enthalpy of binding of PnAA 
phosphonate oxygen atoms to the basic binding pocket. This enthalpic contribution of the 
phosphate binding pocket is reflected in the reduction of kcat values by mutagenesis, concomitant 
with increase in KM values (Table 3.1). Another structural finding which supports this hypothesis 
is the positioning of the side chain of Arg108 residue in the PhnY apo crystal structure in 
presence of Pi (Figure 3.5) and in the presence of PnAA (Figure 3.7). In the presence of Pi, the 
Arg108 side chain is too far to coordinate to the oxygen atoms of Pi and is hence moved away 
from the active site. This is analogous to an Arg108Ala mutation with respect to the active site. 
However binding of PnAA organizes the Arg108 side chain to a substrate binding productive 
conformation, where it is absolutely required for efficient catalysis, as the Arg108Ala mutant is 
nearly 2000 fold catalytically less proficient than the wild type enzyme (as judged by the ratio of 
kcat/KM values). 
  
Structure of the ternary complex with NAD
+
 and PnAA offers insight into the deacylation 
state of the enzyme 
 As ALDHs follow ordered sequential kinetics for substrate oxidation (Cobessi et al., 
2000; D'Ambrosio et al., 2006; Marchal and Branlant, 1999; Marchal et al., 2000), structural data 
on a cofactor bound complex can only be achieved in a ternary complex. In order to determine 
the enzyme active site architecture by the concomitant binding of the substrate and the cofactor 
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molecules, we attempted to co-crystallize the enzyme with fivefold molar excess of the substrate 
as compared to the cofactor. Once crystals were obtained, they were soaked with crystallization 
solution supplemented with 5 mM of NAD
+
 and harvested by cryoprotection and vitrification in 
liquid nitrogen at different time points, prior to data collection. We envisaged that this approach 
should potentially yield an architecture which would describe the tetrahedral geometry around 
the aldehyde carbon prior to hydride transfer and in which the cofactor is in the productive 
hydride transfer conformation. Alternately, it should yield the planar geometry around the 
aldehyde carbon subsequent to the hydride transfer with the cofactor is positioned in the 
conformation which would support deacylation of the transition state by nucleophilic attack by a 
water molecule. The two scenarios can also offer an insight into the rate limiting step of the 
ALDH catalytic cycle (discussed in detail in a later section). Visualization of the first scenario 
will suggest that the hydride transfer step is rate limiting, while visualization of the second 
scenario might suggest that the deacylation step is rate limiting. 
 However, this experimental approach, despite our exhaustive efforts in diffraction data 
collection after different time points after the crystal soaking, was unsuccessful in describing 
either of the two functional states for the enzyme. The electron density maps obtained for the 
cofactor after all time points demonstrated a lack of electron density for the nicotinamide ring of 
the cofactor (Figure 3.8), and hence were not used for the description of the cofactor. Similar 
results were obtained when PhnY was crystallized in complex with NAD
+
 alone. These 
observations have been reported in literature before, and their functional implications with 
respect to the proposed reaction mechanism are discussed in greater detail in a later section. 
 However the stereochemistry around the Cβ atom of PnAA has shifted to a planar sp2 
hybridization, as judged by the bond angles between the three atoms- (i) PnAA-aldehyde O (ii) 
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PnAA-Cβ (iii) PnAA-Cα atoms (120.9°), and the bond angle between (i) PnAA-aldehyde O (ii) 
PnAA-Cβ (iii) Cys291-Sγ (118.4°) (Figure 3.8B). This shift in stereochemistry is indicative of 
the post-hydride state of the enzyme. This is also supported by the cofactor nicotinamide ring not 
being positioned in the productive hydride transfer conformation. The most unexpected result, 
however, was the finding of the side chain positioning of the catalytic base residue- Glu254 (vide 
infra). The glutamate side chain carboxylate points inwards towards the active site, but enzyme 
deacylation has not yet occurred. This leads us to postulate that deacylation, rather than hydride 
transfer is the rate limiting step for the ALDH reaction mechanism. 
  
Structure of the ternary complex with NAD
+
 and PnA 
 A complete description for all atoms of the NAD
+
 cofactor could only be obtained when 
wild type PhnY enzyme was co-crystallized with the cofactor and the reaction product- PnA. The 
2.1 Å resolution cocrystal structure of PhnY in complex with NAD
+
 and PnA shows clear and 
continuous density for the cofactor in all copies of the monomer peptides in the crystallographic 
asymmetric unit (Figure 3.9). In this structure, NAD
+
 is bound such that the nicotinamide ring is 
situated at the interface of the cofactor-binding and catalytic domains. Interactions stabilizing 
this conformation of the cofactor are described starting from the adenine ring, and proceeding to 
the nicotinamide ring.  
 The adenine ring of NAD
+
 is positioned in a hydrophobic pocket defined by Val238, 
Leu241 and Ile242 on one face, and Pro214 at the other face. The 2’ and 3’ hydroxyls of the 
adenosine ribose sugar are both stabilized by interactions with Lys181 side chain amine. The 2’ 
hydroxyl makes additional contacts with Glu184, while the 3’ hydroxyl contacts the backbone 
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amide of Thr183 and the backbone carbonyl of Thr155. The carboxyl side chain of Glu385 
provides the only interaction for the nicotinamide ribose 2’ and 3’ hydroxyl groups. The 
nicotinamide ring is nearly parallel to the Cys291 side chain, which is situated at the re- face of 
the nicotinamide ring. Although the distance between the Cys291-Sγ atom and the nicotinamide 
C4 atom is only 2.3 Å, the two atoms are unlikely to be covalently linked. There is no continuous 
electron density between the Cys291-Sγ and the nicotinamide C4 atoms, unlike the case of P. 
aeruginosa betaine ALDH that does indeed form a covalent complex between these atoms (Diaz-
Sanchez et al., 2011a, b). A hydrophobic binding pocket composed of Pro156, Met163 and 
Thr233 is located at the si- face of the nicotinamide ring. A comparative decrease in 
conformational ordering of the cofactor, starting from the adenine to the nicotinamide terminus 
of NAD
+
, is evident in the quality of the difference electron density maps (Figure 3.9).  
 The ternary complex structure with NAD
+
 shows Glu385 side chain provides the only 
interaction with the nicotinamide ribose 2’ and 3’ hydroxyl groups. Consequently, the 
Glu385Ala mutation results in a 300 fold reduction in kcat value to (6.91 ± 0.87) × 10
-3
 sec
-1
. In 
order to elucidate the molecular basis for this reduction in catalytic activity, we solved the 2.3 Å 
resolution cocrystal structure of PhnY Glu385Ala mutant enzyme in complex with NAD
+
. The 
structure shows that cofactor binding occurs in a non-productive manner that would hinder 
hydride transfer and likely accounts for the lowered activity of this mutant (data not shown). We 
could not determine the KM values for NAD
+
 or PnAA for this mutant due to the drastic 
reduction in activity, but, based on the cocrystal structure, we speculate that the KM values with 
respect to PnAA would not be altered to same degree as that for NAD
+.
  
 The PhnY-NAD
+
-PnA cocrystal structure also allows for the description of the structural 
changes at the active site that accompany the oxidation of the substrate PnAA to product PnA. 
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The cocrystal structure is consistent with a non-covalent product bound complex, as evidenced 
by the fact that the electron density between the carboxylate carbon atom of PnA and the 
Cys291-Sγ is discontinuous, and that the distance between the two atoms in the refined structure 
is 3.7 Å (Figure 3.9). Relative to the PnAA complex structure, the position of the PnAA-Cα atom 
and the adjoining Cβ-carboxylate has shifted, such that only one of the carboxylate oxygen 
atoms now co-ordinates with the Asn158 side chain amide, while no interactions exist for the 
other oxygen atom. In addition, the tetrahedral angle at the PnAA-Cα carbon is reduced by about 
5
o
. These features distinguish the PnA product structure from that of the covalent complex with 
the PnAA intermediate. 
 
Conformational flexibility of the cofactor is a prerequisite for the proposed reaction 
mechanism for PhnY 
 In the proposed reaction mechanism for ALDHs, the reduced cofactor is not released 
from the enzyme prior to deacylation, but rather ‘flips-out’ from the enzyme active site to adopt 
alternate conformations (Cobessi et al., 2000; D'Ambrosio et al., 2006). These alternate 
conformations of the cofactor have been extensively investigated in literature, and at least three 
different conformations have been structurally described with the cofactor occupying varying 
positions that may reflect different spatial positions along the reaction trajectory. A conserved 
feature of all these cofactor conformations is the relatively higher thermal (B) factors for the 
nicotinamide ring and the preceding ribose sugar atoms, and lower B values for the adenine ring 
and the succeeding ribose sugar. This is also clearly reflected in the electron density maps 
obtained for the cofactor in various different studies, with a lack of electron density for the 
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nicotinamide ring of the cofactor in some examples. A major determinant for whether the 
nicotinamide ring of the cofactor could be positioned into the enzyme active site is the 
conformation of the side chain of the catalytic Cys291. In the PhnY apo crystal structure, the 
Cys291-Sγ atom is in a position which would sterically clash at the re face of nicotinamide ring 
π-electron system. Upon binding to the substrate PnAA, the Cys291 side chain thiol undergoes a 
120° rotation along the Cys291-Cβ atom. The outward rotation of the cysteine side chain makes 
sufficient room for the nicotinamide side chain to be positioned in a productive conformation for 
catalysis, thus providing the first structural premise for the ordered-sequential mechanism. A 
superposition of the PhnY-PnAA cocrystal structure with that of PhnY-PnA-NAD
+
 cocrystal 
structure reveals that the active site geometry defined by the two structures is apt for the transfer 
of the hydride from the tetrahedral thiohemiacetal carbon (described by the PnAA cocrystal 
structure) to the C4 carbon atom from the re face of the cofactor nicotinamide ring (described by 
the PnA-NAD
+
 cocrystal structure) (Figure 3.10). The thiohemiacetal intermediate is arranged 
such that the hydride to be transferred to the cofactor would point towards the re face of the 
nicotinamide ring. The change in the pucker of the nicotinamide ring subsequent to hydride 
transfer may result in steric clashes with these closely spaced atoms, and is presumed to be 
responsible for the cofactor adopting the 'flipped-out' conformation reported in literature, and as 
observed in the Glu385Ala-NAD
+
 cocrystal structure. 
 The second premise for the ordered-sequential mechanism is provided by the position of 
the side chain of Glu254. Based on the structural data and sequence alignments (Figure 3.6), 
Glu254 was presumed to the general base that deprotonates a water molecule for nucleophilic 
attack to initiate the deacylation half reaction. The PhnY-Glu254Ala mutant enzyme was found 
to be catalytically inactive. The manner in which the cofactor binds in the hydride transfer 
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conformation described above occludes the Glu254 side chain from pointing towards the active 
site by steric clash between the Glu254 side chain and the si face of the nicotinamide ring of the 
cofactor. Hence, before the cofactor nicotinamide ring departs the active site subsequent to the 
hydride transfer, the second deacylation half reaction cannot occur. The fact that the cofactor 
binding for hydride transfer precludes deacylation of the enzyme provides a rationale for the 
observed flexibility of the nicotinamide ring. It should be noted that the Glu254 is markedly 
flexible, and does not have any strong stabilizing contacts in its occluded state. This 
conformational flexibility of the catalytic base has previously been observed for other ALDHs 
(Bains et al., 2011). We also observe Glu254 positioned in this occluded state in the substrate 
and product cocrystal structures, while it is relatively disordered in several of the apo structure 
monomers. Hence the driving force for the conformational change of the Glu254 side chain to 
bring it to a catalytically efficient state is not immediately clear.  
 Based on our structural and kinetic data, a reaction mechanism scheme for PhnY can be 
proposed (Figure 3.11). Pursuant to this scheme, binding of PnAA active site causes the rotation 
of the side chain of Cys291. This removes the steric occlusion for the nicotinamide ring of the 
cofactor caused by the Cys291-Sγ atom in the apo state of the enzyme. Thus the cofactor can 
now be positioned so that the hydride of the thiohemiacetal intermediate points towards to the re 
face of the nicotinamide ring, and is aptly positioned to be transferred to the C4 atom of the 
nicotinamide ring. Subsequent to hydride transfer, the thiohemiacetal intermediate converts to a 
planar thioester. This structural change, in conjunction with the loss in planarity of the 
nicotinamide ring subsequent to hydride transfer causes the cofactor to leave the active site of the 
enzyme. The departure of the cofactor allows the catalytic base- Glu254 to be correctly 
positioned so that it can deprotonate a water molecule and position it correctly for nucleophilic 
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addition at the thioester intermediate. This addition generates a thiohemiketal intermediate which 
is resolved by the departure of the Cys291 side chain to yield PnA. Differences in the mode of 
binding of PnAA and PnA within the PhnY active site cause the departure of the product and the 
enzyme regenerates for the next catalytic cycle. 
 
Cocrystal structure with phosphorylated aldehyde substrate G3P and cofactor NAD
+
 
 In order to determine the catalytic repertoire of the PhnY enzyme, we explored 
dehydrogenation activity of PhnY for non-physiological phosphorylated substrates. A 
hypothetical phosphorylated mimic of PnAA would be unstable in aqueous buffers due to the 
presence of a phosphate anhydride, with demonstrated increase in its labile nature at neutral to 
alkaline pH (Lipmann, JBC, 1944). Hence, G3P (3 in Figure 3.2) was chosen as a candidate 
substrate mimic. PhnY could indeed accept G3P as a substrate, as judged by the 
spectrophotometric assay (Figure 3.12), albeit with a much reduced kcat value of 0.039 ± 0.002 
sec
-1
, which is nearly 1500 fold slower than G3P oxidation by S. mutans GAPDH (Cobessi et al., 
2000) (Table 3.1). This demonstrates that the active site of PhnY is adapted for the oxidation of 
PnAA, as compared to the GAPDH active site which is adapted for G3P acceptance. The 
postulated structural basis of this substrate preference is delineated in this section. The low level 
of activity, coupled with the high enzyme concentration needed for detection, precluded the 
determination of KM, as initial turnover rates could not be measured reproducibly at lower 
substrate concentrations.  
 The crystal structure of the PhnY enzyme in presence of G3P was determined by co-
crystallizing the enzyme with 10 mM G3P and 1 mM NAD
+
. Racemic mixture of G3P was 
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obtained from Sigma-Aldrich and directly used without further purification. Though the 
crystallization conditions remained the same, diffraction quality co-crystals of the enzyme could 
not be obtained with G3P alone, as with the physiological substrate PnAA described previously. 
Electron density could not be observed in the 2.1 Å co-crystal structure obtained for the entirety 
of the cofactor. Electron density for the cofactor is missing for the nicotinamide ring and the 
ribose sugar connected to it. As discussed previously, this lack of electron density has previously 
been observed for other members of the ALDH family (Cobessi et al., 2000; D'Ambrosio et al., 
2006; Langendorf et al., 2010).  
 Unambiguous robust electron density for all atoms of the G3P substrate molecule can be 
observed in the active site (Figure 3.13). No major secondary or tertiary structural 
rearrangements are required for the accommodation of G3P, as compared to the binding of 
PnAA in the active site. The phosphate group bearing carbon atom of G3P is denoted as Cα, 
followed by the Cβ bearing the hydroxyl, and the Cγ bearing the aldehyde group. The aldehyde 
carbon of G3P is covalently bonded to the side chain sulfur atom of Cys291-Sγ atom and is 
positioned 1.7 Å away. The stereochemistry around the G3P-Cγ atom, as determined by the bond 
angles, points towards a tetrahedral geometry. Though the complex with G3P has been obtained 
in the presence of the cofactor, this tetrahedral geometry indicates that the hydride transfer to the 
cofactor has not yet occurred. This probably is a consequence of 10 fold higher concentration of 
G3P than that of NAD
+
 used during crystallization. The aldehyde oxygen atom, which is thus 
modeled as a hydroxyl is 2.7 Å away from the side chain amide of Asn158. No interactions can 
be observed for the Cβ-hydroxyl, and the bridging oxygen atom of the phosphate moiety to the 
Cα methylene carbon atom. The phosphate moiety of G3P is positioned analogously to the 
phosphonate group of PnAA, by hydrogen bond interactions with the basic triad formed by 
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Arg108 (Nη1 – O1 distance of 3.0 Å) (Nη2 – O1 distance of 3.3 Å), Arg290 (Nη2 - O2 distance 
of 2.9 Å) and Arg447 (Nη2 – O2 distance of 3.1 Å) (Figure 3.14). 
 
Elasticity of the phosphate binding pocket; structural basis for substrate specificity in 
ALDHs 
 A comparison of the structure of PhnY-PnAA, with that of GAPDH-G3P-NADPH (PDB 
Code: 2ESD), provides the framework to probe the structural requirements necessary to 
differentiate between a phosphonate and phosphate ester within the ALDH active site. It should 
be noted that the cofactor bound to GAPDH in PDB- 2ESD is not in a productive hydride 
transfer conformation and is hence assumed not to provide any constraints upon substrate 
binding in the active site. A superposition of the PhnY-PnAA (Figure 3.14A) structure with that 
of the GAPDH-G3P-NADPH (Figure 3.14B) complex shows that the two substrates, PnAA and 
G3P, differ by the distance between the aldehyde carbon, on which catalysis occurs, and the 
phosphonate/phosphate head group that provides the major binding interactions. The G3P 
substrate in GAPDH is bound in a distinctly planar sp
2
 conformation in all four monomers, and 
the stereochemistry at this atom was established based on control experiments that demonstrated 
that reduction of the cofactor had occurred within the crystals (D'Ambrosio et al., 2006).  
 While the two structures can be aligned with high conservation of secondary structural 
elements, a view of the phosphonate/phosphate binding pocket reveals that the selectivity for a 
particular substrate is built into the active site primarily by the relative positions of the three Arg 
residues (Figure 3.14). When the two catalytic site Cys (PhnY-Cys291 and GAPDH-Cys284) are 
superimposed, the aldehyde carbon and oxygen atoms of the substrate also align, along with the 
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side chain of PhnY-Asn158 and GAPDH-Asn154. However, due to a longer distance between 
the aldehyde carbon and the phosphate head group in G3P, GAPDH-Arg103 and GAPDH-
Arg283 are significantly pushed away from the active site as compared to the corresponding 
residues- PhnY-Arg108 and PhnY-Arg290 respectively. GAPDH-Arg437 (analogous to PhnY-
Arg447) is also distorted away from the PhnY phosphate binding site. A rationale can also be 
derived for the mutation of the highly conserved GAPDH-Tyr155 to a histidine (PhnY-His159). 
His159 provides an additional contact to one of the phosphonate oxygen atoms and a bulkier 
tyrosine side chain could not be accommodated at this position due to steric clash with the 
closely spaced phosphonate group in the PhnY active site. Thus, we hypothesize that the 
phosphate binding pocket is fairly elastic and this freedom to adopt slightly different 
conformations on a highly conserved secondary and tertiary structural core provides for the 
modulation of substrate preference for ALDH enzymes.  
 This argument hypothesizing the conformational elasticity of the phosphate binding 
pocket is lent further credence by two observations of the present study. Firstly, aligning the 
PhnY cocrystal structures in the presence of inorganic phosphate and substrate PnAA 
demonstrates a similar elasticity of the phosphate binding pocket (Figure 3.5 and Figure 3.7). 
The inorganic phosphate deviates significantly from the expected binding site delineated by the 
phosphonate group in the PnAA cocrystal structure. The phosphate is moved towards the 
catalytic Cys291 residue and makes contacts with Asn158 side chain as well. This lateral shift of 
the phosphate ion makes the Arg108 residue side chain to lose contacts with the phosphate and it 
can then be positioned away from the active site by stabilizing interactions with Asp111. 
Secondly, a comparison of the PhnY-PnAA structure with that of the PhnY-NAD
+
-PnA structure 
(Figure 3.7 and Figure 3.9) demonstrates a movement of the phosphonate group of PnA in the 
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opposite direction; towards the phosphate binding pocket. As the PnA-Cβ cannot be covalently 
bonded to Cys291-Sγ, PnA is laterally shifted away from the catalytic site and towards the 
phosphonate binding site. This lateral shift in the PnA phosphonate oxygen atoms is 
accommodated by a corresponding shift in the Arg108 side chain. Rather surprisingly, of the four 
residues which comprise of the phosphonate binding pocket for PhnY, only Arg108 is placed on 
an α-helix, while His159, Arg290 and Arg447 are all placed on loops at the interface of the 
catalytic domain and the cofactor binding domain. Hence the modulation of the phosphate 
binding pocket elasticity primarily by the movement of the Arg108 residue was rather 
unexpected. 
 A comparison of the GAPDH and PhnY active sites with their respective substrates 
bound also provides a rationale for the requirement of a phosphate ester substrate (G3P) by 
GAPDH, while PhnY accepts a phosphonate substrate (PnAA). The bridging phosphate ester 
oxygen atom in G3P is coordinated by the side chain guanidine group of GAPDH-Arg437 
residue. One of the Nη atoms of Arg437 is placed 2.6 Å away from this oxygen atom and thus 
forms a strong hydrogen bonding interaction (highlighted in red in Figure 3.14B). This 
interaction is absent in the PhnY-PnAA complex active site. The corresponding Arg residue for 
PhnY- Arg447 is positioned away from the bridging PnAA-Cα atom and the Nη atom of Arg447 
side chain contacts one of the phosphonate oxygen atoms at a distance of 2.8 Å (Figure 3.14A). 
An additional interaction for G3P phosphate ester oxygen atom is also provided by the side chain 
of GAPDH-Tyr155 residue, while the analogously placed PhnY-His159 residue only hydrogen 
bonds to the phosphonate oxygen atoms of PnAA. Hence it can be postulated that the 
requirement for the acceptance of a phosphate ester substrate for an ALDH enzyme led to 
additional interaction of the enzyme active site residue side chains with the phosphate bridging 
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ester oxygen atom (highlighted in red in Figure 3.14B).These interactions have consequently 
been lost for a phosphonate molecule, thus providing an example of substrate directed evolution 
in the ALDH family. 
 
Structurally restrained diversification of the substrate portfolio for ALDHs 
 It should be noted that although the substrates of PhnY and GAPDH resemble each other, 
PhnY is more than an order of magnitude slower than the reported kinetic values for S. mutans 
GAPDH (Marchal et al., 2000). This kinetic observation can be explained on the basis of the 
vicinity of the oxygen atom of the thiohemiacetal intermediate to other molecules of the substrate. 
For PhnY, the thiohemiacetal transition state Cβ-hydroxyl is positioned only 2.9 Å away from 
one of the phosphonate oxygen atoms (Figure 3.7). On the other hand, for GAPDH the 
corresponding hydroxyl has no such destabilizing steric/electrostatic repulsions from the G3P 
phosphate oxygen atoms. In addition, the G3P substrate has taken advantage of the free rotation 
possible around the G3P-Cβ carbon to position the 2' hydroxyl away from the oxygen atom of 
the thiohemiacetal intermediate. A similar arrangement is hypothetically possible for the PhnY 
substrate as well, as free rotation is possible at the PnAA-Cα atom. In such a hypothetical, more 
energetically favorable scenario for substrate binding in the PhnY active site, the phosphorus 
atom would rather be positioned where one of the hydrogen atoms is for the PnAA-Cα atom, and 
would thus be positioned away from the Cβ aldehyde oxygen atom. However, such a positioning 
of the phosphonate group would make the phosphonate oxygen atoms lose all contacts with 
PhnY-His159 and PhnY-Arg290 side chains. However, by analogy to the active site for GAPDH, 
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and by the kinetic data obtained in this study for the His159Ala and Arg290Ala mutations, such 
a hypothetical enzyme-substrate complex would not be catalytically proficient.  
 Another argument in support of the above discussion is provided by the comparison 
between G3P binding in the PhnY and GAPDH active sites. In GAPDH active site, G3P is fully 
extended with the aldehyde oxygen atom being more than 7.0 Å away from the nearest 
phosphate oxygen atom. However, for G3P binding in the PhnY active site, the tetrahedral angle 
between the G3P Cγ-Cβ-Cα atoms has been reduced to only 96.5 degrees (Figure 3.14C). Hence, 
we would like to propose that PhnY represents a classical example of how diverse catalytic 
activities have been built upon a conserved structural core in nature. This divergence of activity, 
concomitant with the preservation of structure at a kinetic cost for catalysis, has not been 
previously demonstrated in the ALDH superfamily. 
 
Overall structure of apo wild type PhnA enzyme 
 The PhnA protein from S. meliloti 1021 was heterologously produced in E. coli with an 
amino-terminal hexahistidine tag. For crystallization, the tag was removed via thrombin protease 
cleavage. Initial crystallographic phases for the wild-type PhnA were determined by single 
isomorphous replacement using diffraction data collected on native crystals soaked with mercury 
salts, and the structure has been subsequently refined against data to 1.35 Å resolution. Relevant 
data collection and refinement statistics are provided in Table 3.2. The overall structure of PhnA 
is shown in Figure 3.15. 
 The structure of PhnA consists of two distinct domains, a core domain that is highly 
homologous within members of the AP superfamily, and a divergent capping domain that has 
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only previously been observed in the structure of NPP from Xanthomonas axonopodis pv. citri 
(Zalatan et al., 2006) and in the crystal structure of PnA hydrolase from P. fluorescens 23F (Kim 
et al., 2011). The core domain comprises residues Met4-Gly85, Asp104-Met253, and Ser376-
Ala416 and consists of a seven-membered β sheet flanked by eight α helices on either side. The 
capping domain has a typical α/β/α fold and is composed of residues Lys254-Arg375. Of 
particular note is the β-loop-β appendage comprising of residues Ile86-Asn103, which extends 
from the helices of the core domain and contacts the central β sheet of the capping domain 
(Figure 3.15). This appendage is also present in the crystal structure of NPP (Zalatan et al., 2006), 
but absent in the structures of Aps hydrolyzing phosphate monoesters. The PhnA structures 
described here are more complete and of higher resolution than the previously reported structure 
of P. fluorescens 23F PnA hydrolase (PDB ID: 1EI6) (Kim et al., 2011), in which several 
residues proximal to the active site were disordered and consequently were not modeled. Of note 
the current structure presents complete modeling of all residues of the β-loop-β appendage and 
all surface loops of the core domain, along with alternate conformations of several residues, 
primary among which is the M2 metal binding residue, Asp29 (vide infra). 
 
Active site metal ion 
 Members of the AP superfamily are characterized by the presence of two requisite metal 
ions, and the nature of the metal-coordinating protein ligands is highly conserved (Coleman, 
1992). Likewise, PhnA contains two metal ions (referred to as M1 and M2, consistent with 
nomenclature for this superfamily) with M1 coordinated by His215, His377, and Asp211 and M2 
coordinated by Asp29, Asp250, and His251 (Figures 3.16 and Figure 3.18). As in other members 
of the AP superfamily, metal M2 likely activates the catalytic Thr68 for nucleophilic attack at the 
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phosphorus atom (Ghosh et al., 1986; Kim et al., 2011; Schwartz and Lipmann, 1961) and metal 
M1 likely stabilizes the leaving group generated after hydrolysis and activates a water molecule 
for nucleophilic displacement at the phosphorus atom during hydrolysis of the phosphorylated 
enzyme intermediate (Coleman, 1992). 
 The bound metal ions in PhnA (as purified from heterologous over expression in E. coli) 
are zinc ions; their identity and location were determined using anomalous diffraction data 
collected at the zinc absorption edge (Figure 3.16A). Interestingly, the distance between the two 
metal ions was 4.6 Å. This distance is significantly greater than the distance between the metal 
ions in E. coli AP (4.26-4.28 Å; PDB ID: 1ED9) (Figure 3.16B) and NPP (4.26-4.36 Å; PDB ID: 
2GSN) (Figure 3.16C), and to the best of our knowledge is greater than the distance reported for 
any other AP superfamily members (Stec et al., 2000; Zalatan et al., 2006). 
 In alkaline phosphatases, a third metal (typically magnesium) is located in the active site 
and is postulated to be critical for deprotonation of the serine side chain, and subsequent 
generation of the alkoxide nucleophile (Kim and Wyckoff, 1991). This third metal is absent in 
PhnA, as has also been observed in the structure of NPP (Zalatan et al., 2006). Absence of the 
third metal ion in NPP has led to re-evaluation of its role in phosphoryl group transfer reactions 
mediated by APs. More recent studies comparing the reactivities of monoester and diester 
substrates suggest that the magnesium ion stabilizes a non-bridging oxygen atom in the transition 
state for phosphate monoester hydrolysis (Zalatan et al., 2008). In the PhnA structure, side chains 
of residues Cys27, Asp29, Asn72, Tyr206, and Thr208 form a hydrogen bonding network 
replacing the region corresponding to the third metal site in alkaline phosphatases. The 
mechanistic implications of the absence of this third metal in the structure of PhnA are not 
immediately clear. 
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Metal ion specificity 
 APs can utilize a vast array of divalent metal ions in the catalytic M1 and M2 positions, 
with the metal ion specificity subject to change by alterations in the active site amino acid side 
chains (Wojciechowski and Kantrowitz, 2002). To probe the specific metal ion preference for 
PhnA, we monitored the catalytic efficiency of the enzyme that was overexpressed and purified 
from E. coli, and after its incubation with Mg
2+
, Zn
2+
, Co
2+
, Fe
2+
, and Mn
2+
 (Table 3.3). As 
previously reported (Borisova et al., 2011), the enzyme purified from E. coli efficiently catalyzed 
the hydrolysis of PnA without addition of metal ions. When PhnA was incubated with Zn
2+
 prior 
to the activity assay, only a small improvement in kcat was observed along with an increase in KM. 
However, when PhnA was pre-incubated with Mn
2+
 or Fe
2+
, two to three fold improvement in 
kcat was observed with only small variations in the KM values (Table 3.3). Activity assays in the 
presence of Mg
2+
 or Co
2+
 resulted in decreased kcat values with a substantially lower KM value of 
PhnA reconstituted with Co
2+
 compensating for the lower turnover number of this enzyme. 
 Enzyme purified from E. coli was treated with the metal ion chelator 
ethylenediaminetetraaceticacid (EDTA) to remove the metal ions already bound to the enzyme. 
The resulting apo-PhnA was devoid of enzymatic activity. However, the activity was fully 
reconstituted by brief incubation of PhnA with different divalent metal ions prior to the activity 
assays (Table 3.3). Thus, addition of Zn
2+
 produced a form of PhnA with the kinetic parameters 
nearly identical to those of the as-isolated enzyme. The greatest increase in the enzymatic 
activity was observed upon reconstitution of EDTA-treated PhnA with Mn
2+
 resulting in a 
kcat/KM value four-fold higher than that found for as-isolated PhnA. When combinations of equal 
concentrations of either Fe
2+
 and Zn
2+
 or Mn
2+
 and Zn
2+
 were tested for apo-PhnA reconstitution, 
the activity of the enzyme did not exceed that of Zn-reconstituted PhnA suggesting that it is 
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present predominantly as the Zn-bound form in either preparation and that PhnA has the greatest 
affinity for Zn
2+
. 
 In order to probe whether differences in activity were a consequence of structural 
changes between the zinc and manganese substituted enzymes, we collected anomalous 
diffraction data on Mn
2+
-substituted PhnA. Double difference Fourier maps were calculated 
which showed unambiguous positive density for metal ions in the M1 and M2 positions only at 
the manganese absorption edge assuring that both sites of the recombinant PhnA are occupied by 
manganese under the conditions used. The structure of Mn
2+
-PhnA is virtually identical to that of 
Zn
2+
-PhnA including the metal-metal distance (4.6 Å), suggesting that the structural results 
detailed below are valid for enzyme containing either metal. It should be noted that the values of 
kinetic constants observed for any of the metal-bound forms of PhnA (Table 3.3) are within the 
physiologically relevant range. Thus, it is likely that the identity of the PhnA-bound metal in 
vivo is strongly influenced by the intracellular levels of metal ions. It is likely that the 
recombinant isolation of PhnA as a zinc-bound form is reflective not only of its metal ion 
selectivity but also of the intracellular Zn
2+
, Mn
2+
, and Fe
2+
 ion levels, estimated in E. coli at 
approximately 100 μM for zinc and iron and 10 μM for manganese (Outten and O'Halloran, 
2001). The intracellular levels of metal ions in S. meliloti 1021 have not been reported to date. 
 
Model for a transition state structure 
 Hydrolysis of phosphate esters by APs takes place by an in-line double displacement 
mechanism in which the alkoxide ion, generated on a serine or threonine side chain, first attacks 
the tetracoordinated phosphorus atom. This displacement of a metal-stabilized leaving group by 
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the enzyme nucleophile occurs via a trigonal bipyramidal transition state, leading to the 
formation of a covalent phosphoseryl (or phosphothreonyl) intermediate (Coleman, 1992). 
Hydrolysis of this intermediate involves attack of a metal-bound hydroxide onto the phosphorus 
atom displacing the Ser/Thr via another trigonal bipyramidal transition state. The covalent 
adduct of orthovanadate ion with the catalytic serine or threonine side chain mimics the trigonal 
bipyramidal geometry of the transition state with the nucleophile and the leaving group 
occupying the axial positions; three of the oxygen atoms attached to the vanadium atom occupy 
the equatorial positions. Complexes with vanadate have been reported for both AP and NPP and 
have led to insights into the stabilization of the reaction transition state (Holtz et al., 1999; 
Zalatan et al., 2006). These structural data have facilitated the identification of stabilizing 
interactions for each of the equatorial oxygen atoms. For both enzymes, one oxygen atom is 
directed in between the metal ions and is stabilized by electrostatic interactions. Two other 
equatorial oxygen atoms in E. coli AP are stabilized by interactions with the guanidinium group 
of Arg166. For NPP, in which phosphate diester hydrolysis results in two, instead of three, non-
bridging equatorial oxygen atoms, Asn111 (in X. axonopodis) interacts with one of the oxygen 
atoms to stabilize the transition state. 
 In order to delineate the interactions that occur in the transition state for phosphonate C-P 
bond hydrolysis by PhnA, we have determined the co-crystal structure of a covalent complex 
with orthovanadate at 1.65 Å resolution (Figure 3.17A and Figure 3.20). As observed for NPP 
(Zalatan et al., 2006) and AP (Holtz et al., 1999), the trigonal bipyramidal structure of the 
orthovanadate adduct is slightly distorted, with the O-V-O bond angle for the axial oxygen atoms 
being 168
o
 in PhnA compared to 157
o
 for NPP and 170
o
 for AP. But unlike AP and NPP, the 
three equatorial oxygen atoms are not in a plane with the vanadate atom but tilted towards the 
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M2 ion (Figure 3.20). The side chain hydroxyl of Thr68 is placed in one of the axial positions 
and the oxygen atom at the other axial position interacts with the zinc ion in the M1 site, which 
corresponds to the leaving group stabilization by the metal ion in a phosphate ester hydrolysis 
reaction. One of the equatorial oxygen atoms is situated in between the zinc atoms at a distance 
of 1.8 Å to M2 and a longer distance of 2.6 Å to M1, while the second equatorial oxygen is 
within hydrogen bonding distance (2.7 Å) of the amide bond nitrogen of Thr68. However, unlike 
NPP, where an additional hydrogen bond from the side chain of Asn111 further stabilizes the 
equatorial oxygen, no appropriately placed amino acid side chains are within hydrogen bonding 
distance. A water molecule coordinated by the side chain of Asn89 is placed 3.5 Å away from 
this equatorial oxygen and this water molecule additionally interacts with the backbone nitrogen 
of Asn69 (Figure 3.20). When Asn89 was replaced with valine the catalytic activity of the PhnA-
Asn89Val mutant was reduced approximately 10
4
-fold as compared to the wild-type PhnA 
(Table 3.4). Crystal structure of the Asn89Val mutant determined at 1.8 Å resolution revealed 
that both metal ions are preserved in the mutant structure and no major rearrangements of the 
amino acid side chains around the active site could be observed. However, the arrangement of 
the water molecules in the active site is different from that of the wild-type enzyme (data not 
shown) supporting the contribution of the water-mediated contact to Asn89 side chain to 
transition state stabilization. In AP, the third equatorial oxygen atom is hydrogen bonded to 
Arg166; in NPP, this oxygen carries a substituent in the phosphodiester substrate and does not 
have any interaction partners in the NPP crystal structure. In PhnA, this third oxygen makes 
water-mediated contacts in the PhnA-vanadate structure (Figure 3.20). A water molecule, 
hydrogen bonded to the carboxylate side chain of Asp29 is positioned 3.2 Å away. 
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Crystal structure of PhnA with acetate bound 
 Diffraction data from crystals of PhnA soaked with PnA reveal the appearance of 
electron density consistent with an acetate ion bound to the M1 metal ion (Figures 3.17B and 
3.19). Two lines of evidence suggest that the resultant electron density for acetate derives from 
turnover of the PnA substrate by PhnA: first, diffraction data from crystals grown under identical 
conditions but without the addition of PnA do not show density for acetate; second, no 
contamination of acetate could be detected in samples of PnA used for co-crystallization as 
determined by proton NMR spectroscopy.  
 In the 2.0 Å resolution PhnA-acetate co-crystal structure, both oxygen atoms of the 
acetate ion are coordinating to the M1 metal ion at a distance of 2.1 Å (Figure 3.19). 
Coordination of the two oxygen atoms of the carboxylate moiety of acetate by the M1 metal ion 
places the methyl group of acetate 2.4 Å from the M1 metal ion and 3.9 Å from the M2 metal ion. 
Although not observed in the structure, the spacing between the acetate and M2 metal ion is 
sufficient to accommodate a phosphate group covalently bound to Thr68. One water molecule is 
positioned 2.85 Å away from the methyl group of the acetate and is stabilized by hydrogen bond 
interactions with the backbone carbonyl of Ile287 and backbone amide nitrogen of Asn69. 
 
Co-crystal structure of PhnA-Thr68Ala with PnA and postulated reaction mechanism 
 Attempts at co-crystallization of wild-type PhnA enzyme with substrate, or soaking of 
apo wild-type enzyme crystals with PnA were unsuccessful as across all concentrations of 
substrate employed, catalytic turnover of the substrate lead to incorporation of the acetate ion in 
the active site of the enzyme and no density of the phosphate moiety could be observed. Hence 
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co-crystallization of PnA with Thr68Cys, Thr68Ala, and Thr68Gly mutants (exhibiting 
approximately 10
5
, 10
3
, and 10
5
-fold decreases in activity, respectively, Table 3.4) was attempted. 
Of these, crystals could not be obtained for the Thr68Gly mutant enzyme, while crystals of the 
Thr68Cys enzyme led to incorporation of malate ion from the crystallization condition into the 
active site (data not shown). Crystals could also be obtained for the Thr68Ala mutant and 
showed robust density for PnA in the active site (Figures 3.17C and 3.21). The identity of the 
ligand is affirmed by the presence of strong electron density at a position corresponding to the 
electron dense phosphorus atom of the substrate. The phosphonate group of the substrate 
molecule is bound in a manner consistent with the transition state model predicted by the 
vanadate covalent crystal structure. The phosphorus atom is 3.4 Å away from the side chain 
methyl group of alanine at position 68 (corresponding to the position of the Thr nucleophile). 
One oxygen atom of the phosphonate of PnA points towards the M2 metal ion and is positioned 
at a distance of 2.0 Å. A second oxygen atom is hydrogen bonded to the backbone amide of 
Ala68, 2.7 Å from the amide nitrogen. A water mediated hydrogen bond exists between Asp29 
and the third oxygen atom (Figure 3.21). Another equidistant water molecule is also hydrogen 
bonded to the side chain of Asn69. Superposition of the apo wild-type PhnA structure to the 
PhnA-Thr68Ala-PnA structure positions the catalytic threonine side chain hydroxyl 1.8 Å from 
the phosphorus atom and the theoretical bond angle between the hydroxyl oxygen, phosphorus 
atom and methylene group of PnA is 163
o
, close to the 168
o
 seen for the vanadate transition state 
mimic. For comparison, the bond length between the vanadate atom and the catalytic threonine 
hydroxyl oxygen in the covalent complex is 2.0 Å. Thus the position of the phosphonate group in 
the Thr68Ala mutant is slightly skewed towards the threonine hydroxyl as compared to the 
vanadate transition state model. 
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 The acetate moiety of the substrate is bound in a different manner to the Thr68Ala mutant 
compared to the acetate-bound state of the wild-type enzyme described above. While the acetate 
ion binds to the M1 metal ion in a bidentate manner in wild-type PhnA, the substrate acetate 
moiety binds to M1 of the Thr68Ala mutant in a monodentate fashion with one of the oxygen 
atoms at a distance of 2.5 Å from M1 and the second oxygen pointing away from the metal, and 
hydrogen bonded to a solvent molecule. This water in turn is hydrogen bonded to the backbone 
carbonyl of Ile287 (Figure 3.21). The distance of the methylene group of PnA to the M1 metal 
ion is 2.2 Å, close to the observed distance of 2.4 Å between the M1 ion and the methyl group of 
bound acetate; the distance to M2 is 4.4 Å. As a consequence of binding of the substrate to both 
metals the carbon-carbon-phosphorus bond angle is quite small (102
o
) with the carbon-
phosphorus bond oriented in a way that upon its cleavage would allow electron delocalization 
into the π system of the metal-bound carboxylate. Hence, it appears that the bound conformation 
of PnA to the Thr68Ala mutant resembles the productive complex for catalysis. 
 
Asymmetric stabilization of the transition state by slight alterations in the active site of 
PhnA 
 The suggested mode of monodentate stabilization of an enolate intermediate by a metal 
ion is reminiscent of mandelate racemase enzyme. Mechanistic and crystallographic studies of 
this enzyme have demonstrated that an enolate intermediate of mandelate is stabilized by a 
divalent magnesium ion that binds only one of the oxygen atoms of the intermediate. This 
oxygen also interacts with a Lys. The second oxygen atom of the enolate of mandelate is 
coordinated by a strictly conserved glutamate side chain, and the enolate anion is further 
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stabilized by resonance with an aromatic ring (Kallarakal et al., 1995). In PhnA, only a water 
molecule is hydrogen bonded to the second oxygen of the carboxylate. 
 From our data, the stabilization of developing negative charge on the leaving group by 
the M1 metal ion appears to be a conserved feature of the alkaline phosphatase superfamily 
members, albeit the manner by which the active site geometry is used differs considerably from 
phosphate ester hydrolysis. Compared to AP and NPP, PhnA must activate a much weaker, 
carbon-based leaving group instead of an oxygen-based leaving group. As a measure of leaving 
group ability, the pKa of the conjugate acid of the acetate enolate is likely to be >30 (Richard and 
Amyes, 2001) compared to a typical alcohol pKa of ~15-18). In addition to the different leaving 
group ability, the charge distribution on the leaving group is also significantly different. During 
phosphate ester hydrolysis, significant charge build-up occurs on the bridging oxygen of the 
leaving group and this charge is stabilized by the M1 ion (Zalatan and Herschlag, 2006). For 
phosphonate hydrolysis, the charge is delocalized such that most of the charge likely resides on 
the oxygen atoms of the acetate enolate (Figure 3.22). This charge would be situated further from 
the oxygen of the threonine nucleophile coordinated to the M2 ion. Thus, a longer metal-metal 
distance appears to be required to simultaneously stabilize the developing charge on the leaving 
group with the M1 ion and activate the threonine nucleophile with the M2 ion. The involvement 
of Thr68 as a nucleophile is supported by a recent study on PhnA from P. fluorescens 23F (Kim 
et al., 2011) that reported loss of activity when the corresponding residue was mutated and that 
demonstrated labeling of the threonine hydroxyl with a phosphate group when incubated with 
γP-ATP, a slow substrate for PhnA. Thus, only the relatively long Zn-Zn distance allows the 
PnA substrate to simultaneously bind to both metals in a conformation that supports formation of 
an acetate enolate intermediate.  
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 How PhnA can stabilize the much weaker leaving group with essentially the same active 
site architecture as that of AP and NPP to achieve effective catalysis is at present not clear. 
Unlike the extensive studies of enzymatic and non-enzymatic hydrolysis of phosphate 
monoesters and phosphate diesters, which have provided a detailed picture of transition state 
structures, very little is known about the transition state structure for C-P bond cleavage. 
Although at present it is not clear which features of the active site geometry of PhnA facilitate 
efficient catalysis beyond electrostatic stabilization of the leaving group, a plausible explanation 
can be offered for the previously reported poor activity for phosphate ester hydrolysis (Kim et al., 
2011). AP has been shown to utilize strong electrostatic stabilization of the negative charge of 
the non-bridging oxygen atoms by the binuclear Zn
2+
 cluster (Nikolic-Hughes et al., 2005). On 
the basis of structures of AP with vanadate bound (PDB Code: 1B8J) (Holtz et al., 1999), one of 
the non-bridging oxygen atoms is believed to interact with both metals in the transition state 
(Figure 3.23). On the other hand, the vanadate structure of PhnA is decidedly non-symmetric 
with the corresponding equatorial oxygen, interacting much more strongly with M2 than with 
M1. 
 The formation of a stabilized enolate dianion was also recently proposed for PnA 
hydrolysis by P. fluorescens 23F PhnA based on structural and mechanistic studies (Kim et al., 
2011). In that study, two lysine residues (Lys126 and Lys128) were implicated in furnishing 
potential stabilization of the enolate intermediate. These residues are conserved in S. meliloti 
1021 PhnA (Lys130 and Lys132), however, they do not appear to be involved in any binding 
interactions with the active site ligands in any of the structures reported here. The active sites of 
S. meliloti 1021 and P. fluorescens 23F enzymes are very similar with the Zn-Zn distance 
slightly shorter in the latter (4.47 Å). However, a few differences exist between the two enzymes, 
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most notably the recombinant enzyme from S. meliloti 1021, as isolated from E. coli, is 
monomeric, whereas the enzyme from P. fluorescens 23F is a dimer (Kim et al., 2011). Detailed 
mechanistic studies will be required to distinguish between the two strategies of enolate 
stabilization proposed based on the structural information. 
 
Crystal structure of inhibitor PnF-bound PhnA 
 Kinetic analyses in previous studies (Kim et al., 2011; McGrath et al., 1995) have 
identified PnF as an inhibitor of PnA hydrolase. Quinn and coworkers hypothesized that the 
inhibition of PnA hydrolase from P. fluorescens 23F could be due to the similar structures of 
PnA and PnF (McGrath et al., 1995). In order to delineate the inhibitory mechanism of PnF, we 
determined the crystal structure of PhnA in the presence of PnF to a resolution of 1.6 Å (Figure 
3.17D). While no rearrangement of the metal binding side chains was observed, the distance 
between the zinc ions increased to 4.7 Å. 
 Compared to the vanadate binding site in the covalent complex described previously, the 
phosphonate moiety of PnF is skewed towards the M1 zinc ion. One oxygen atom of the 
phosphonate is stabilized by electrostatic interactions with the M1 ion positioned 1.85 Å away 
(Figure 3.17D). A water-mediated hydrogen bonding interaction also exists between a second 
oxygen atom of the phosphonate moiety and the side chain of Asp29. Similarly, the third oxygen 
atom interacts with the side chain of Asn89 through a water-mediated hydrogen bond. However, 
the phosphorus atom is rather far (3.4 Å) from the side chain of the catalytic Thr68 residue for 
nucleophilic attack of the alkoxide ion on this atom. The angle defined by the oxygen atom of the 
Thr68 side chain and the C-P bond is 71
o
, suggesting that inhibitor binding does not mimic 
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substrate binding but rather that it binds in a non-productive manner. The carboxylate group is 
positioned towards the sites of stabilization of the vanadate equatorial oxygen atoms. One of the 
carboxylate oxygen atoms is 3.0 Å away from the backbone amide of Thr68 and is involved in a 
hydrogen bonding interaction, and the other oxygen atom is stabilized by a water molecule, 
which in turn is hydrogen-bonded to the side chain of Asn89 and backbone amide of Asn69. 
Hence, based upon the predicted reaction transition state, as delineated by the PnA co-crystal 
structure and vanadate covalent complex structure, inhibition of enzymatic activity by PnF does 
not seem to be dependent upon an analogous binding mode of the substrate and inhibitor 
molecules, but rather upon the tight but non-productive binding interactions of this molecule in 
the active site of the enzyme. In the crystal structure of PnA with AP (Holtz et al., 2000), which 
has a shorter Zn-Zn distance, PnA is bound in the active site in a conformation analogous to the 
PnF binding observed in this study for PhnA, hence acting as a competitive inhibitor of AP 
rather than a substrate. 
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Future directions 
 The productive hydride transfer complex described for PhnY in this study is a hypothetic 
model generated by the superpositioning of the PhnY-PnAA and PhnY-NAD
+
-PnA crystal 
structures. Visualization of this state of the enzyme experimentally has been elusive, despite our 
exhaustive efforts in this regard. An attractive strategy would be mutation of the catalytic 
Cys291 residue to alanine, and then probe the crystal structure of the enzyme in the presence of 
PnAA and NAD
+
. Though such a PhnY-Cys291Ala mutant would undoubtedly loose the 
covalent contact with the substrate, it would also alleviate the steric hindrance for the proper 
positioning of the cofactor nicotinamide ring in the active site. The molecular biological 
groundwork towards the realization of this aim has been laid, with the construction of the mutant 
plasmid, and purification of the PhnY-Cys291Ala enzyme. Crystallization of the ternary 
complex has not been achieved to date, as crystals could not be reproduced in the original 
condition. We aim to exhaustively screen crystallization conditions in aim to generate diffraction 
quality crystals of the ternary complex, and determine the high resolution co-crystal structure. 
Several questions remain unanswered with respect to the involvement of the active site 
residues in the vicinity of the catalytic threonine residue of PhnA. Analogous to the model of 
transition state stabilization in AP and NPP, PhnA-Asn89 should ideally be suitably placed to 
make contacts with the phosphonate equatorial oxygen atoms. However, our present structural 
data identifies it to be too distant to be in direct contact with the oxygen atoms. The exact 
reasoning of why the phosphonate hydrolase active site diverges in this respect as compared to 
AP and NPP is not presently clear. 
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 In order to address this issue, we aimed to generate crystal structures of mutant of PhnA 
in which the Asn89 residue has been replaced with a variety of hydrophobic, basic and acidic 
amino residues. An array of PhnA- Asn89Ala, Asn89Lys, Asn89Arg, Asn89Glu, Asn89Asp and 
Asn89Gln mutants was generated, and recombinant proteins purified and crystallized as for the 
wild type and Thr89Ala enzyme. We seek to determine the high resolution crystal structure of 
these mutants, and in conjunction with the kinetic characterization, aim to elucidate the exact 
catalytic role of these residues. A previous study delineating the crystal structure of P. 
aeruginosa PhnA enzyme also hinted at alteration in the kinetic properties of the enzyme by the 
mutation of two histidine residues which lie on the β-appendage. These histidine residues are 
also conserved in PhnA, though the present crystal structures do not shed light on their mode of 
involvement in catalysis. We also aim generate crystal structures of these mutants and probe in 
molecular detail the alterations in the PhnA active site due to their mutagenesis.  
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Tables 
 
Table 3.1 Steady state kinetic parameters for PhnY wild type and mutant enzymes. 
 KM (µM) kcat (sec
-1
) 
PnAA as substrate 
Wild type 3.2 ± 0.2 2.1 ± 0.4 
Cys291Ala n.d.
 1
 n.d. 
Glu254Ala n.d. n.d. 
Asn158Ala n.d. (4.3 ± 0.4) × 10
-3
 
Arg108Ala 75.1 ± 10.4 (25.7 ± 0.9) × 10
-3
 
His159Ala 136.6 ± 12.4 (16.3 ± 1.4) × 10
-2
 
Arg290Ala n.d. (4.8 ± 0.8) × 10
-3
 
Arg447Ala 392.9 ± 27.8 (35.1 ± 4.9) × 10
-3
 
Glu385Ala n.d. (6.9 ± 0.9) × 10
-3
 
G3P as substrate 
Wild type n.d. (3.9 ± 0.2) × 10
-2
 
Cys291Ala n.d. n.d. 
 
1 
n.d.: Not determined. Low levels of activity precluded kinetic parameter determination. 
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Table 3.2 PhnA Data collection, phasing and refinement statistics. 
 
 PhnA (native) 
PhnA-
Vanadate 
PhnA-PnA 
PhnA-Acetate PhnA-PnF 
Data collection      
Space group P43212 P43212 P43212 P43212 P43212 
Cell dimensions      
a, b, c (Å)
111.8, 111.8, 
72.8 
111.1, 111.1, 
72.4 
111.4, 111.4, 
72.8 
111.4, 111.4, 
72.9 
111.6, 111.6, 
72.5 
Resolution (Å)
1 
50-1.35 (1.4-
1.35) 
50-1.8 (1.83-
1.8) 
40-2.0 (2.07-
2.0) 
50-2.0  (2.03-
2.0) 
50-1.6 (1.66-
1.6) 
Rsym (%) 6.8 (60.8) 6.5 (69.3) 7.5 (47.4) 7.1 (16.9) 8.0 (38.0) 
I / (I) 36.8 (1.7) 36.2 (2.2) 32.1 (2.5) 47.5 (5.5) 33.0 (3.9) 
Completeness(%) 98.3 (84.6) 98.0 (91.6) 99.4 (94.3) 100.0 (99.9) 99.3 (96.4) 
Redundancy 10.4 (4.0) 10.9 (7.8) 11.2 (5.5) 11.3 (10.9) 11.3 (9.0) 
Refinement      
Resolution (Å) 25.0-1.35 25.0-1.8 25.0-2.0  25.0-2.0  25.0-1.6 
No. reflections 94,012 39,623 29,711  29,946  57,337 
Rwork / Rfree
2 19.7/20.9 20.5/24.1 18.9/23.4  17.6/21.9  19.3/21.6 
Number of atoms      
Protein 3204 3194 3192  3199 3200  
Metal 2 2 2 2 2 
Ligand - 5 8 4 7 
Water 583 351 280 379 565 
 
1
 Highest resolution shell is shown in parenthesis. 
2
 R-factor = (|Fobs|-|Fcalc|)/ |Fobs| and R-free is the R value for a test set of reflections consisting 
of a random 5% of the diffraction data not used in refinement. 
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Table 3.3 Kinetic parameters for PnA hydrolysis by PhnA in the presence of different 
metal ions (10 μM). 
 
PhnA-N-His kcat, s
-1
 KM, μM kcat/KM, M
-1
s
-1
 kcat/KM, rel. 
As isolated
a
 0.9 ± 0.03 22.1 ± 2.3 4.1 × 10
4
 1 
+Zn
2+a
 1.1 ± 0.02 36.8 ± 1.8 2.9 × 10
4
 0.7 
+Fe
2+
 3.6 ± 0.1 43.0 ± 4.7 8.4 × 10
4
 2.0 
+Mn
2+
 2.6 ± 0.1 33.7 ± 2.8 7.7 × 10
4
 1.9 
+Co
2+
 0.6 ± 0.02 11.1 ± 1.6 5.1 × 10
5
 1.2 
+Mg
2+
 0.2 ± 0.01 33.9 ± 4.8 0.5 × 10
4
 0.1 
Apo PhnA No activity detected 
+Mn
2+
 5.5 ± 0.2 33.7 ± 3.0 16.2 × 10
4
 4.0 
+Fe
2+
 3.6 ± 0.2 44.1 ± 7.7 8.0 × 10
4
 2.0 
+Zn
2+
 1.2 ± 0.03 30.3 ± 3.0 3.8 × 10
4
 0.9 
 
a
Reported in (Borisova, et al., 2011) 
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Table 3.4 Initial rates for PnA hydrolysis by wild-type PhnA and by PhnA mutants. 
PhnA-N-His 
variant 
V/[E], s
-1
 
0.2 mM PnA
a 
V/[E], s
-1
 
1 mM PnA
a 
wild-type 3.8 ± 0.4 3.4 ± 0.5 
Thr68Ala8A (2.4 ± 0.2) × 10
-3
 (1.9 ± 0.2) × 10
-3
 
Thr68Cys (5.3 ± 0.7) × 10
-5
 (2.5 ± 0.5) × 10
-5
 
Thr68Gly (1.7 ± 0.4) × 10
-5
 (2.9 ± 0.4) × 10
-5
 
Asn89Val (2.9 ± 0.2) × 10
-4
 (3.3 ± 0.2) × 10
-4
 
 
a
 The activity of these mutants was too low to obtain accurate kinetic parameters. Because the 
activities at two different substrate concentrations are very similar (with the exception perhaps of 
Thr68Gly), the values shown likely represent kcat. 
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Figures 
 
Figure 3.1 Mimicry of phosphate and carboxylate groups of enzyme reaction intermediates 
by phosphonate compounds. Hydrolysis of the rhizocticin (left) tri-peptide generates APPA 
(boxed) which mimics the intermediate for the threonine synthase enzyme (right). Hydrolysis of 
dehydrophos (left) and subsequent hydrolytic rearrangement of the 1-aminovinyl-phosphonate 
O-methyl ester (boxed) generates a structural analog of pyruvate (right) which inhibits pyruvate 
dehydrogenase and pyruvate oxidase. FR900098 (left) is an analog of 1-deoxy-d-xylulose 5-
phosphate (right), which is a substrate for the isoprenoid biosynthetic enzyme deoxyxylulose 
reducto-isomerase. Widely used herbicide molecule glyphosate inhibits the EPSP synthase 
enzyme by mimicking the phosphoenol pyruvate oxonium ion (right) transition state of the 
enzyme. Phosphonate bonds are shown in blue. Bioactivity for these molecules is owed to the 
stability of the C-P bond, as compared to the labile nature of the O-P bond.  
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Figure 3.2 Biochemical pathways for microbial degradation of phosphonate molecules in 
nature. Phosphonate bonds are shown in blue. Enzymes are labeled in red and the compounds 
are labeled in blue. Reaction catalyzed by PhnY is boxed. (A) Phosphonate degradation 
pathways characterized previous to Borisova et. al., 2011. Note that only one reaction for the 
highly substrate promiscuous C-P lyase pathway is shown. (B) 2-AEP is converted to PnAA (1) 
by PhnW, which is oxidized to PnA (2) by PhnY and subsequently hydrolyzed by PhnA in a 
novel phosphonate degradation pathway in S. meliloti 1021. PhnY can also oxidize G3P (3) (vide 
infra). 
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Figure 3.3 Size exclusion chromatography elution profile for PhnY. PhnY elution profile is 
shown as a solid line with linear fit (dashed line) of peak elution volumes for molecular weight 
standard proteins shown as square dots. Chromatography was performed using Superdex 200 HR 
10/30 analytical gel filtration column (GE Lifesciences) in buffer 20 mM HEPES-Na (pH 7.5), 
300 mM KCl, at a flow rate of 0.5 mL/min. The molecular weight standards were Blue Dextran 
(~2,000,000 Da), beta-amylase (~200,000 Da), Albumin (~66,200 Da), carbonic anhydrase 
(~29,000 Da) and cytochrome c (~12,400 Da) and were obtained from Sigma. 
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Figure 3.4 Overall structure of the PhnY dimer. The cofactor binding domain of one 
monomer is shown in red, the catalytic domain in orange, and the dimerization domain in cyan. 
The other monomer is shown in cartoon representation with a partially transparent surface 
superimposed. The β-sheets of the second monomer are colored blue. 
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Figure 3.5 Stereoview of active site of PhnY in complex with inorganic phosphate (Pi). Pi 
and amino acid side chains are shown in stick-ball representation with the carbon atoms colored 
in yellow. The sulfur atom of Cys291 side chain is denoted by arrow. Superimposed is a 
difference Fourier electron density map (contoured at 3.0  over background and shown in blue 
and 9.0 over background and shown in red) calculated with coefficients |Fobs| - |Fcalc| and phases 
from the final refined model with the coordinates of Pi and side chain of Arg108 deleted prior to 
one round of refinement. Hydrogen bonds are shown as black dashes. 
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Figure 3.6 Primary sequence alignment between experimentally verified ALDH members. 
Sm_PhnY: S. meliloti PhnY, Rn_PhnY: R. nubinhibens PhnY, Sm_GAPDH: S. mutans GAPDH, 
Ec_SsALDH: E. coli succinic semialdehyde dehydrogenase, Pa_BetALDH: P.aeruginosa 
betaine ALDH. The absolutely conserved catalytic nucleophile cysteine, catalytic  
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(Figure 3.6 contd.) 
base glutamate and the oxyanion stabilizing asparagine residues are highlighted in pink and 
marked by (^) under the sequences. The phosphate/phosphonate binding pocket forming arginine, 
histidine and tyrosine residues are highlighted in blue and boxed. These residues are not 
conserved in Ec_SsALDH and Pa_BetALDH. All residues of interest are highlighted by (*) 
above the sequences. 
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Figure 3.7 Active site of PhnY in covalent complex with PnAA. The PnAA substrate and 
amino acid side chains are shown in stick-ball representation with the carbon atoms colored in 
green and yellow respectively. The sulfur atom of Cys291 side chain is denoted by arrow. 
Superimposed is a difference Fourier electron density map (contoured at 3.0 over background 
and shown in blue and 9.0 over background and shown in red) calculated with coefficients |Fobs| 
- |Fcalc| and phases from the final refined model with the coordinates of PnAA deleted prior to 
one round of refinement. Hydrogen bonds are shown as black dashes. (A)Stereoview of the 
PhnY active site, with (B) angles around the PnAA-Cβ atom labeled. Note that the angles around 
the PnAA-Cβ atom denote a tetrahedral geometry which can be achieved only prior to hydride 
transfer the cofactor NAD
+
. Though not immediately apparent, the PnAA-Cβ atom in (B) is 
below the plane of the paper. 
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Figure 3.8 PhnY in covalent complex with substrate PnAA and truncated cofactor NAD
+
. The PnAA substrate, NAD
+
 cofactor 
and amino acid side chains are shown in stick-ball representation and colored as before. The sulfur atom of Cys291 side chain is 
denoted by arrow. Superimposed is a difference Fourier electron density map (contoured at 3.0 over background and shown in blue 
and 9.0 over background and shown in red) calculated with coefficients |Fobs| - |Fcalc| and phases from the final refined model with the 
coordinates of PnAA and NAD
+
 deleted prior to one round of refinement. Hydrogen bonds are shown as black dashes.(A)Stereoview 
of the PhnY active site, with (B) angles around the PnAA-Cβ atom labeled. Note that the angles around the PnAA-Cβ atom denote a 
planar geometry which can be achieved only after hydride transfer the cofactor NAD
+
. 
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Figure 3.9 Stereoview of active site of PhnY in non-covalent complex with product PnA and cofactor NAD
+
. The PnAproduct, 
NAD
+
 cofactor and amino acid side chains are shown in stick-ball representation and colored as before. The sulfur atom of Cys291 
side chain is denoted by arrow. Superimposed is a difference Fourier electron density map (contoured at 3.0 over background and 
shown in blue and 9.0 over background and shown in red) calculated with coefficients |Fobs| - |Fcalc| and phases from the final refined 
model with the coordinates of PnA and NAD
+
 deleted prior to one round of refinement. Hydrogen bonds are shown as black dashes. 
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Figure 3.10 Model of the PhnY active site for hydride transfer from PnAA to NAD
+
. The 
model is derived from the superposition of the PhnY crystal structure in the presence of PnAA 
and the PhnY crystal structure in the presence of PnA and NAD
+
. Oxyanion stabilizing 
interactions for the PnAA Cβ hydroxyl are shown as black dashes. Note the relative positioning 
of the PnAA Cβ atom, and the C4 atom of the nicotinamide ring. Also the catalytic base- Glu254 
is sterically occluded by the cofactor. Rotation of the Cys291 side chain thiol by 120⁰ away from 
the active site would clash with the nicotinamide ring. 
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Figure 3.11 Proposed reaction mechanism for PhnY. Side chain thiol of Cys291 attacks at the 
aldehyde carbon atom of PnAA to generate a thiohemiacetal intermediate which is stabilized by 
hydrogen bonding with Asn158 side chain. A hydride is then transferred from the intermediate to 
the C4 atom of the nicotinamide rind of the cofactor. The cofactor departs from the active site 
allowing the catalytic base, Glu254 to correctly position and deprotonate a water molecule for 
attack at the Cys291 bound sp
2
 hybridized carbon atom. The intermediate thus generated resolves 
itself by departure of the Cys291 side chain and PnAA is released. 
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Figure 3.12 Relative activity of wild type PhnY to oxidize PnAA and G3P to PnA and 3-
phosphoglycerate respectively. Activity is measured by absorbance increase due to production 
of NADH from NAD+ during the course of the reaction. Curve 1 (red) corresponds to PnAA as 
substrate, curve 2 (blue) to G3P as substrate and curve 3 (black) is a negative control without 
enzyme with PnAA as substrate. 
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Figure 3.13 Stereoview of active site of PhnY in covalent complex with G3P. The G3P 
substrate and amino acid side chains are shown in stick-ball representation with the carbon atoms 
colored in green and yellow respectively. The sulfur atom of Cys291 side chain is denoted by 
arrow. Superimposed is a difference Fourier electron density map (contoured at 3.0 over 
background and shown in blue and 9.5 over background and shown in red) calculated with 
coefficients |Fobs| - |Fcalc| and phases from the final refined model with the coordinates of G3P 
deleted prior to one round of refinement. Hydrogen bonds are shown as black dashes. 
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Figure 3.14 Active site arrangements for binding of (A) PnAA in PhnY active site, (B) G3P 
in GAPDH active site, and (C) G3P in PhnY active site. The substrate molecules are shown in 
blue. Putative hydrogen bonding interactions are shown as dashed lines. The distances between 
hydrogen bonded atoms are labeled. Note the extended nature of G3P in GAPDH active site, and 
the contorted nature of G3P in PhnY active site.  
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Figure 3.15 Crystal structure of S. meliloti PhnA. The core domain is shown in blue, the 
capping domain in pink and the beta appendage in gold. The two zinc ions bound at the interface 
of the core and the capping domains are shown as green spheres.   
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Figure 3.16 Active site view of PhnA as compared to AP and NPP.(A) Stereo view of PhnA 
active site showing a Bijvoet difference map, calculated using Fourier coefficients |F(+)| and |F(-
)| from data collected at the zinc absorption edge and phases from the final refined model without 
any metal ions. The map is contoured at 3 (in blue) and 10 (in red).The coordinates from the 
final refined model are superimposed and the two metal ions are shown as green spheres. The 
active site view (B) of E. coli AP (PDB Code: 1B8J) and (C) of X. axonopodis NPP (PDB Code: 
2GSO), both in complex with the inhibitor vanadate (colored in cyan) are shown for comparison. 
Water molecules are omitted for clarity.  
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Figure 3.17 Stereo views of PhnA active site with various ligands bound.(A) Stereo view 
showing the active site features of the PhnA-vanadate structure. The vanadate is colored in cyan, 
polypeptide residues are shown in yellow and the active site metals are shown as green spheres. 
Superimposed is a difference Fourier electron density map (contoured at 3 over background in  
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(Figure 3.17 contd.) 
blue and 8 over background in pink) calculated with coefficients |Fobs| - |Fcalc| and phases from 
the final refined model with the coordinates of vanadate deleted prior to one round of refinement. 
(B) Stereo view of the active site features of the PhnA-acetate complex. Residues are colored as 
above and superimposed is a difference Fourier electron density map (contoured at 3 over 
background in blue) calculated with coefficients |Fobs| - |Fcalc| and phases from the final refined 
model with the coordinates of acetate deleted prior to one round of refinement. (C) Stereo view 
of the active site features of the PhnA-Thr68Ala-PnA complex. Residues are colored as above 
and superimposed is a difference Fourier electron density map (contoured at 3.3 over 
background in blue and 10 over background in pink) calculated with coefficients |Fobs| - |Fcalc| 
and phases from the final refined model with the coordinates of PnA deleted prior to one round 
of refinement. (D) Stereo view of the active site features of the PhnA-PnF complex. Residues are 
colored as above and superimposed is a difference Fourier electron density map (contoured at 3 
over background in blue and 8 over background in pink) calculated with coefficients |Fobs| - 
|Fcalc| and phases from the final refined model with the coordinates of PnF deleted prior to one 
round of refinement. In all panels, water molecules are omitted for clarity. 
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Figure 3.18 Active site view of the structure of PhnA. The water molecules are shown as cyan 
spheres. Metal ions are shown as green spheres. Enzyme carbon atoms are shown in yellow, 
oxygen in red and nitrogen in blue. Note that two different conformations of Asp29 are shown. 
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Figure 3.19 Active site view of the structure of PhnA with acetate bound. The water 
molecules are shown as cyan spheres. Metal ions are shown as green spheres. Enzyme carbon 
atoms are shown in yellow, oxygen in red and nitrogen in blue. Acetate carbon atoms are shown 
in blue.  
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Figure 3.20 Active site view of the structure of PhnA with vanadate bound. The water 
molecules are shown as cyan spheres. Metal ions are shown as green spheres. Enzyme carbon 
atoms are shown in yellow, oxygen in red and nitrogen in blue. Vanadium atom is shown in grey. 
Note that Asn89 is too distant to make direct contacts with the equatorial oxygen atoms of the 
transition state mimic, as found in the crystal structures of AP and NPP. Rather Asn89 makes 
water mediated contacts with the transition state mimic. 
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Figure 3.21 Active site view of the structure of PhnA-Thr68Ala with PnA bound. The water 
molecules are shown as cyan spheres. Metal ions are shown as green spheres. Enzyme carbon 
atoms are shown in yellow, oxygen in red and nitrogen in blue. Phosphorus atom is shown in 
orange. 
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Figure 3.22 Putative mechanism for PnA hydrolysis by PhnA. Note the monodentate binding 
of the acetate moiety of PnA by the M1 metal ion. 
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Figure 3.23 Scheme of (A) S. meliloti PhnA active site structure with vanadate bound used 
as transition state model as compared to (B) NPP (PDB Code: 2GSO) and (C) AP (PDB 
Code: 1B8J). Note the asymmetric nature of the equatorial oxygen atom co-ordination between 
the active site metal ions in the PhnA active site, as opposed to the symmetric nature of the same 
vanadate equatorial oxygen atom binding in the NPP and AP active site. Also note that the AP 
active site possess an additional Mg
+2 
ion, which is absent from PhnA and NPP active sites. 
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